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1 
 A comprehensive summary of the work to be incorporated in the thesis entitled 
“Studies on Development of Analytical Method, Validation and Applications for 
Some Drugs” has been described as under. 
 
PART - [A]:  HPLC METHOD DEVELOPMENT AND VALIDATION OF SOME 
PHARMACEUTICAL FORMULATIONS. 
 
PART - [B]:  DEVELOPMENT AND VALIDATION OF A STABILITY 
INDICATING UPLC ASSAY METHOD FOR DETERMINATION 
OF LEFLUNOMIDE IN TABLET FORMULATION. 
 
PART - [C]:  STUDIES ON SIMULTANEOUS ESTIMATION OF 
SPIRONOLACTONE AND FUROSEMIDE FROM DRUG 
PRODUCT BY HIGH PERFORMANCE THIN LAYER 
CHROMATOGRAPHY (HPTLC).  
 
PART - [D]:  UV-VISIBLE SPECTROPHOTOMETRIC METHOD 
DEVELOPMENT AND VALIDATION OF LAMOTRIGINE IN 
TABLET FORMULATION. 
 
INTRODUCTION 
 
  Pharmaceutical analytical chemistry is an important part in monitoring the quality 
of pharmaceutical products for safety and efficacy. With the advancement in synthetic 
organic chemistry and other branches of chemistry including bioanalytical sciences and 
biotechnology, the scope of analytical chemistry has enhanced to, much higher levels. 
The emphasis in current use of analytical methods particularly involving advance 
analytical technology has made it possible not only to evaluate the potency of active 
ingredients in dosage forms and APIs but also to characterize, elucidate, identify and 
quantify important constituents like active moiety, impurities, metabolites, isomers, chiral 
components and prediction of the degradations likely impurities being generated. 
Pharmacopoeias rely more on instrumental techniques rather than the classical wet 
chemistry method.     
 In the present research work a modest attempt has been made to develop validated 
analytical methods for the determination of single or combined dosage form. Estimation 
of degradants generated during formulation and storage of finished products using 
techniques like UV-Visible Spectrophotometer, HPLC, HPTLC and UPLC.  
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PART-[A]:  HPLC METHOD DEVELOPMENT AND VALIDATION OF SOME 
PHARMACEUTICAL FORMULATIONS. 
The research work undertaken in these studies mainly addresses for 
development of HPLC assay methods and validation according to ICH guidelines.  
Aim of work: 
To develop HPLC method for the estimation of some active pharmaceutical 
ingredient from their single/combine pharmaceutical dosage forms by HPLC and to 
perform the validation procedure for same. 
 
EXPERIMENTAL WORK:  
 
Development of analytical method   Validation of analytical method 
1. Selection of mobile phase   1.  Specificity  
2. Selection of stationary phase    2.  Linearity and range  
3. Choice of flow-mode and flow rate 3.  Precision and Intermediate 
                     precision  
4. Wave-length    4.  Accuracy  
5. Injection volume / Concentration 5.  Robustness  
6. Selection of diluents    6. Solution stability  
 
We have undertaken the work on different bioactive compounds which are 
described as under the following section, 
 
Section-I: Development and validation of a stability indicating HPLC assay method 
for determination of Leflunomide in tablet formulation. 
 
F
F
F
O
N
O
 
[1] 
   Leflunomide is chemically 5-Methyl-N-[4(trifluromethyl)phenyl]-isoxazole-4-
carboxamide [Fig.1]. Its molecular formula is C12H9F3N2O2 having molecular weight 
270.207 g/mole. Leflunomide is a pyrimidine synthesis inhibitor belonging to the 
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DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically 
and pharmacologically very heterogeneous. 
 
Developed chromatographic parameters are as under: 
Mobile phase  : -  Buffer : Acetonitrile (40:60, v/v) 
     Buffer : 20mM Ammonium acetate buffer 
Column   : - Wakosil II 5C8RS 4.6 x 150mm, 5 μm 
Flow rate  : - 1 ml/min 
Wavelength  : - 260 nm 
Injection volum e : -  20 µl       
Diluent   : -  Buffer : Acetonitrile (50:50, v/v) 
  
 The developed procedure has been evaluated for the specificity, linearity, 
accuracy, precision, limit of detection, limit of quantification and robustness in order to 
ascertain the stability of the analytical method. It has been proved that it was specific, 
linear, precise, accurate and robust and stability indicating. Hence, the method is useful 
for routine quality control analysis and also for determination of stability. 
 
Section-II: HPLC method development and validation of combine dosage form of 
Cefixime and Ornidazole in tablets. 
 
N
O OH
CH2
O
NH
O
NOO
OH
N
SNH2
HH
N
N
N+
O-
O
OH
Cl
 
 
                                    [2]                                                                           [3] 
Cefixime is chemically (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy 
methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylic acid [Fig.2]. Its molecular formula is C16H15N5O7S2  having molecular 
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weight 453.45 gm/mole. Cefixime is an oral third generation cephalosporin antibiotic. It 
is used to treat gonorrhea, tonsilitis,  and pharyngitis. Ornidazole is chemically 1-chloro-
3-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol [Fig.3]. Its molecular formula is 
C7H10ClN3O3
protozoan
   having molecular weight 219.63 gm/mole. Ornidazole is a drug that cures 
some  infections. It is used by the poultry industry. It has been investigated for 
use in Crohn's disease after bowel resection. 
 
Developed chromatographic parameters are as under: 
 
Mobile phase : -  Water : Acetonitrile : Methanol (50:25:25, v/v) 
Column  : -  Aqurasil SS 4.6 x 150mm, C-18 5 μm  
Flow rate  : -  0.6 ml/min 
Wavelength : -  304 nm 
Injection volume    : -         20 µl       
Diluent  : -  Methanol 
  
 The developed procedure has been evaluated for the specificity, linearity, 
accuracy, precision and robustness. It has been proved that it was specific, linear, precise, 
accurate and robust. Hence, the method is useful for routine quality control analysis.  
 
Section-III: HPLC method development and validation of combine dosage form of 
Atenolol and Indapamide in tablets. 
 
N
CH3
NH
O
Cl
S
O
O
NH2
NH2
O
O
OH
NH CH3
CH3
 
   [4]      [5] 
 
Atenolol is chemically (RS)-2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy] 
phenyl}acetamide [Fig.4] and its molecular formula is C14H22N2O3, and molecular 
weight is 266.34 gm/mole. Atenolol can be used to treat cardiovascular diseases and 
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conditions such as hypertension, coronary heart disease, arrhythmias, angina and to treat 
and reduce the risk of heart complications following myocardial infarction. Indapamide is 
chemically 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoyl-benzamide [Fig.5]. 
Its molecular formula is C16H16ClN3O3S  having molecular weight 365.84 gm/mole. 
Indapamide is a non-thiazide sulphonamide diuretic drug. generally used in the treatment 
of hypertension, as well as decompensated cardiac failure. 
 
Developed chromatographic parameters are as under: 
 
Mobile phase : -  Buffer : Acetonitrile (50:50, v/v)  
          Buffer : 20mM potassium dihydrogen orthophosphate  
  Buffer PH 3.0 adjust with phosphoric acid  
Column  : -  Phenomenex (Gemini) C18, 4.6 x 250mm, 5µm  
Flow rate  : -  0.8 ml/min 
Wavelength : -  241 nm 
Injection volume : - 20 µl       
Diluent  : -  Buffer : Acetonitrile (50:50, v/v)  
 
The developed procedure has been evaluated for the specificity, linearity, 
accuracy, precision, limit of detection, limit of quantification and robustness in order to 
ascertain the stability of the analytical method. It has been proved that it was specific, 
linear, precise, accurate and robust and stability indicating. Hence, the method is useful 
for routine quality control analysis and also for determination of stability.  
  
 
PART - [B]:  DEVELOPMENT AND VALIDATION OF A STABILITY 
INDICATING UPLC ASSAY METHOD FOR DETERMINATION 
OF LEFLUNOMIDE IN TABLET FORMULATION 
           The research work undertaken in this study in the area of pharmaceuticals 
and mainly addresses method development for determination of leflunomide in drug 
product by UPLC. Developed analytical method was validated for its intended application 
as per ICH guideline.  
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Aim of work: 
 
To develop stability indicating ultra performance liquid chromatographic method 
for the estimation of leflunomide from the pharmaceutical dosage form by UPLC and to 
perform the validation procedure for same. 
 
Developed Chromatographic parameters are as under: 
 
Mobile phase : -  Buffer : Acetonitrile (40:60, v/v)      
    Buffer : 20 mM Ammonium acetate buffer  
Column  : - Waters Acquity BEH C18, 2.4 x 50mm, 1.7μ 
Flow rate  : - 0.4 ml/min 
Wavelength : -  260 nm 
Injection volume : - 5.0 µl       
Column oven temp : -  35 °C 
Sample temp : -  15 °C 
Diluent  : -        Buffer : Acetonitrile (50:50 v/v) 
  
 The developed procedure has been evaluated over the specificity, linearity, 
accuracy, precision and robustness in order to ascertain the stability of the analytical 
method. It has been proved that it was specific, linear, precise, accurate and robust and 
stability indicating. Hence, the method is useful for routine quality control analysis and 
also for determination of stability. 
 
PART - [C]:  STUDIES OF SIMULTANEOUS ESTIMATION OF 
SPIRONOLACTONE AND FUROSEMIDE FROM DRUG 
PRODUCT BY HIGH PERFOMANCE THIN LAYER 
CHROMATOGRAPHY (HPTLC) 
O
S
O CH3
O
O
Cl
S
O
NH2
O
O OH
NH
O
[6] [7]  
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 Spironolactone is chemically 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-
carbolactone [Fig.6]. Its molecular formula is C24H32O4
aldosterone receptors
S having molecular weight 
416.58 gm/mole. Spironolactone inhibits the effect of aldosterone by competing for 
intracellular  in the distal tubule cells. Furosemide is chemically 4-
Chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid [Fig.7]. Its molecular 
formula is C12H11ClN2O5S  having molecular weight 330.74gm/mole. Furosemide, an 
anthranilic acid derivative, is a potent diuretic that inhibits the active reabsorption of 
chloride in the diluting segment of the loop of Henle, thus preventing the reabsorption of 
sodium, which passively follows chloride. This loop diuretic is commonly used for the 
treatment of renal diseases, congestive heart failure and hypertension. 
 
Aim of work: 
 
To develop high performance thin layer chromatographic method for 
simultaneous estimation of spironolactone and furosemide from their pharmaceutical 
dosage form by HPTLC and to perform the validation procedure for same. 
Developed chromatographic parameters are as under: 
 
Development chamber     : -  CAMAGE Twin Trough Camber 
Stationary phase           : -  Silica gel GF254 precoated on aluminum sheet  
Mobile phase                    : -  Ethyl acetate : Hexane(80:20) 
Chamber saturation          : -  45 mins 
 Sample applicator            : -  CAMAGE LINOMAT V 
 Band                                :-  6mm 
 Space                               :-   9 mm 
 Scanning Speed               :-   20mm/sec 
 Development distance     :-  8 cm 
 Drying of plate                :- Room temperature 
 Densitometric scanner    :-  CAMAGE TLC SCANNER 
 Lamp                               :-  Deuterium  
 Wavelenth                       :- 254 nm 
 Volume            :-  5µl 
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The study was carried out by high performance thin layer chromatography 
(HPTLC).The method was developed by using Silica Gel 60F254 HPTLC plates coated 
on aluminum sheet as a stationary phase. A suitable developing solvent that gave good 
resolution between the drug and standard was developed. The detection was carried out 
using UV-spectrophotometer. The developed procedure has been evaluated over the 
specificity, linearity, accuracy, precision and ruggedness in order to ascertain the stability 
of the analytical method. It has been proved that it was specific, linear, precise, accurate. 
Hence, the method is useful for routine quality control analysis. 
 
PART - [D]:  UV-VISIBLE SPECTROPHOTOMETRIC METHOD 
DEVELOPMENT AND VALIDATION OF LAMOTRIGINE AND 
IT’S TABLETS FORMULATION. 
 
 
 
 
 
 
 
 
 
Lamotrigine is chemically 6-(2, 3-Dichlorophenyl)-1, 2, 4-triazine-3, 5-diamine 
[Fig.8] and its molecular formula is C9H7N5Cl2
N
N
N
Cl
Cl
NH2NH2
[8]
, and molecular weight is 256.09 
gm/mole. Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is 
chemically unrelated to existing antiepileptic drugs, has been used successfully to treat 
essential trigeminal neuralgia. 
The research work undertaken in this study in the area of pharmaceuticals and 
mainly addresses method development for determination of lamotrigine in drug product 
by UV Visible spectrophotometer. Developed analytical method was validated for its 
intended application as per ICH guideline.  
 
Aim of work: 
To develop spectrophotometric method for the estimation of lamotrigine and it’s 
tablets formulation by UV Visible spectrophotometer and to perform the validation 
procedure for same. 
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Developed Spectrophotometer parameters are as under: 
Detection  : - 308 nm 
Cell path length : -  1 cm 
Diluent  : -  Methanol : Water (50:50, v/v) 
  
The developed procedure has been evaluated over the specificity, linearity, 
accuracy, precision and robustness in order to ascertain the stability of the analytical 
method. It has been proved that it was specific, linear, precise, accurate and robust. 
Hence, the method is useful for routine quality control analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PART - A 
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1. NEED FOR DRUG ANALYSIS 
The number of drugs introduced into the market is increasing every year. These 
drugs may be either new entities or partial structural modification of the existing one [1]. 
Very often there is a time delay from the date of introduction of a drug into the market to 
the date of its inclusion in pharmacopoeias. This happens because of the possible 
uncertainties in the continuous and wider usage of these drugs, reports of new toxicities 
(resulting in their withdrawal from the market), development of long-suffering opposition 
and introduction of better drugs by competitors. Under these conditions, standards and 
analytical procedures for these drugs may not be available in the pharmacopoeias. It 
becomes necessary, therefore to develop newer analytical methods for such drugs. 
Also quality is important in every product or service but it is vital in medicines as 
it involves life. Quality control is a concept, which strives to produce a perfect product by 
series of measures designed to prevent and eliminate errors at different stage of 
production. The decision to release or reject a product is based on one or more type of 
control action. With the growth of pharmaceutical industry during last several years, there 
has been rapid progress in the field of pharmaceutical analysis involving complex 
instrumentation. Providing simple analytical procedure for complex formulation is a 
matter of most importance. 
In brief, the reasons for the development of newer methods of drug analysis are: 
 The drug or drug combination may not be official in any pharmacopoeias, 
 A proper analytical procedure for the drug may not be available in the literature due to 
patent regulations, 
 Analytical methods may not be available for the drug in the form of a formulation due 
to the interference caused by the formulation excipients, 
 Analytical methods for the quantitation of the drug in biological fluids may not be 
available, 
 Analytical methods for a drug in combination with other drugs may not be available, 
 The existing analytical procedures may require expensive reagents and solvents. It 
may also involve cumbersome extraction and separation procedures and these may 
not be reliable. 
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2. CHROMATOGRAPHIC METHODS [2,3] 
Modern pharmaceutical formulations are complex mixtures containing one or 
more therapeutically active ingredients, to a number of inert materials like excipients, 
disintegrates, colors and flavors. In order to ensure quality and stability of the final 
product, the pharmaceutical analyst must be able to separate the mixtures into individual 
components prior to quantitative analysis.  
Chromatography is the powerful techniques in which differential migration of 
components take place between two phases, one is stable which is known as stationary 
phase and another is movable which is known as a mobile phase. Species in the sample 
undergo repeated interactions (partitions) between the mobile phase and stationary phase. 
The stationary phase may be solid or a liquid (supported on a solid or a gel), and packed 
in a column, spread as a layer or film. The mobile phase may be gaseous or liquid. Those 
solutes, distributed preferentially in the mobile phase, will move rapidly through the 
system than those distributed preferentially in the stationary phase. This forms the basis 
of separation of component present in a sample [4]. The distribution of a solute between 
two phases results from the balance of forces between solute molecules and the molecule 
of each phase.  It reflects the relative attraction or repulsion that molecule or ions of the 
competing phase shown for the solute and for them.  These forces can be polar in nature 
arising from permanent on induced and dipole moment. In ion exchange chromatography, 
the forces on the solute molecules are substantially ionic in nature but include polar and 
non-polar forces as well. 
 
Chromatographic method must having essentially, 
 Stationary phase, 
 Mobile phase, 
 Sample injection system, 
 Solvent delivery system , 
 Column (support for stationary phase), 
 Detection by detecting agent. 
         All chromatographic methods involve modifications in these basic components.  
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Classification of Chromatographic Methods [5] 
                                                                          CHROMATOGRAPHY 
 
 
                      
                 Gas Chromatography                                                                              Liquid Chromatography 
 
 
Gas liquid                                         Gas Solid Chromatography (GSC) 
Chromatography (GLC)                                                
 
          Liquid-liquid                            Liquid-solid                                Ion exchange              Exclusion 
          Chromatography                  Chromatography                        Chromatography         Chromatography                                                                              
(LSC)                                                 (LSC)                                         (IEC)                          (EC) 
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Chromatographic methods can be classified according to the nature of the stationary and 
mobile phases [6].   
The different types of chromatography are:  
1. Adsorption chromatography  
2. Partition chromatography   
3. Ion exchange chromatography  
4. Size exclusion or gel permeation chromatography.  
 The modern instrumental techniques of GLC and HPLC provide excellent 
separation and allow accurate assay of very low concentrations of wide variety of 
substance in complex mixtures. 
 
2.1 High Performance Liquid Chromatography (HPLC)[7-9] 
 This is a sophistication of the century-old technique and is the most widely used 
of all the analytical separation techniques. In high performance liquid chromatography 
(HPLC) the liquid mobile phase is forced through the stationary phase under pressure. A 
simple HPLC includes a solvent reservoir to hold the mobile phase, a pump to pressurize 
the mobile phase, and injector to allow injection of a small volume of the sample mixture 
under high pressure, a column containing the bed of stationary phase, a detector to detect 
the presence of components as they exit the column, and a recorder to record the detector 
signal [10]. 
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Most of the drugs in dosage forms can be analyzed by HPLC technique because of 
the several advantages like rapidity, specificity, accuracy, precision and ease of 
automation in this method. HPLC method eliminates tedious extraction and isolation 
procedures. Some of the advantages are [11]: 
 Speed (analysis can be accomplished in 20 minutes or less), 
 Greater sensitivity (various detectors can be employed), 
 Improved resolution (wide variety of stationary phases), 
 Reusable columns (expensive columns but can be used for many analysis), 
 Ideal for the substances of low volatility, 
 Easy sample recovery, handling and maintenance, 
 Instrumentation tends itself to automation and quantitation (less time and less   
labor), 
 Precise and reproducible, 
 Calculations are done by integrator itself, 
 Suitable for preparative liquid chromatography on a much larger scale. 
 
There are different modes of separation in HPLC. They are normal phase mode, 
reversed phase mode, reverse phase ion pair chromatography, affinity chromatography 
and size exclusion chromatography (gel permeation and gel filtration chromatography) 
[12]. 
In the normal phase mode, the stationary phase is polar and the mobile phase is 
nonpolar in nature. In this technique, nonpolar compounds travel faster and are eluted 
first. This is because of the lower affinity between the nonpolar compounds and the 
stationary phase. Polar compounds are retained for longer times because of their higher 
affinity with the stationary phase. These compounds, therefore take more times to elute. 
Normal phase mode of separation is therefore, not generally used for pharmaceutical 
applications because most of the drug molecules are polar in nature and hence take longer 
time to elute.  
Reversed phase mode is the most popular mode for analytical and preparative 
separations of compound of interest in chemical, biological, pharmaceutical, food and 
biomedical sciences. In this mode, the stationary phase is nonpolar hydrophobic packing 
with octyl or octa decyl functional group bonded to silica gel and the mobile phase is 
polar solvent.  
Introduction… 
 
 
 
14 
 
An aqueous mobile phase allows the use of secondary solute chemical equilibrium 
(such as ionization control, ion suppression, ion pairing and complexation) to control 
retention and selectivity. The polar compound gets eluted first in this mode and nonpolar 
compounds are retained for longer time. As most of the drugs and pharmaceuticals are 
polar in nature, they are not retained for longer times and hence elute faster. The different 
columns used are octa decyl silane (ODS) or C18, C8, C4, etc., (in the order of increasing 
polarity of the stationary phase) [13]. 
 
In ion exchange chromatography, the stationary phase contains ionic groups 
like NR3+ or SO3- , which interact with the ionic groups of the sample molecules. This is 
suitable for the separation of charged molecules only. Changing the pH and salt 
concentration can modulate the retention.  
 
Ion pair chromatography may be used for the separation of ionic compounds 
and this method can also substitute for ion exchange chromatography. Strong acidic and 
basic compounds may be separated by reversed phase mode by forming ion pairs 
(columbic association species formed between two ions of opposite electric charge) with 
suitable counter ions. This technique is referred to as reversed phase ion pair 
chromatography or soap chromatography.  
 
Affinity chromatography uses highly specific biochemical interactions for 
separation. The stationary phase contains specific groups of molecules which can adsorb 
the sample if certain steric and charge related conditions are satisfied. This technique can 
be used to isolate proteins, enzymes as well as antibodies from complex mixtures.  
 
Size exclusion chromatography separates molecules according to their molecular 
mass. Largest molecules are eluted first and the smallest molecules last. This method is 
generally used when a mixture contains compounds with a molecular mass difference of 
at least 10%. This mode can be further subdivided into gel permeation chromatography 
(with organic solvents) and gel filtration chromatography (with aqueous solvents). 
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Figure 1: A schematic diagram of HPLC equipment 
 
Various components of HPLC are [14,15]:
(a) A solvent delivery system, including pump, (b) Sample injection system, (C) A 
chromatographic column, (d) A detector, (e)  A strip chart recorder,   (f) Data handling 
device and microprocessor control. 
                              
    
a) Solvent delivery system [16,17] 
A mobile phase is pumped under pressure from one or several reservoir and flows 
through the column at a constant rate. For normal phase separation-eluting power 
increases with increasing polarity of the solvent but for reversed phase separation, eluting 
power decreases with increasing polarity. A degasser is needed to remove dissolved air 
and other gases from the solvent. Special grades of solvents are available for HPLC and 
these have been purified carefully in order to remove absorbing impurities and particulate 
matter to prevent these particles from damaging the pumping or injection system or 
clogging the column. 
Pumps 
The pump is one of the most important components of HPLC, since its 
performance directly affects retention time, reproducibility and detector sensitivity. Three 
main types of pumps are used in HPLC to propel the liquid mobile phase through the 
system. These are:  
1. Displacement pump 
 It produces a flow that tends to independent of viscosity and backpressure and 
also output is pulse free. But it possesses limited capacity (250 ml).  
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2. Reciprocating pump 
It has small internal volume (35 to 400 µl), their high output pressure (up to 
10,000 psi) and their constant flow rates, but it produces a pulsed flow. 
3. Pneumatic or constant pressure pump 
They are pulse free; suffer from limited capacity as well as a dependence of flow 
rate on solvent viscosity and column backpressure. They are limited to pressure less than 
2000 psi.  
 
b) Sample injection system 
Insertion of the sample onto the pressurized column must be as a narrow plug so 
that the peak broadening attributable to this step is negligible. The injection system itself 
should have no dead (void) volume. 
There are three important ways of introducing the sample into injection port: 
 Loop injection: In which, a fixed amount of volume is introduced by making use of 
fixed volume loop injector. 
 Valve injection: In which, a variable volume is introduced by making use of an 
injection valve. 
 On column injection: In which, a variable volume is introduced by means of a syringe 
through a septum. 
 
c) Chromatographic column 
The column is usually made up of heavy glass or stainless steel tubing to 
withstand high pressure. The columns are usually 10-30 cm long and 4-10 mm inside 
diameter containing stationary phase at particle diameter of 25 µm or less. Columns with 
an internal diameter of 5 mm give good results because of compromise between 
efficiency, sample capacity, and the amount of packing and solvent required. 
 
Column packing 
The packing used in modern HPLC consists of small, rigid particles having a 
narrow particle size distribution. There are three main types of column packing in HPLC. 
1. Porous, polymeric beds  
Porous, polymeric beds based on styrene divinyl benzene co-polymers used in ion 
exchange and size exclusion chromatography. For analytical purpose these have now 
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been replaced by silica based, packing which are more efficient and more stable. 
2. Porous layer beds 
Consisting of a thin shell (1-3 µm) of silica or modified silica on an spherical inert 
core (e.g. Glass). After the development of totally porous micro particulate packing, these 
have not been used in HPLC. 
3. Totally porous silica particles (dia. <10 µm) 
These packing have widely been used for analytical HPLC in recent years. 
Particles of diameter >20 µm are usually dry packed, while particles of diameter <20 µm 
are slurry packed in which particles are suspended on a suitable solvent and the slurry so 
obtained is driven into the column under pressure. 
 
d) Detectors 
The function of the detector in HPLC is to monitor the mobile phase as it merges 
from the column. Detectors are usually of two types:  
1. Bulk property detectors 
It compares overall changes in a physical property of the mobile phase with and 
without an eluting solute. e.g. Refractive index, dielectric constant or density. 
2. Solute property detectors 
It responds to a physical property of the solute, which is not exhibited by the pure 
mobile phase. e.g. UV absorbance, fluorescence or diffusion current. Such 
detectors are about 1000 times more sensitive giving a detectable signal for a few 
nanograms of sample [18]. 
 
2.2 Quantitative analysis in HPLC [19, 20] 
Three methods are generally used for quantitative analysis. They are the external 
standard method, the internal standard method and the standard addition method. 
 
2.2.1 External standard method 
 The external standard method involves the use of a single standard or up to three 
solutions. The peak area or the height of the sample and the standard use are compared 
directly. One can also use the slope of the calibration curve based on standard that contain 
known concentrations of the compound of interest. 
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2.2.2 Internal standard method 
A widely used technique of quantitation involves the addition of an internal 
standard to compensate for various analytical errors. In this approach, a known compound 
of a fixed concentration is added to the known amount of samples to give separate peaks 
in the chromatograms to compensate for the losses of the compounds of interest during 
sample pretreatment steps. Any loss of the component of interest will be accompanied by 
the loss of an equivalent fraction of the internal standard. The accuracy of this approach 
obviously dependence on the structural equivalence of the compounds of interest and the 
internal standard. The requirements for an internal standard are: 
 It must have a completely resolved peak with no interferences, 
 It must elute close to the compound of interest, 
 It must behave equivalent to the compound of interest for analysis like pretreatments, 
derivative formations, etc., 
 It must be added at a concentration that will produce a peak area or peak height ratio 
of about unity with the compound, 
 It must not be present in the original sample, 
 It must be stable, nonreactive with sample components, column packing and the 
mobile phase and 
 It is desirable that this compound is commercially available in high purity. 
  The internal standard should be added to the sample prior to sample preparation 
procedure and homogenized with it. To be able to recalculate the concentration of a 
sample component in the original sample, we have to demonstrate first the response 
factor. The response factor (RF) is the ratio of peak areas of sample component (Ax) and 
the internal standard (AISTD) obtained by injecting the same quantity. It can be calculated 
by using the formula, 
RF = Ax / AISTD 
On the basis of the response factor and strength of the internal standard (NISTD), 
the amount of the analyte in the original sample can be calculated using the formula,                               
X =AS / RF × AISTD × N
The calculations described above can be used after proving the linearity of the 
calibration curve for the internal standard and the analytical reference standard of the 
compound of interest. When more than one component is to be analyzed from the sample, 
the response factor of each component should be determined in the calculations using 
ISTD 
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similar formula. 
2.2.3 Standard addition method 
   In the standard addition method, a known amount of the standard compound is 
added to the sample solution to be estimated. This method is suitable if sufficient amount 
of the sample is available and is more realistic in the sense that it allows calibration in the 
presence of excipients or other components. As gradient elution can be a source of 
additional error in quantitative analysis. It is also necessary to keep the flow rate and the 
mobile phase composition constant. The sample should be dissolved in the mobile phase. 
If the solvent used in the preparing the sample solution and the mobile phase are not 
identical, the analysis can become less accurate and it is also possible that the detector 
response is more dependent on the sample. 
 
2.3 Method development and design of separation method [21,22] 
 Methods for analyzing drugs in multi component dosage forms can be developed, 
provided one has knowledge about the nature of the sample, namely, its molecular 
weight, polarity, ionic character and the solubility parameter. An exact recipe for HPLC, 
however, cannot be provided because method development involves considerable trial 
and error procedures. The most difficult problem usually is where to start, what type of 
column is worth trying with what kind of mobile phase. In general one begins with 
reversed phase chromatography, when the compounds are hydrophilic in nature with 
many polar groups and are water soluble.  
The organic phase concentration required for the mobile phase can be estimated 
by gradient elution method. For aqueous sample mixtures, the best way to start is with 
gradient reversed phase chromatography. Gradient can be started with 5-10% organic 
phase in the mobile phase and the organic phase concentration (methanol or acetonitrile) 
can be increased up to 100% within 30-45min. Separation can then be optimized by 
changing the initial mobile phase composition and the slope of the gradient according to 
the chromatogram obtained from the preliminary run. The initial mobile phase 
composition can be estimated on the basis of where the compounds of interest were 
eluted, namely, at what mobile phase composition.  
Changing the polarity of mobile phase can alter elution of drug molecules. The 
elution strength of a mobile phase depends upon its polarity, the stronger the polarity, 
higher is the elution. Ionic samples (acidic or basic) can be separated, if they are present 
Introduction… 
 
 
 
20 
 
in undissociated form. Dissociation of ionic samples may be suppressed by the proper 
selection of pH.  
The pH of the mobile phase [23] has to be selected in such a way that the 
compounds are not ionized. If the retention time is too short, the decrease of the organic 
phase concentration in the mobile phase can be in steps of 5%. If the retention time is too 
long, an increase of the organic phase concentration is needed.  
In UV detection, good analytical results are obtained only when the wavelength is 
selected carefully. This requires knowledge of the UV spectra of the individual 
components present in the sample. If analyte standards are available, their UV spectra can 
be measured prior to HPLC method development. 
The molar absorbance at the detection wavelength is also an important parameter. 
When peaks are not detected in the chromatograms, it is possible that the sample quantity 
is not enough for the detection. An injection of volume of 20 µl from a solution of              
1 mg/ml concentration normally provides good signals for UV active compounds around 
220 nm. Even if the compounds exhibit higher λmax, they absorb strongly at lower 
wavelength. It is not always necessary to detect compounds at their maximum 
absorbance. It is, however, advantageous to avoid the detection at the sloppy part of the 
UV spectrum for precise quantitation. When acceptable peaks are detected on the 
chromatogram, the investigation of the peak shapes can help further method development.  
The addition of peak modifiers to the mobile phase can affect the separation of 
ionic samples. For examples, the retention of the basic compounds can be influenced by 
the addition of small amounts of triethylamine (a peak modifier) to the mobile phase. 
Similarly for acidic compounds small amounts of acids such as acetic acid can be used. 
This can lead to useful changes in selectivity.  
When tailing or fronting is observed, it means that the mobile phase is not totally 
compatible with the solutes. In most case the pH is not properly selected and hence partial 
dissociation or protonation takes place. When the peak shape does not improve by lower 
(1-2) or higher (8-9) pH, then ion-pair chromatography can be used. For acidic 
compounds, cationic ion pair molecules at higher pH and for basic compounds, anionic 
ion-pair molecules at lower pH can be used. For amphoteric solutes or a mixture of acidic 
and basic compounds, ion-pair chromatography is the method of choice. 
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Figure 2 Different peak shapes are observed during method development in HPLC 
 
The low solubility of the sample in the mobile phase can also cause bad peak 
shapes. It is always advisable to use the same solvents for the preparation of sample 
solution as the mobile phase to avoid precipitation of the compounds in the column or 
injector. Optimization can be started only after a reasonable chromatogram has been 
obtained.   
A reasonable chromatogram means that more or less symmetrical peaks on the 
chromatogram detect all the compounds. By slight change of the mobile phase 
composition, the position of the peaks can be predicted within the range of investigated 
changes. An optimized chromatogram is the one in which all the peaks are symmetrical 
and are well separated in less run time.  
The peak resolution can be increased by using a more efficient column (column 
with higher theoretical plate number, N), which can be achieved by using a column of 
smaller particle size, or a longer column. These factors, however, will increase the 
analysis time. Flow rate does not influence resolution, but it has a strong effect on the 
analysis time. 
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 The parameters that are affected by the changes in chromatographic conditions are 
[24]: 
a. Resolution (Rs
b. Capacity factor (k'), 
), 
c. Selectivity (α), 
d. Column efficiency (N) and 
e. Peak asymmetry factor (As
 
). 
a. Resolution (Rs
Resolution is the parameter describing the separation power of the complete 
chromatographic system relative to the particular components of the mixture. The 
resolution, R
) 
s, of two neighboring peaks is defined as the ratio of the distance between 
two peak maxima. It is the difference between the retention times of two solutes divided 
by their average peak width. For baseline separation, the ideal value of Rs is 1.5. It is 
calculated by using the formula, 
Rs = Rt2 - Rt1 / 0.5 (W1 + W2) 
Where,  Rt1 and Rt2 are the retention time of components 1 and 2 and 
 W1 and W2
 Capacity factor 
 are peak width of components 1 and 2. 
There are three fundamental parameters that influence the resolution of a 
chromatographic separation: 
 Selectivity 
 Column efficiency 
 
b. Capacity Factor (k') 
 Capacity factor is the ratio of the reduced retention volume to the dead volume. 
Capacity factor, k', is defined as the ratio of the number of molecules of solute in the 
stationary phase to the number of molecules of the same in the mobile phase. Capacity 
factor is a measure of how well the sample molecule is retained by a column during an 
isocratic separation. The ideal value of k' ranges from 2-10. Capacity factor can be 
determined by using the formula, 
k' =  V1 - V0 / V0 
Where, V1 = 
             V
retention volume at the apex of the peak (solute) and  
0 = void volume of the system. 
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The values of k' of individual bands increase or decrease with changes in solvent 
strength. In reversed phase HPLC, solvent strength increases with the increase in the 
volume of organic phase in water/ organic mobile phase. Typically an increase in 
percentage of the organic phase by 10% by volume will decrease k' of the bands by a 
factor of 2-3. 
 
Adjusting capacity factor (k'): 
Good isocratic method usually have a capacity factor (k') in the range of 2 -10 
(typically 2 – 5). Lower values may give inadequate resolution. Higher values are usually 
associated with excessively broad peak and unacceptably long run time. If the shift in k' 
value is observed with both analyst and the column test solution, the problem is most 
likely due to change in column, temperature or mobile phase composition. This is true if 
the shift occurs gradually over series of run. 
Capacity factor (k') values are sensitive to: 
 Solvent strength 
 Composition 
 Purity 
 Temperature 
 Column chemistry 
 Sample 
 
c. Selectivity (α) 
The selectivity (or separation factor),α, is a measure of relative retention of two 
components in a mixture. Selectivity is the ratio of the capacity factors of both peaks, and 
the ratio of its adjusted retention times. Selectivity represents the separation power of 
particular adsorbent to the mixture of these particular components. 
This parameter is independent of the column efficiency; it only depends on the 
nature of the components, eluent type, and eluent composition, and adsorbent surface 
chemistry. In general, if the selectivity of two components is equal to 1, then there is no 
way to separate them by improving the column efficiency. 
       The ideal value of α is 2. It can be calculated by using formula, 
α= V2 – V1 / V1 – V0     = k1'/ k2' 
       Where,   V0 
                  V
= the void volume of the column, 
1 and V2 = the retention volumes of the second and the first peak 
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respectively. 
Adjusting selectivity (α) 
When troubleshooting changes in selectivity (α), the approach is similar to the 
approach used in the capacity factor. When selectivity (α) is affected, the corrective 
action depends on whether the problem is mobile phase or column related. Be sure to 
compare results obtained with the test solution to those observed when the column was 
new. 
Selectivity (α) values are sensitive to: 
 Changes in mobile phase composition (pH ionic strength) 
 Purity 
 Temperature 
 
d. Column efficiency/ Band broadening 
 Efficiency N, of a column is measured by the number of theoretical plates per 
meter. It is a measure of band spreading of a peak. Similar the band spread, higher is the 
number of theoretical plates, indicating good column and system performance. Column 
with N ranging from 5,000 to 1,00,000 plates/meter are ideal for a good system.  
 Efficiency is calculated using the formula, 
N = 16 Rt2 / W
 Age and history of the column 
2 
  Where, Rt is the retention time and W is the peak width. 
A decline in measured column efficiency may be due to: 
 Extra column band broadening (such as due to malfunctioning injector or improper 
tubing i.d.) 
 Inappropriate detector setting 
 Change in flow rate and solvent viscosity 
You can recognize problems in your separation due to a loss of column efficiency 
when the width or shapes of all peaks are affected. 
 
Methods of measuring column efficiency (N) 
  Method used for the measurement and calculation of column include (in order to 
sensitivity to abnormal peak shape): 
 Asymmetry based (most sensitive to tailing or fronting) 
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 5 sigma 
 4 sigma 
 Tangent 
 3 sigma 
 ½ height 
 2 sigma (least sensitive to tailing or fronting) 
 Chose the method that best suits your operating requirements. It is critical that the 
same method always be used and executed reproducibly. 
 
e. Peak asymmetry factor (As) 
 Peak asymmetry factor, As, can be used as a criterion of column performance. The 
peak half width, b, of a peak at 10% of the peak height, divided by the corresponding 
front half width, a, gives the asymmetry factor. 
As = 
2.3 Validation of analytical method [25-29] 
b / a 
 For a well-packed column, an asymmetry factor of 0.9 to 1.1 should be 
achievable. 
 
“Validation is an act of proving that any procedure, process, equipment, material, 
activity or system performs as expected under given set of conditions and also give the 
required accuracy, precision, sensitivity, ruggedness, etc.” 
When extended to an analytical procedure, depending upon the application, it 
means that a method works reproducibly, when carried out by same or different persons, 
in same or different laboratories, using different reagents, different equipments, etc. 
The various validation parameters are: 
a) Accuracy,  
b) Precision(repeatability and reproducibility), 
c) Linearity and Range, 
d) Limit of detection(LOD)/ Limit of quantitation (LOQ), 
e) Selectivity/ Specificity, 
f) Robustness/ Ruggedness and 
g) Stability and System suitability studies. 
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Advantages of Analytical method Validation 
 The biggest advantage of method validation is that it builds a degree of confidence, 
not only for the developer but also to the user. 
 Although the validation exercise may appear costly and time consuming, it results 
inexpensive, eliminates frustrating repetitions and leads to better time management in 
the end. 
 Minor changes in the conditions such as reagent supplier or grade, analytical setup 
are unavoidable due to obvious reasons but the method validation absorbs the shock 
of such conditions and pays for more than invested on the process. 
Method validation is required when 
1. A new method has been developed 
2. Revision of established method 
3. When established methods are used in different laboratories and different analysts etc. 
4. Comparison of methods required 
5. When quality control indicates method changes. 
 
Key parameters of the analytical method validation 
It is important for one to understand the parameters or characteristics involved in 
the validation process. The various performance parameters, which are addressed in a 
validation exercise, are grouped as follows. 
a) Accuracy 
The accuracy of an analytical method may be defined as the closeness of the test 
results obtained by the method to the true value. It is the measure of the exactness of the 
analytical method developed. Accuracy may often express as percent recovery by the 
assay of a known amount of analyte added. 
Accuracy may be determined by applying the method to samples or mixtures of 
excipients to which known amount of analyte have been added both above and below the 
normal levels expected in the samples. Accuracy is then calculated from the test results as 
the percentage of the analyte recovered by the assay. Dosage form assays commonly 
provide accuracy within 3-5% of the true value. 
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The ICH documents recommend that accuracy should be assessed using a 
minimum of nine determinations over a minimum of three concentration levels, covering 
the specified range (i.e. three concentrations and three replicated of each concentration). 
b) Precision 
The precision of an analytical method is the degree of agreement among 
individual test results when the method is applied repeatedly to multiple samplings of 
homogenous samples. This is usually expressed as the standard deviation or the relative 
standard deviation (coefficient of variation). Precision is a measure of the degree of 
reproducibility or of the repeatability of the analytical method under normal operating 
circumstances. 
Repeatability involves analysis of replicates by the analyst using the same 
equipment and method and conducting the precision study over short period of time while 
reproducibility involves precision study at 
 Different occasions, 
 Different laboratories, 
 Different batch of reagent, 
 Different analysts, 
 Different equipments. 
 
1)   Determination of repeatability 
Repeatability can be defined as the precision of the procedure when repeated by 
same analyst under the same operating conditions (same reagents, equipments, settings 
and laboratory) over a short interval of time. 
It is normally expected that at least six replicates be carried out and a table showing 
each individual result provided from which the mean, standard deviation and co-efficient 
of variation should be calculated for set of n value. The RSD values are important for 
showing degree of variation expected when the analytical procedure is repeated several 
time in a standard situation. (RSD below 2% for assays in finished product). 
The ICH documents recommend that repeatability should be assessed using a 
minimum of nine determinations covering the specified range for the procedure (i.e. three 
concentrations and three replicates of each concentration or using a minimum of six 
determinations at 100% of the test concentration). 
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2)  Determination of reproducibility 
Reproducibility means the precision of the procedure when it is carried out under 
different conditions-usually in different laboratories-on separate, identical samples taken 
from the same homogenous batch of material. Comparisons of results obtained by 
different analysts, by the use of different equipments, or by carrying out the analysis at 
different times can also provide valuable information. 
 
c) Linearity and range 
The linearity of an analytical method is its ability to draw out test results that are 
directly (or by a well defined mathematical transformation) proportional to the analyte 
concentration in samples within a given range. Linearity usually expressed in terms of the 
variance around the slope of regression line calculated according to an established 
mathematical relationship from test results obtained by the analysis of samples with 
varying concentrations of analyte. 
The linear range of detectability that obeys Beer’s law is dependent on the 
compound analyzed and the detector used. The working sample concentration and 
samples tested for accuracy should be in the linear range. The claim that the method is 
linear is to be justified with additional mention of zero intercept by processing data by 
linear least square regression. Data is processed by linear least square regression 
declaring the regression co-efficient and b of the linear equation y= ax + b together with 
the correlation coefficient of determination. For the method to be linear the r value should 
be close to1. 
The range of an analytical method is the interval between the upper and lower 
levels of the analyte (including these levels) that have been demonstrated to be 
determined with precision, accuracy and linearity using the method as written. 
 
d) Limit of Detection and Limit of Quantitation 
1)   Limit of detection 
  The limit of detection is the parameter of limit tests. It is the lowest level of 
analyte that can be detected, but not necessarily determined in a quantitative fashion, 
using a specific method under the required experimental conditions. The limit test thus 
merely substantiates that the analyte concentration is above or below a certain level. 
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The determination of the limit of detection of instrumental procedures is carried 
out by determining the signal-to-noise ratio by comparing test results from the samples 
with known concentration of analyte with those of blank samples and establishing the 
minimum level at which the analyte can be reliably detected. A signal-to-noise ratio of 
2:1 or 3:1 is generally accepted. 
The signal-to-noise ratio is determined by dividing the base peak by the standard 
deviation of all data points below a set threshold. Limit of detection is calculated by 
taking the concentration of the peak of interest divided by three times the signal-to-noise 
ratio. 
For spectroscopic techniques or other methods that rely upon a calibration curve 
for quantitative measurements, the IUPAC approach employs the standard deviation of 
the intercept (Sa) which may be related to LOD and the slope of the calibration curve, b, 
by 
LOD = 3.3 Sa / b 
2)    Limit of quantitation 
  Limit of quantitation is a parameter of quantitative assays for low levels of 
compounds in sample matrices such as impurities in bulk drugs and degradation products 
in finished pharmaceuticals. The limit of quantitation is the lowest concentration of 
analyte in a sample that may be determined with acceptable accuracy and precision when 
the required procedure is applied. 
It is measured by analyzing samples containing known quantities of the analyte 
and determining the lowest level at which acceptable degrees of accuracy and precision 
are attainable, Where the final assessment is based on an instrumental reading, the 
magnitude of background response by analyzing a number of blank samples and 
calculating the standard deviation of this response. The standard deviation multiplied by a 
factor (usually 10) provides an estimate of the limit of quantitation. In many cases, the 
limit of quantitation is approximately twice the limit of detection. 
 
e) Selectivity and Specificity 
The selectivity of an analytical method is its ability to measure accurately and 
specifically the analyte of interest in the presence of components that may be expected to 
be present in the sample matrix. 
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If an analytical procedure is able to separate and resolve the various components 
of a mixture and detect the analyte qualitatively the method is called selective. On the 
other hand, if the method determines or measures quantitatively the component of interest 
in the sample matrix without separation, it is said to be specific. 
Hence one basic difference in the selectivity and specificity is that, while the 
former is restricted to qualitative detection of the components of a sample, the latter 
means quantitative measurement of one or more analytes. 
Selectivity may be expressed in terms of the bias of the assay results obtained 
when the procedure is applied to the analyte in the presence of expected levels of other 
components, compared the results obtained when the procedure is applied to the analyte 
in the presence of expected levels of other components, compared to the results obtained 
on the same analyte without added substances. When the other components are all known 
and available, selectivity may be determined by comparing the test results obtained on the 
analyte with and without the addition of the potentially interfering materials. When such 
components are either unidentified or unavailable, a measure of selectivity can often be 
obtained by determining the recovery of a standard addition of pure analyte to a material 
containing a constant level of the other components. 
 
f) Robustness and Ruggedness 
1) Robustness 
The robustness of an analytical method is a measure of its capacity to remain 
unaffected by small but deliberate variation in method parameters and provides an 
indication of its reliability during normal usage. The determination of robustness requires 
that methods characteristic are assessed when one or more operating parameter varied. 
2) Ruggedness 
  The ruggedness of an analytical method is the degree of reproducibility of test 
results obtained by the analysis of the same samples under a variety of normal test  
conditions such as different laboratories, different analysts, using operational and 
environmental conditions that may differ but are still within the specified parameters of 
the assay. The testing of ruggedness is normally suggested when the method is to be used 
in more than one laboratory. Ruggedness is normally expressed as the lack of the 
Introduction… 
 
 
 
31 
 
influence on the test results of operational and environmental variables of the analytical 
method. 
For the determination of ruggedness, the degree of reproducibility of test result is 
determined as function of the assay variable. This reproducibility may be compared to the 
precision of the assay under normal condition to obtain a measure of the ruggedness of 
the analytical method. 
 
g) Stability and System suitability tests 
Stability of the sample, standard and reagents is required for a reasonable time to 
generate reproducible and reliable results. For example, 24 hour stability is desired for 
solutions and reagents that need to be prepared for each analysis. 
System suitability test provide the added assurance that on a specific occasion the 
method is giving, accurate and precise results. System suitability test are run every time a 
method is used either before or during analysis. The results of each system suitability test 
are compared with defined acceptance criteria and if they pass, the method is deemed 
satisfactory on that occasion. The nature of the test and the acceptance criteria will be 
based upon data generated during method development optimization and validation 
experiments. 
 
Table1.1: Data elements required for assay validation 
 
Analytical 
Performance 
Characteristics 
Assay 
Category I 
Assay Category II 
Assay 
Category III 
Assay 
Category IV Quantitative 
tests 
Limit 
tests 
Accuracy X X May be May be  
Precision X X  X  
Specificity X X X May be X 
Limit of 
Detection 
  X May be  
Limit of 
Quantitation 
 X  May be  
Linearity X X  May be  
Range X X May be May be  
 
Where, X indicates the tests to be performed. 
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Category I: Analytical methods for quantitation of major components of bulk drug 
substances or active ingredients including preservatives in finished pharmaceutical 
products. 
Category II: Analytical methods for determination of impurities in bulk drugs or for 
determination of degradation compounds in finished pharmaceutical products. 
Category III: Analytical methods for determination of performance characteristics (e.g. 
dissolution, drug release). 
Category IV: Identification tests. 
 
 
3.   OBJECTIVE OF THE WORK 
 
 The specific and main objectives of the work are:  
[Part A] 
Section I : 
Development and validation of a stability indicating HPLC assay method for 
determination of leflunomide in tablet formulation. 
Section II : 
HPLC method development and validation of combine dosage form of cefixime and 
ornidazole in tablets. 
Section III : 
HPLC method development and validation of combine dosage form of atenolol and 
indapamide in tablets. 
[Part B] 
Development and validation of a stability indicating UPLC assay method for 
determination of leflunomide in tablet formulation. 
 [Part C] 
Studies of simultaneous estimation of furosemide and spironolactone from drug product 
by high perfomance thin layer chromatography (HPTLC). 
[Part D] 
UV-Visible Spectrophotometric method development and validation of lamotrigine and 
it’s tablets formulation. 
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3.1 Instrument use for whole research work 
 
3.1.1 Chromatographic system 
 The chromatographic system used to perform development and validation of this 
assay method was comprised of a LC-10ATvp binary pump, a SPD-M10Avp photo diode 
array detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing 
system (Class-VP 6.13 SP2, Shimadzu) and the UPLC system of Waters Acquity with 
PDA was also used. 
 
3.1.2 HPTLC Chromatographic system 
The chromatographic system used to perform development and validation of this 
assay method was Camag Linomat V Sample applicator, Camag Twin trough glass 
chamber and Camag TLC scanner III equipped with Cats 3 Version software. 
 
3.1.3 Spectrophotometer system 
 The spectrophotometer system used to perform development and validation of this 
assay method was model Phamaspec-UV-1700, Shimadzu, Kyoto, Japan and data 
processing system (UV probe, Shimadzu). 
 
3.1.4 Other instruments 
 Ultrasonic Bath (SONICA, Spincotech Pvt. Ltd., Mumbai). 
 pH-Meter (Li-610, Elico Ltd. India) 
 Hot Air Oven (Nova Instruments, India) 
 Digital Balance (Metller Toledo, Japan) 
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SECTION I: DEVELOPMENT AND VALIDATION OF A STABILITY 
INDICATING HPLC ASSAY METHOD FOR DETERMINATION OF 
LEFLUNOMIDE IN TABLET FORMULATION  
 
1.    INTRODUCTION TO LEFLUNOMIDE 
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD 
(disease-modifying antirheumatic drug) class of drugs, which are chemically and 
pharmacologically very heterogeneous[1, 2]. 
The substance is sold under the brand name Arava by Sanofi-Aventis. It is 
available for oral administration as tablets containing 10, 20, or 100 mg of active drug. 
Arava also contains some inactive ingredients, which could cause allergies or 
intolerances. Arava was approved by FDA and in many other countries (e.g., Canada, 
Europe) in 1998. 
 
1.1  Description 
   Leflunomide is chemically 5-Methyl-N-[4(trifluromethyl)phenyl]-isoxazole-4-
carboxamide [Figure 1]. Its molecular formula is C12H9F3N2O2 
F
F
F
O
N
O
having molecular weight 
270.207 g/mole. Leflunomide is a pyrimidine synthesis inhibitor belonging to the 
DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically 
and pharmacologically very heterogeneous. 
 
                      
              Figure: 1  5-Methyl-N-[4(trifluromethyl)phenyl]-isoxazole-4-carboxamide 
 
1.2  Basic chemical and pharmacological data 
1 .2.1  Mechanism of action 
Leflunomide is an immunomodulatory drug inhibiting dihydroorotate 
dehydrogenase (an enzyme involved in de novo pyrimidine synthesis) (abbreviation 
DHODH) [3]. Genuine antiproliferative activity has been proven. Additionally, several 
experimental models (both in vivo and in vitro) have demonstrated an anti-inflammatory 
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effect. This double action is supposed to slow progression of the disease and to cause 
remission/relief of symptoms of rheumatoid arthritis and psoriatic arthritis such as joint 
tenderness and decreased joint and general mobility in human patients. 
 
1.2.2   Pharmacokinetics 
Arava tablets are 80% bioavailable. Co-administration with a high fat meal did not 
have a significant impact on plasma levels of the active metabolite teriflunomide. 
Following oral administration, leflunomide is metabolized to teriflunomide which is 
responsible for essentially all of the drug's activity in vivo. Studies of the 
pharmacokinetics of leflunomide have primarily examined the plasma concentrations of 
teriflunomide. Plasma levels of unchanged leflunomide are occasionally detected, but at 
very low levels. Some minor metabolites have been noticed to occur in human plasma, 
which do not account for the beneficial drug effects. Teriflunomide is metabolized in the 
liver at cytosolic and microsomal sites and further excreted as well renally and billary. 
 
 Absorption and need for loading dose 
After oral administration, peak plasma levels of teriflunomide occurred between 
6–12 hours after dosing. Due to its very long half-life (approximately 2 weeks), a loading 
dose of 100 mg for 3 days was used in clinical studies to reach steady-state levels quickly. 
Without a loading dose, it is estimated that steady-state plasma concentrations would 
require nearly two months of dosing to be reached. The resulting plasma levels following 
both loading doses and continued clinical dosing indicate that plasma levels are dose 
proportional. Teriflunomide can be found as late as 2 years after termination of therapy in 
human plasma in sufficient levels to cause severe harm to pregnant women or to cause 
significant interactions. If quick removal from the body is necessary, an eleven day 
scheme with cholestyramine or the use of activated charcoal is indicated and will soon 
decrease plasma levels below the critical limit of 0.02mg/l. Limited experience shows that 
teriflunomide is not dialysable. 
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2. LITERATURE REVIEW 
The literature reviews regarding leflunomide suggest that various analytical 
methods were reported for its determination as drug, in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of leflunomide are as under: 
 
2.1 S. S. Abbas, L. I. Bebawy, L A Fattah, H. H. Refaat have developed   
spectrophotometric stability-indicating methods for the determination of leflunomide in 
the presence of its degradates. They studied five simple and sensitive methods were 
developed for the determination of leflunomide (I) in the presence of its degradates 4-
trifluoromethyl aniline (II) and 3-methyl-4-carboxy isoxazole (III).  Method A was based 
on differential derivative spectrophotometry by measuring the delta(1)D value at 279.5 
nm.  Beer's law was obeyed in the concentration range of 2.00-20.00 microg/mL with 
mean percentage accuracy of 100.07 +/- 1.32.  Method B depended on first-derivative 
spectrophotometry and measuring the amplitude at 253.4 nm.  Method C was based on 
the reaction of degradate (II) with 2,6-dichloroquinone-4-chloroimide (Gibbs reagent).  
The colored product was measured at 469 nm.  Method D depended on the reaction of 
degradate (II) with para-dimethyl aminocinnamaldehyde (p-DAC).  The absorbance of 
the colored product was measured at 533.4 nm.  Method E utilized 3-methyl-2-
benzothiazolinone hydrazone in the presence of cerric ammonium sulfate with degradate 
(II).  The green colored product was measured at 605.5 nm [4]. 
2.2 M. Molinaro, C. Carazzone, D. Barbano, F. Abbiati, M. Alessiani, M. Regazzi 
have assessment of an LC-MS method for plasma quantification of the new 
immunosuppressant FK778 through comparison with HPLC -UV.  FK778 is a new 
immunosuppressive agent, derived from the leflunomide-active metabolite A77 1726.  It 
inhibits de novo pyrimidine nucleotide synthesis showing efficacy in the prevention and 
treatment of rejection in experimental transplant models.  They aim of this work was to 
develop an HPLC-MS method to measure FK778 in plasma for pharmacokinetic studies.  
The equipment used for mass evaluation was an HLPC coupled to an ion trap analyzer 
through an electrospray source.  After precipitation of plasma proteins with acetonitrile, 
the supernatant was injected onto an analytical RP-C18 column.  Chromatographic 
separation was performed under isocratic conditions, using a mobile phase consisting of 
ammonium acetate buffer and acetonitrile (55:45. vol/vol).  The HPLC-MS method was 
applied to pharmacokinetics in animal models showing comparable results to those 
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obtained by an HPLC-UV assay at 290 nm.  Good agreement was observed in the plasma 
FK778 concentration versus time curves [5]. 
2.3   C. Vivien, G. Bruce, Charles and E. T. Susan have developed method for  
rapid determination of the active leflunomide metabolite A77 1726 in human plasma by 
high-performance liquid chromatography. A simple method for the measurement of the 
active leflunomide metabolite A77 1726 in human plasma by HPLC is presented. The 
sample workup was simple, using acetonitrile for protein precipitation. Chromatographic 
separation of A77 1726 and the internal standard, α-phenylcinnamic acid, was achieved 
using a C18 column with UV detection at 305 nm [6]. 
2.4   L. Hong, Z. Ma have been developed method for the determination of   
leflunomide  in tablets by  HPLC. They have used the chromatography column was 
Diamonsil C18 (250 mm×4.6 mm, 5 µm) with methanol: water: acetic acid (75: 25: 0.1) 
as mobile phase at wavelength 260 nm.  There was a good linear relationship between 
leflunomide content and peak area in the range of 0.1-10.0 mg/L [7]. 
2.5  S. Jiang, L. Kang, G. Yan, Z. Li, Y. Wang, D. Zhang have been developed 
method for the determination of  leflunomide  and related compounds by reverse phase  
high   performance   liquid   chromatography. They was presented a reversed phase HPLC 
method for the determination of  leflunomide [8]. 
2.6   S. Weng has developed method for the determination of 3-methyl-isomer and 
related substances in  leflunomide  by RP- HPLC. A RP-HPLC (reverse phase-high 
performance liquid chromatography) method was established for the determination of 3-
methyl-isomer and its related substances in leflunomide.  The chromatographic analysis 
was performed on Hypersil ODS2 column (4.6 mm×250 mm, 5 µm).  The mobile phase 
consisted of acetonitrile-methanol-0.01 mol·L-1
2.7  D. Yeniceli, D. Dogrukol-Ak, M. Tuncel  have been developed method for the  
determination of  leflunomide  in tablets by  high   performance   liquid   chromatography. 
They studied; a reverse phase high performance liquid chromatography (HPLC) method 
was validated and applied for the determination of leflunomide in tablets.  
Chromatographic separation of leflunomide and oxazepam as an internal standard was 
carried out on a C18 column (50 mm, 3 mm i.d.) using a mobile phase, consisting of 
methanol and water (60:40, vol./vol.), at a flow rate of 0.5 mL min
 phosphate buffer (25:25:50).  The flow 
rate was 1.0 mL·min-1.  The detection wavelength was at 261 nm, with injection volume 
20 µL.  The 3-methyl-isomer was separated from leflunomide [9].   
-1 and UV detection at 
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260 nm. The retention times for oxazepam and leflunomide were 2.6 and 5.2 min, 
respectively. The validated quantification range of the method was 2.7 × 10-6 to 5.5 × 10-5 
M for leflunomide [10].   
2.8  S. V. Rao, K. K. Sunanda, N. M. Rao, A. A. Rao I. L. Maheswari  and G. 
Srinubabu have been developed and validation of LC method for the determination of 
leflunomide in pharmaceutical formulations using an experimental design. A rapid and 
sensitive RP-HPLC method with UV detection (260 nm) for routine analysis of 
leflunomide in a pharmaceutical formulation was developed. Chromatography was 
performed with mobile phase containing a mixture of acetonitrile and phosphate buffer 
(60:40, v/v) with flow rate of 0.8 ml min−1.  Quantitation was accomplished with internal 
standard method [11]. 
2.9   D. S. Miron, C. Soldattelli and E. E. S. Schapoval have been developed HPLC 
with diode-array detection for determination of leflunomide in tablets. Method conditions 
were determined by assay of a photodegraded sample of leflunomide. Optimum 
chromatographic performance was obtained with a C18
2.12  Q. Zhu, J. Hu, H. Sun have  been developed method for the determination of 
leflunomide by RP- HPLC. They developed method for determination of leflunomide by 
 column and acetonitrile-water as 
mobile phase. Comparison of spectra recorded with a diode-array detector during elution 
of the leflunomide peak enabled determination of method specificity [12]. 
2.10  S. Weng has developed method for determination of leflunomide  tablets by  
HPLC.  A HPLC method was established for the amount determination of leflunomide 
tablets.  Hypersil ODS2 column (4.6 mm × 250 mm, 5 µm) and acetonitrile-methanol-
0.01 mol/L potassium dihydrogen phosphate (35:35:30) as a mobile phase at a flow rate 
of 1.0 mL/min, were used [13]. 
2.11  M. S. Mohamed, N. G. Mohamed, N. M. El Kousy have been developed 
stability study of drug contains amine group (leflunomide) by  chromatographic  methods.  
They were presented a stability indicating TLC densitometric method for the 
determination of  leflunomide (LEF) in presence of its induced alkali degradation product 
and a stability study of LEF in different media by HPLC method. The proposed TLC 
densitometric method was based on the separation of LEF from its alkali degradation 
product by TLC followed by densitometric measurement of the spots of the intact drug at 
290 nm.  Separation is performed at silica gel F254 (20 × 20 cm) plates using methanol: 
acetonitrile: distiiled water (35: 40: 25) as a developing system [14].  
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reversed-phase HPLC was established by using a Hypersil ODS C18 column and 
methanol-water-phosphoric acid as mobile phase.  The detection wavelength was at 260 
nm.  The flow rate was 1.0 mL min-1.  Naphthalene or p-phenylphenol was selected as the 
internal standard [15].    
2.13  Q. Zhu, J. Hu, H. Sun, H. Song have developed determination of leflunomide  
and A 77-1726 by RP- HPLC. A method for the determination of leflunomide and A 77-
1726 was established by using reversed-phase HPLC on a Hypersil C18 column with 
MeCN-acetate buffer solution as the mobile phase for gradient elution.  The wavelengths 
for measurement were 260 and 290 nm, respectively.  The flow rate was 1.4 mL min-1.  
Cinnamic acid was selected as the internal standard [16].  
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3.   AIM OF PRESENT WORK  
            As per discussion in the literature review, UV,TLC,LC-MS and HPLC methods 
for the determination of leflunomide in pharmaceutical dosage forms or in metabolite and 
plasma are reported.  HPLC is the most commonly used method for analysis of 
leflunomide. An extensive literature survey reveals few HPLC methods for estimation of 
leflunomide in pharmaceutical dosage forms as well as biological fluids; however, not all 
of these are stability indicating. Most of the reported methods either do not include stress 
degradation studies or are not completely validated, and they are cumbersome, time-
consuming and expensive. Method validation is an essential step in drug analysis. The 
process confirms that the analytical procedure employed for the analysis is suitable for its 
intended use and shows reliability of the results produced by any method. The primary 
objective of the present work was thus to develop and validate a stability indicating 
HPLC method for the assay of leflunomide from its dosage form (tablets). This work also 
deals with the forced degradation of leflunomide under stress condition like acid 
hydrolysis, base hydrolysis, and oxidation, thermal and photolytic stress. Hence, the 
method is useful for routine quality control analysis and also for determination of 
stability. 
 
The aim and scope of the proposed work are as under: 
 To develop suitable HPLC method for leflunomide. 
 Forced degradation study of leflunomide under stress condition 
 To resolve all major impurities generated during the force degradation studies of 
leflunomide. 
 Perform the validation for the developed method. 
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4. EXPERIMENTAL 
4.1 Materials  
Leflunomide standard was provided by Hetero drugs Ltd. Leflunomide tablets 
containing 10mg leflunomide and the inactive ingredient used in drug matrix were 
obtained from market. Analytical grade ammonium acetate was purchased from Sisco 
Research Pvt. Ltd., Mumbai (India). HPLC grade methanol and water were obtained from 
Spectrochem Pvt. Ltd., Mumbai (India). Analytical grade hydrochloric acid, glacial acetic 
acid, sodium hydroxide pellets and 30% v/v hydrogen peroxide solution were obtained 
from Ranbaxy Fine Chemicals, New Delhi (India).  
 
4.2 Instrumentation 
The chromatographic system used to perform development and validation of this 
assay method was comprised of a LC-10ATvp binary pump, a SPD-M10Avp photodiode-
array detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing 
system (Class-VP 6.13 SP2, Shimadzu).  
 
4.3     Mobile phase preparation 
  The mobile phase consisted of acetonitrile – 0.02M ammonium acetate buffer (60: 
40, v/v). To prepare the buffer solution, 1.5416 g ammonium acetate were weighed and 
dissolve in 1000 ml HPLC grade. Mobile phase was filtered through a 0.45 μm nylon 
membrane (Millipore Pvt. Ltd. Bangalore, India) and degassed in an ultrasonic bath 
(Spincotech Pvt. Ltd., Mumbai).  
 
4.4   Diluent  Preparation  
A mixture of acetonitrile-buffer (50:50, v/v) was used as diluent. 
 
4.5 Standard Preparation  
Standard solution containing leflunomide (100 µg/mL) was prepared by 
dissolving accurately about 10.0 mg in 100 mL volumetric flask by diluent [acetonitrile-
buffer (50:50, v/v)] (stock standard solution). 10 mL of stock solution was pipetted out 
into 50 mL volumetric flask and dilute up to mark with diluent (standard solution). The 
concentration obtain was 20 µg/mL of leflunomide. 
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4.6 Test Preparation  
Twenty tablets were weighed and the average weight of tablet was determined. 
From these, five tablets were weighed and transfer into a 500 ml volumetric flask. About 
50 ml diluent was added and sonicated for a minimum 30 min. with intermittent shaking.  
Then content was brought back to room temperature and diluted to volume with diluent. 
The sample was filtered through 0.45μm nylon syringe filter. 10 mL of filtrate stock 
solution was pipetted out into 50 mL volumetric flask and dilute up to mark with diluent 
The concentration obtained was 20 μg/ml of Lelunomide.  
 
4.7 Chromatographic Conditions  
Chromatographic analysis was performed on SGE SS Wakosil (150mm ×  4.6mm 
i.d., C8RS 5 µm particle size) column. The mobile phase was consisted of acetonitrile and 
0.02M ammonium acetate buffer (60:40, v/v). The flow rate of the mobile phase was 
adjusted to 1.0 mL/min and the injection volume was 20 µl. Detection was performed at 
260nm. 
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5.  RESULT AND DISCUSSION 
5.1 Development and Optimization of the HPLC Method 
 Proper selection of the method depends upon the nature of the sample (ionic or 
ionisable or neutral molecule), its molecular weight and solubility. Leflunomide is 
dissolved in polar solvent hence RP-HPLC was selected to estimate them. To develop a 
rugged and suitable HPLC method for the quantitative determination of leflunomide, the 
analytical conditions were selected after testing the different parameters such as diluents, 
buffer, buffer concentration, organic solvent for mobile phase and mobile phase 
composition and other chromatographic conditions. Our preliminary trials using different 
composition of mobile phases consisting of water with methanol or acetonitrile, did not 
give good peak shape.  
 The mobile phase consisted of acetonitrile – 0.02M ammonium acetate buffer (60: 
40, v/v). To prepare the buffer solution, 1.5416 g ammonium acetate was weighed and 
dissolves in 1000 ml HPLC grade water. Mobile phase was filtered through a 0.45 μm 
nylon membrane (Millipore Pvt. Ltd. Bangalore, India) and degassed in an ultrasonic bath 
(Spincotech Pvt. Ltd., Mumbai).  
 By using 0.02M ammonium acetate buffer in 1000 ml of buffer and keeping 
mobile phase composition as acetonitrile-ammonium acetate buffer (60: 40, v/v), best 
peak shape was obtained. For the selection of organic constituent of mobile phase, 
acetonitrile was chosen to reduce the longer retention time and to attain good peak shape.  
Figure 2 and 3 represents wavelength selection and PDA scan of standard preparation. 
Figure 4 and 5 represents the chromatograms of standard and test preparation 
respectively. 
 
Figure 2: Wavelength selection of standard preparation 
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Figure 3: PDA scan of standard preparation 
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Figure 4: Chromatogram of standard preparation 
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Figure 5: Chromatogram of test preparation 
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5.2 Degradation Study 
The degradation samples were prepared by transferring powdered tablets, 
equivalent to 10.0 mg leflunomide into a 250 mL round bottomed flask. Then drug 
content were employed for acidic, alkaline and oxidant media and also for thermal and 
photolytic stress conditions. After the degradation treatments were completed, the stress 
content solutions were allowed to equilibrate to room temperature and diluted with 
diluent to attain 20 µg/ mL leflunomide concentrations. Specific degradation conditions 
were described as follows.  
 
5.2.1 Acidic condition 
Acidic degradation study was performed by heating the drug content in 1 N HCl at 
60° C for 30 min and mixture was neutralized. In acidic degradation, it was found that 
around 4 % of the drug degraded. (Figure 6) 
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Figure 6: Chromatogram of acidic forced degradation study 
 
5.2.2 Alkaline condition 
Alkaline degradation study was performed by ambient temperature in 0.005N 
NaOH for 45 min and mixture was neutralized. In alkali degradation, it was found that 
around 3-4 % of the drug degraded. (Figure 7) 
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Figure 7: Chromatogram of alkali forced degradation study 
 
5.2.3 Oxidative condition 
Oxidation degradation study was performed by heating the drug content in 30% 
v/v H2O2
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 at 80° C for 45 min. Major degradation was found in oxidative condition that 
product was degraded up to 24 %. The major impurity peaks was found at 1.62 min. 
(Figure 8) 
 
Figure 8: Chromatogram of oxidative forced degradation study 
 
5.2.4 Thermal condition 
Thermal degradation was performed by exposing solid drug to dry heat of 80˚  C in 
a conventional oven for 72 hr. In thermal degradation, it was found that around 0.90% of 
the drug degraded. (Figure 9) 
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Figure 9: Chromatogram of thermal degradation study 
 
5.2.5 Photolytic condition 
Photolytic degradation study was performed by exposing the drug content in UV-
light for 72 hours. In photolytic degradation, it was found that around 0.86% of the drug 
degraded. (Figure 10) 
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Figure 10: Chromatogram of UV-light degradation study 
 
5.3 Method Validation 
5.3.1 Specificity 
   The specificity of the method was determined by checking the interference of 
placebo with analyte and the proposed method was eluted by checking the peak purity of 
leflunomide during the force degradation study. The peak purity of the leflunomide was 
found satisfactory (0.9999) under different stress condition. There was no interference of 
any peak of degradation product with drug peak. 
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5.3.2 Linearity 
Seven points calibration curve were obtained in a concentration range from 8-32 
μg/ml for leflunomide. The response of the drug was found to be linear in the 
investigation concentration range and the linear regression equation was y = 8E+06x-
1652.8 with correlation coefficient 0.9983. (Figure 11) Chromatogram obtain during 
linearity study were shown in figure 12-18. 
 
Linerity study for Leflunomide
y = 8E+06x - 1652.8
R2 = 0.9983
-1000000
0
1000000
2000000
3000000
4000000
0 0.1 0.2 0.3 0.4 0.5
Concentration(mg/ml)
Pe
ak
 a
re
a
 
Figure 11: Linearity curve for Leflunomide 
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Figure 12: Linearity study chromatogram of level-1 (40%) 
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Figure 13: Linearity study chromatogram of level-2 (60%) 
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Figure 14: Linearity study chromatogram of level-3 (80%) 
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Figure 15: Linearity study chromatogram of level-4 (100%) 
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        Figure 16: Linearity study chromatogram of level-5 (120%) 
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         Figure 17: Linearity study chromatogram of level-6 (140%) 
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Figure 18: Linearity study chromatogram of level-7 (160%) 
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5.3.3 LOD and LOQ 
 The limit of detection and limit of quantification were evaluated by serial dilutions 
of leflunomide stock solution in order to obtain signal to noise ratio of 3:1 for LOD and 
10:1 for LOQ. The LOD value for Leflunomide was found to be 0.008 ppm and the LOQ 
value 0.04 ppm. Chromatogram of LOD and LOQ study were shown in Figure 19-20. 
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Figure 19: Chromatogram of LOD Study of Leflunomide  
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Figure 20: Chromatogram of LOQ study of Leflunomide 
 
5.3.4 Precision 
 The result of repeatability and intermediate precision study are shown in Table 1. 
The developed method was found to be precise as the %RSD values for the repeatability 
and intermediate precision studies were < 0.63 % and < 0.69 %, respectively, which 
confirm that method was precise. 
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Table 1: Evaluation data of precision study 
Set Intraday (n = 6) Interday (n = 6) 
1 101.3 100.6 
2 101.1 99.1 
3 100.7 101.0 
4 100.8 99.8 
5 99.6 100.5 
6 101.3 100.6 
Mean 100.8 100.3 
Standard deviation 0.64 0.69 
% RSD 0.63 0.69 
 
 
5.3.5 Accuracy  
  The HPLC area responses for accuracy determination are depicted in Table 2. The 
result shown that best recoveries  (99.58 - 100.17 %) of the spiked drug were obtained at 
each added concentration, indicating that the method was accurate. Chromatogram obtain 
during accuracy study were shown in Figure 21-23. 
 
Table 2: Evaluation data of accuracy study 
Level (%) 
 
Amount added 
concentration a
Amount found 
concentration 
(mg/ml) 
 a % Recovery  
(mg/ml) 
% RSD 
50 0.01007 0.01002 99.58 1.41 
100 0.01993 0.01997 100.17 1.07 
150 0.03007 0.03002 99.86 0.93 
 
a Each value corresponds to the mean of three determinations 
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Figure 21: Accuracy study chromatogram of level-1 (50%) 
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Figure 22: Accuracy study chromatogram of level-2 (100%) 
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Figure 23: Accuracy study chromatogram of level-3 (150%) 
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5.3.6 Solution stability study 
  Table 3 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 8˚ C and ambient temperature, as during this time the result was 
not decrease below the minimum percentage. 
Table 3: Evaluation data of solution stability study 
Intervals 
% Assay for test 
preparation solution 
stored at 2-8˚C 
% Assay for test preparation 
solution stored at ambient 
temperature 
Initial 100.9 100.9 
12 h 100.5 100.3 
24 h 99.9 99.7 
36 h 99.0 99.0 
48 h 98.9 98.9 
 
5.3.7 Robustness 
  The result of robustness study of the developed assay method was established in 
Table 4. The result shown that during all variance conditions, assay value of the test 
preparation solution was not affected and it was in accordance with that of actual. System 
suitability parameters were also found satisfactory; hence the analytical method would be 
concluded as robust. Chromatogram obtain during robustness study were shown in figure 
24-28. 
Table 4: Evaluation data of robustness study 
Robust conditions % Assay 
System suitability parameters 
Theoretical plates Asymmetry 
Flow 0.9 ml/min 101.9 6598 0.89 
Flow 1.1 ml/min 102.5 6434 1.92 
ACN-Buffer (62: 38,v/v) 101.3 5922 1.45 
ACN-Buffer (58: 42,v/v) 99.9 5536 1.64 
Column change 100.2 5878 0.17 
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Figure 24: Standard chromatogram (0.9 ml/min flow rate) 
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Figure 25: Standard chromatogram (1.1 ml/min flow rate) 
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      Figure 26: Standard chromatogram (ACN-Buffer (62: 38, v/v)) 
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      Figure 27: Standard chromatogram (ACN-Buffer (58: 42, v/v)) 
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Figure 28: Standard chromatogram (Column change) 
 
5.3.8 System suitability 
  A system suitability test of the chromatographic system was performed before 
each validation run. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate and % RSD of peak area were determined for same. 
Acceptance criteria for system suitability, asymmetry not more than 2.0, Theoretical plate 
not less then 5000 and % RSD of peak area not more then 2.0, were full fill during all 
validation parameter.  
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6. CALCULATIONS AND DATA 
 Calculation formula used 
    
1. Calculation formula for % assay of   Leflunomide 
 
WeightTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay 500
50
10
100
% ×××=  
 
StandardofPotency
ClaimLable
WeightTestMean
×××
10
50  
 
2. Relative standard deviation 
 
100% ×=
sMeasurmentofValueMean
sMeasurmentofDeviationStandard
RSD  
 
3. Recovery 
100×=
AddedAmount
foundAmount
Recovery%  
 
4. Amount found  
ionConcentratStandard
AreaStandardMean
AreaTestMean
mlmgFoundAmount ×=)/(  
 
5. Amount added 
   
Volume
Weight(mg/ml)AddedAmount =  
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Specificity Study for Analytical Method Validation of Leflunomide Tablets 
 
Standard weight (mg) 9.9     
Standard dilution 100 10 50   
Standard potency 100 %     
Standard concentration (mg/ml) 0.0198     
      
Replicate 1 2 3 4 5 
Standard area 1808432 1840253 1816260 1828070 1810243 
Mean standard area 1820652     
Stdev. 13380.88     
% RSD 0.73     
 
Replicate Test area 
1 1852173 
2 1853398 
Mean Test Area 1852786 
Test Weight (mg) 520.6 
Label claim (mg) 10 
Mean Test Weight (mg) 104.1 
% Assay 100.7 % 
 
 
Calculation: 
Prototype calculation for one set: 
 
6.520
500
50
10
100
9.9
1820652
1852786% ×××=Assay 100
10
1.104
10
50
×××  
 
   = 100.7 % 
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Linearity Study for Analytical Method Validation of Leflunomide Tablets 
 
 
 
 
 
 
 
Standard weight (mg) 10.0     
Standard dilution 100 10 50   
Standard potency 100.0 %     
Standard concentration (mg/ml) 0.02     
Concentration of linearity stock 
solution (mg/ml) 0.10 
    
      
Replicate 1 2 3 4 5 
Standard area 1994701 2001115 1976720 1998747 1982769 
Mean standard area 1990810     
Stdev 9460.60     
% RSD 0.48     
Concentration 
level (%) 
Volume of 
linearity stock 
solution taken (ml) 
Diluted to 
(ml) 
Final 
concentration 
(mg/ml) 
Mean area 
40 4.0 50 0.0800 824173 
60 6.0 50 0.1200 1200159 
80 8.0 50 0.1600 1599143 
100 10.0 50 0.2000 1985006 
120 12.0 50 0.2400 2300324 
140 14.0 50 0.2800 2844738 
160 16.0 50 0.3200 3229026 
  Correlation co-efficient 0.9985 
  Slope 100043718.8 
  Intercept -3364.66 
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Precision Study for Analytical Method Validation of Leflunomide Tablets 
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 1854050 517.2 101.3 
Set 2 1861426 520.1 101.1 
Set 3 1864182 522.9 100.7 
Set 4 1857379 520.3 100.8 
Set 5 1859035 527 99.6 
Set 6 1869721 521.2 101.3 
  Mean 100.8 
  Stdev 0.64 
  % RSD 0.63 
 
 
Calculation: 
Prototype calculation for one set: 
 
2.517
500
50
10
100
2.10
1879590
1854050% ×××=Assay 100
10
1.104
10
50
×××  
 
     = 101.3 % 
 
 
 
 
Standard weight (mg) 10.2     
Standard dilution 100.0 10 50  
Standard potency 100.0 %     
Label claim (mg) 10     
Mean test weight (mg) 104.1     
Standard concentration (mg/ml) 0.022     
      
Replicate 1 2 3 4 5 
Standard area 1879400 1899528 1860614 1862533 1895876 
Mean standard area 1879590     
Stdev. 18123.35     
% RSD 0.96     
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Intermediate precision study for Analytical Method Validation of Leflunomide 
Tablets 
 
Standard weight (mg) 10.5     
Standard dilution 100 10 50   
Standard potency 100.0 %     
Label claim (mg) 10     
Mean test weight (mg) 104.1     
Standard concentration (mg/ml) 0.021     
 
Replicate 1 2 3 4 5 
Standard area 1978682 1970722 1974659 1936770 1988255 
Mean standard area 1969818     
Stdev. 19589.00     
% RSD 0.99     
 
Description Mean area Test weight (mg) % Assay 
Set 1 1889640 520.9 100.6 
Set 2 1869685 523.3 99.1 
Set 3 1880105 516.7 101.0 
Set 4 1866764 519.2 99.8 
Set 5 1905558 526.1 100.5 
Set 6 1893090 522.0 100.6 
  Mean 100.3 
  Stdev 0.69 
  % RSD 0.69 
 
Calculation: 
Prototype calculation for one set: 
 
520.9
500
50
10
100
5.10
1969818
1889640% ×××=Assay 100
10
1.104
10
50
×××     
 
                = 100.6 % 
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Comparison for Precision and Intermediate Precision Study for Analytical Method 
Validation for Leflunomide Tablets 
 
 Set %Assay 
Precision study 
1 101.3 
2 101.1 
3 100.7 
4 100.8 
5 99.6 
6 101.3 
Intermediate precision study 
1 100.6 
2 99.1 
3 101.0 
4 99.8 
5 100.5 
6 100.6 
 Mean 100.5 
 Stdev 0.69 
 % RSD 0.69 
 
 
 
 
Accuracy study for Analytical Method Validation of Leflunomide tablets 
 
 
 
Standard weight (mg) 10     
Standard dilution 100 10 50   
Standard potency 100.0 %     
Standard concentration 
(mg/ml) 0.02     
      
Replicate 1 2 3 4 5 
Standard area 1879031 1876835 1873165 1851423 1850224 
Mean standard area 1866136     
Stdev 14140.5     
% RSD 0.76     
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Solution Stability Study for Analytical Method Validation of Leflunomide Tablets 
 
System suitability of standard preparation for solution stability 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1878278 1869631 1863915 1847318 1817117 
2 1850211 1872058 1838829 1821622 1833189 
3 1850442 1861691 1869999 1832141 1871450 
4 1835810 1865950 1849727 1868811 1831298 
5 1855206 1894245 1854891 1867661 1865992 
Mean 1853989 1872715 1855472 1847511 1843809 
Stdev 15401.03 12656.79 12172.20 21013.25 23653.13 
%RSD 0.83 0.68 0.66 1.14 1.28 
 
 
Solution stability for standard preparation at 2 -8°C 
 After 12 hours After 24 hours After 36 hours 
After 48 
hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1878278 1878278 1878278 1878278 
2 1850211 1850211 1850211 1850211 
3 1850442 1850442 1850442 1850442 
4 1835810 1835810 1835810 1835810 
5 1855206 1855206 1855206 1855206 
1 1881165 1821217 1817736 1830276 
2 1894961 1855473 1836600 1833768 
Mean 1863725 1849520 1846326 1847713 
Stdev 21223.09 17725.42 18949.01 16554.18 
%RSD 1.14 0.96 1.03 0.90 
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Solution stability for standard preparation at room temperature 
 After 12 hours After 24 hours After 36 hours After 48 hours Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1878278 1878278 1878278 1878278 
2 1850211 1850211 1850211 1850211 
3 1850442 1850442 1850442 1850442 
4 1835810 1835810 1835810 1835810 
5 1855206 1855206 1855206 1855206 
1 1871288 1822273 1819577 1891965 
2 1884569 1837046 1829064 1882883 
Mean 1860829 1847038 1845513 1863542 
Stdev 17586.20 17811.62 19370.34 20764.43 
%RSD 0.95 0.96 1.05 1.11 
Solution stability for test preparation at 2 -8°C 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1878278 1869631 1863915 1847318 1817117 
2 1850211 1872058 1838829 1821622 1833189 
3 1850442 1861691 1869999 1832141 1871450 
4 1835810 1865950 1849727 1868811 1831298 
5 1855206 1894245 1854891 1867661 1865992 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 1845687 1846579 1829362 1828331 1811017 
2 1857816 1844600 1840202 1831419 1799570 
Mean 1851752 1845590 1834782 1829875 1805294 
% Assay 100.9 100.5 99.9 99.0 98.9 
Standard weight (mg) 10.1 10.2 10.1 10.0 10.1 
Test weight (mg) 520.6 520.6 520.6 520.6 520.6 
% Difference compare 
to that of Initial  0.4 1.0 1.8 2.0 
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Calculation: 
Prototype calculation for one set: 
 
6.520
500
50
10
100
1.10
1853989
1851752% ×××=Assay 100
10
1.104
10
50
×××  
 
                 = 100.9 % 
 
 
Solution stability for test preparation at room temperature 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1878278 1869631 1863915 1847318 1817117 
2 1850211 1872058 1838829 1821622 1833189 
3 1850442 1861691 1869999 1832141 1871450 
4 1835810 1865950 1849727 1868811 1831298 
5 1855206 1894245 1854891 1867661 1865992 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 1845687 1839228 1825760 1827955 1799719 
2 1857816 1845876 1836855 1830314 1810452 
Mean 1851752 1842552 1831308 1829135 1805086 
% Assay 100.9 100.3 99.7 99.0 98.9 
Standard weight (mg) 10.1 10.2 10.1 10.0 10.1 
Test weight (mg) 520.6 520.6 520.6 520.6 520.6 
% Difference 
compare to that of 
Initial 
 0.5 1.2 1.9 2.0 
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SECTION II: HPLC METHOD DEVELOPMENT AND VALIDATION OF      
COMBINED DOSAGE FORM OF CEFIXIME AND ORNIDAZOLE IN TABLETS 
 
1. INTRODUCTION OF DRUGS 
1.1 Introduction to Cefixime 
Cefixime is an oral third generation cephalosporin antibiotic. It is used to treat 
gonorrhea, tonsilitis,  and pharyngitis. 
 
1.1.1 Description 
Cefixime is chemically (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy 
methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylic acid [Figure 1]. Its molecular formula is C16H15N5O7S2
cephalosporin
 having molecular 
weight 453.45 gm/mole. Cefixime is an oral third generation  antibiotic. It 
is used to treat gonorrhea[1], tonsilitis[2],  and pharyngitis[2]. 
 
 
N
O OH
CH2
O
NH
O
NOO
OH
N
SNH2
HH
 
 
Figure:1 (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy 
methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylic acid 
 
 
 
1.1.2 Phamacology 
Inhibits mucopeptide synthesis in bacterial cell wall. 
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 Pharmacokinetics 
 Distribution : Protein binding is about 65%. 
 Elimination :  About 50% of absorbed dose is excreted unchanged in the urine in 
24 h. Serum t1/2  
 Renal Function Impairment : Moderate impairment (CrCl 20 to 40 mL/min), the 
t
Average 3 to 4 h, but may be as long as 9 h in some healthy 
subjects. 
1/2 prolonged to 6.4 h; severe impairment (CrCl 5 to 20 mL/min), the t1/2 
 Elderly : Average AUCs at steady state in elderly patients are approximately 40% 
higher than average AUCs in healthy adults. 
increased to 11.5 h. 
 Contraindications : Allergy to cephalosporine group of antibiotics. 
1.2 Introduction to Ornidazole 
Ornidazole is a drug that cures some protozoan infections. It is used by the poultry 
industry.It has been investigated for use in Crohn's disease after bowel resection[3]. 
1.2.1 Description 
Ornidazole is chemically 1-chloro-3-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-
2-ol [Figure 2]. It’s molecular formula is C7H10ClN3O3
protozoan
   having molecular weight 219.63 
gm/mole. Ornidazole is a drug that cures some  infections. It is used by the 
poultry industry .It has been investigated for use in Crohn's disease after bowel resection. 
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Figure: 2      1-chloro-3-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol 
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1.2.2 Mechanism of Action 
Ornidazole is a 5-nitroimidazole derivative active against protozoa and anaerobic 
bacteria. It is converted to reduction products that interact with DNA to cause destruction 
of helical DNA structure and strand leading to a protein synthesis inhibition and cell 
death in susceptible organisms. 
Absorption: Readily absorbed (oral and intravaginal); peak plasma concentrations after 2 
hr (oral), 12 hr (intravaginal). 
Distribution: Body tissues and fluids (wide), CSF. Protein-binding: <15%. 
Metabolism: Hepatic. 
Excretion: Via urine (as conjugates and metabolites), via faeces (small amounts); 12-14 
hr (elimination half-life). 
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2. LITERATURE REVIEW 
2.1 Literature Review of Cefixime 
The literature reviews regarding cefixime suggest that various analytical methods 
were reported for its determination as drug, in pharmaceutical formulation and in various 
biological fluids. The literature reviews for analysis of cefixime are as under:  
 
2.1.1 R. Jain, V. K. Gupta, N. Jadon and K. Radhapyari have developed  method for 
the voltammetric determination of cefixime in pharmaceuticals and biological fluids. 
Electroreduction and adsorption of cefixime was studied in phosphate buffer by cyclic 
voltammetry (CV), differential pulse cathodic adsorptive stripping voltammetry 
(DPCAdSV), and square-wave cathodic adsorptive stripping voltammetry (SWCAdSV) 
at hanging mercury drop electrode (HMDE). Cathodic adsorptive stripping voltammetric 
procedures were applied for the trace detrmination of the bulk drug in pharmaceutical 
formulations and in human urine [4]. 
2.1.2 S. F. Choragudi, P. Venkateshwar and V. S. Settaluri have developed novel 
spectrophotometric methods for the determination of cefixime in pharmaceutical 
formulations. The method is based on the formation of colored species on binding of 
cefixime with 0.1% Ferric chloride in H2O in the presence of Potassium ferrocyanide to 
produce a blue colored soln. (λmax at 370 nm) [5]. 
2.1.3 D. G. Shankar, K. Sushma, R. V. Lakshmi, M. N. Reddy, T. K. Murthy and 
S.Y. Rao have developed UV and visible spectrophotometric methods for the 
determination of cefixime. Two spectrophotometric methods were developed for the 
determination of cefixime in pure and in its pharmaceutical formulations.  In UV method 
cefixime showed absorption maxima at 290 nm in aqueous medium, whereas in visible 
spectrophotometric method it reacts with Folin-Ciocalteu (FC) reagent under alkaline 
conditions forming a blue colored chromogen having absorption maxima at 720 nm [6]. 
2.1.4 B. S. Virupaxappa, K. H. Shivaprasad and M. S.Latha have developed a 
simple method for the spectrophotometric determination of cefixime in pharmaceuticals. 
A simple specrtophotometric method for the determination of cefoxamide with 
variamine blue is presented.  The determination is based on the hydrolysis of β-lactum 
ring of cefixime with sodium hydroxide which subsequently reacts with iodate to 
liberate iodine in acidic medium.  The liberated iodine oxidizes variamine blue to violet 
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colored species of maximum absorption at 572nm.  The absorption is measured within 
the pH range of 4.0-4.2 [7].  
2.1.5 R. K. Maheshwari, S. Moondra, M. More, S. P. Prajapati and S. Verma have 
developed quantitative  spectrophotometric determination of cefixime tablet formulation 
using sodium tartarate as hydrotropic solubilizing agent. Based on a large number of 
experiment on solubilization of poorly water-soluble drugs, the author is of the opinion 
that hydrotropy is another type of cosolvency and all water-soluble substances whether 
liqs., solids, or gases may act as solubilizers for poorly water-soluble drugs.  In the 
present investigation, hydrotropic solution of sodium tartarate (2 M) was employed as 
solubilizing agent to solubilize the poorly water-soluble drug cefixime from fine powder 
of its tablet dosage form for spectrophotometric determination in UV region.  Cefixime 
exhibits maximum absorbance at 288 nm and follows Beer's law in concentration range 
of 5-30 mcg/mL [8]. 
2.1.6 R. K. Nanda, J. Gaikwad, A. Prakash, V. K. Ghosh and D. H. Nagore have 
developed method for the estimation of cefixime and erdosteine in its pharmaceutical 
dosage form by spectrophotometric. Two accurate and precise methods were developed 
for the estimation of cefixime and erdosteine in its pharmaceutical dosage form.  First 
method is area under the curve method; the areas under the curve in the range of 294.5-
284.5 nm (for CEF) and 240.0-230.0 nm (for ERD) were selected for the anal.  Second 
method is first order deriv. spectroscopy by solving simultaneous equation, 309.0 nm 
(for CEF) and 227.5 nm (for ERD) were selected for the analysis [9]. 
2.1.7 M. M. Deshpande, A. R. Rote, S. R. Tambe and V. S. Kasture have developed 
method for the spectrophotometric simultaneous determination of cefixime trihydrate 
and ambroxol hydrochloride in tablet dosage form. Two simple, economical, rapid, 
precise, and accurate methods were developed for simultaneous determination of 
cefixime trihydrate and ambroxol hydrochloride in bulk and in their pharmaceutical 
formulations.  The first method based on first deriv. spectrophotometry (Method A) and 
second method based on Vierordt's method (Method B).  The amplitude in first order 
deriv. method is zero-crossing at 238.0 nm and 275.4 nm for ambroxol and cefixime. 
 The amplitude in Vierordt's method at 285.0 nm and 244.4 nm for cefixime and 
ambroxol [10]. 
2.1.8 S. Cai, W. Feng and F. Li have developed a method for determination of 
concentration of cefixime in human plasma by HPLC. An HPLC method to 
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determination the concentration of cefixime in the human plasma was established by 
using HPLC on Thermo Hypersil-Keystone ODS-2 column (5 μm, 4.6 mm x 250 mm) 
with acetonitrile-10 mol L-1 PBS (pH = 2.6) (15:85) as the mobile phase and the 
detection at 291 nm..  The tinidazole was taken as the internal standard [11]. 
2.1.9 V. V. Pisarev, K. V. Zaitseva, L. B. Smirnova, V. G. Belolipetskaya, D. A. 
Kibal'chich and I. E Koltunov have developed method for the determination of 
cefixime blood plasma levels by HPLC. For comparative study of the 
pharmacokinetics of Cemidexor (capsules of 100 mg) and Suprax (capsules of 400 
mg), a method of HPLC with quant. determination of cefixime (the active substance in 
the drugs) in the blood plasma of patients with UV detection.  The data reproducibility 
with an account of the admissibility criterion was observed within the interval of all 
the concentration (0.06-10 mcg/mL).  The accuracy and correctness of the method 
also corresponded to the admissibility criteria.  The lower limit of the quantitative 
determination of the cefexime blood plasma levels was 0.06 mcg/mL.  The 
pharmacokinetics was studied with the open crossed randomized method.  The results 
were sued for calculation of the pharmacokinetic parameters required for estimation of 
the bioequivalence of the drugs.  The statistical analysis of the pharmacokinetic 
parameters showed that cemidoxor and Suprax were bioequivalent [12]. 
2.1.10  B. Huo, L. Zhao, F. Qiu, Y. Sun and Y. Xu have studeid on the content 
determination of cefixime and its pharmacokinetics in human plasma. An HPLC 
method for the determination of cefixime in plasma was presented, and its 
pharmacokinetics in human was studied.  Analysis column was Eclipse XDB-C8 (4.6 
mm x 150 mm, 5 μm), and mobile phase consisted of acetonitrile-PBS (pH 4, 13:87) 
[13]. 
2.1.11  P. B. Shah and K. Pundarikakshudu have developed spectrophotometric, 
difference spectroscopic, and high-performance liquid chromatographic methods for the 
determination of cefixime in pharmaceutical formulations. Three simple and sensitive 
spectrophotometric, difference spectroscopic, and liquid chromatography (LC) methods 
were described for the determination of cefixime.  The 1st method was based on the 
oxidative coupling reaction of cefixime with 3-methyl-2-benzothiazolinone hydrazone 
HCl in presence of ferric chloride.  The absorbance of reaction product was measured at 
the maximum absorbance wavelength (λmax), 630 nm.  The difference spectroscopic 
method is based on the measurement of absorbance of cefixime at the absorbance 
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maximum, 268 nm, and min., 237 nm.  The measured value was the amplitude of 
maxima and min. between 2 equimolar solution of the analyte in different chemical 
forms, which exhibited spectral characteristics.  The conditions were optimized, and 
Beer's law was obeyed for cefixime at 1 to 16 μg/mL and 10 to 50 μg/mL, respectively 
 The 3rd method, high-performance LC, was developed for the determination of 
cefixime using 50 mM potassium dihydrogen phosphate (pH 3.0)-MeOH (78 + 22, 
vol./vol.) as the mobile phase and measuring the response at λmax 286 nm.  The analysis 
was performed on a Lichrospher RPC18 column [14]. 
2.1.12   K. Pasha, C. S. Patil, K. Vijaykumar, S. Ali and V.B. Chimkod have 
developed reverse phase HPLC method for the determination of cefixime in 
pharmaceutical dosage forms. The method was developed using SS aokosil II C18, 
250 × 4.6 mm, 5 μm column with mobile phase composision of acetonitrile methanol 
and 0.5% ammonium acetate 44:16:40 (PH 5).  Flow rate of 0.8 mL/min and UV 
detection at 295 nm linearity was observed over concentration range of 20-100 
μg/mL [15]. 
2.1.13   H. Zhang and Y. Xiao have developed method for the determination of 
cefixime by RP-HPLC. Methods Cefixime was seperated on a Hypersil BDS C18 
column (4.6 mm x 250 mm, 10μm with a mixt. of 0.1 mol·L-1 ammonium acetate 
(adjusted with ammonia solution to pH 7.0) and acetonitrile (96 : 4) as mobile phase. 
 The flow rate was 1.0 mL·min-1
2.1.14   J. Bi and X. Li have developed method for the 
.  The detection wavelength was 254 nm.  The column 
temperature was 35 °C [16]. 
determination of cefixime in 
capsules by HPLC. An HPLC method for determination of cefixime in cefixime 
capsules was established.  A ZORBAX-C8 column (4.6 mm × 250 mm, 5 μm) was used 
with the mobile phase of acetonitrile and 0.25% tetrabutyl-ammonia (25 mL 0.4 mol/L 
tetrabutyl-ammonia was diluted to 1000 mL with water, and the PH value was adjusted 
to 7.0 with 1.5 mol/L phosphoric acid) (1:2, vol./vol.), and the flow rate was 1.0 
mL/min, and the detective wavelength was 288 nm, and the column temperature was set 
at 25° C[17]. 
2.1.15   S. A. Khan, H. S. Lamba, A. Rathour, V. Budhwaar,  Manjusha, R. Pawa 
and P. Sharma have developed  validated HPLC method for simultaneous determination 
of cefixime and cloxacillin in tablets. A  Kromasil C-18 RP (150 × 4.6 mm) X4μ column 
was used.  The mobile phase was pH 6.5 buffer-MeCN (65:35).  The flow rate was 1.2 
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mL/min and eluent was monitored at 225 nm.  The retention times of cefixime and 
cloxacillin were 4.99 and 13.837, respectively [18]. 
2.1.16   G. Rathinavel, P. B. Mukherjee, J. Valarmathy, L. Samueljoshua, M. 
Ganesh, T. Sivakumar and T. Saravanan, have developed a validated RP-HPLC 
method for simultaneous determination of cefixime and cloxacillin in tablets . The process 
was carried out on C18 column (5 μm, 25 cm × 4.6 mm, i.d) with pH 5.0 phosphate 
buffer-MeCN-MeOH (80:17:3) as a mobile phase at a flow rate of 2 mL/min.  The 
wavelength was fixed at 225 nm.  The retention time of cefixime and cloxacillin was 
5.657 and 6.200 min, respectively  [19]. 
2.1.17   M. V. Dhoka, V. T. Gawande and P. P. Joshi have developed method for the 
simultaneous  estimation of cefixime trihydrate and erdosteine in pharmaceutical dosage 
form by using reverse phase - high performance liquid chromatography. Drugs were 
resolved on a  HiQ Sil C8 column (25 cm × 4.6 mm, 5 μm), utilizing mobile phase of Tetra-
Bu Ammonium Hydroxide (0.1 N aqu.) pH adjusted to 6.5 with Orthophosporic acid (10% 
aq.): ACN in a ratio of 2:1.  Mobile phase was delivered at the flow rate of 1.0 mL/min. 
 Ultra violet Detection was carried out at 254 nm.  Separation was completed within 11 min 
[20]. 
2.1.18   K. Kathiresan, R. Murugan, M. S. Hameed, K. G. Inimai and T. Kanyadhara 
have developed  analytical method  and validation of cefixime and dicloxacillin tablets by 
RP-HPLC. A rapid and sensitive RP- HPLC method with UV-150 detection (220 nm) for 
routine analysis of cefixime and dicloxacillin tablet formulation was developed, 
chromatography was performed with mobile phase contg. a  mixture of potassium 
hydroxide buffer and acetonitrile (60:40 vol./vol.) using column C18, inertstil with flow rate 
1.0 mL/min in the range of 20 mL [21]. 
 
2.2 Literature Review of Ornidazole 
  The literature reviews regarding ornidazole suggest that various analytical 
methods were reported for its determination as drug, in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of ornidazole are as under: 
  
2.2.1 Q. Hao, J. Wang and W. Chen have developed method for the determination 
of ornidazole with fluorescence spectrophotometry. The fluorescence 
spectrophotometry for determination of ornidazole was presented.  The fluorescence 
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intensity of Na dodecyl sulfate (SDS) was quenched by ornidazole and the 
fluorescence quenching intensity of SDS-ornidazole system was proportional to the 
amaunt of ornidazole [22]. 
2.2.2 B. Liu, J. Wang, X. Chen and W. Huang have developed  method for the 
determination of ornidazole tablets by fluorescence spectrophotometry.  Fluorescence 
spectrophotometry was adopted at λex 355 nm and λem 412 nm.  The linear range was 
1.0&times;10-6-2.0&times;10-4 mol/L with the RSD of 3.52%.  This method has 
been successfully applied to the determination of ornidazole tablets with satisfactory 
results [23]. 
2.2.3 B. H. M. Mruthyunjayaswamy, S. M. M. Patil and S.A. Raju have 
developed spectrophotometric determination of ornidazole. Three simple, sensitive, 
selective and economical methods (method A, B and C) for the determination of 
ornidazole were described.  Method A, B and C are based on the formation of yellow, 
blood red and blue colored chromogens when reduced ornidazole in situ reacted with 
vanillin, 1,10-phenanthroline in presence of ferric ions and Folin-Ciocalteau (FC) 
reagents exhibiting λmax at 426, 508.8 and 648 nm, respectively, which obeyed Beer's 
law in the concentration range of 5-25, 2-10 and 5-25 μg/mL respectively.  The results 
of analysis for the three methods were validated statistically and by recovery studied. 
The results are comparable with those obtained with UV spectrophotometric method 
in alc. at 312.8 nm [24]. 
2.2.4  G. Mubeen, V. Prakash and K. Uvesh have developed two 
spectrophotometric methods for determination of ornidazole in tablets. Two simple, 
precise and accurate colorimetric methods were developed and validated for 
determination of ornidazole in bulk and tablet formulation.  These methods involves 
formation of complex diazonium salt of reduced ornidazole with metacresol reagent 
and resorcinol reagent which shows absorption maxima (λmax) at 425 nm and 435 nm 
respecively [25]. 
2.2.5 H. Lu, Y. Peng, Y. Lin and Y. Jin have developed method for the  
determination of ornidazole gel by first order derivative spectrophotometry. A method 
for determing the content of ornidazole gel by first-order derivative spectrophotometry 
was presented. The first-order derivative spectrophotometry was used to determination 
the content of Ornidazole gel at a wavelength of 259 nm and 299 nm [26]. 
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2.2.6 B. Zhang and R. Yang have developed method for the determination of the 
content of ornidazole in its mouthwashes by the first-order derivative 
spectrophotometry. A method for determing the content of ornidazole in ornidazole 
mouthwashes by the first-order derivative spectrophotometry was established [27]. 
2.2.7 P. S. Sarsambi and S. A. Raju have developed visible spectrophotometric 
determination of ornidazole from bulk drug and formulations. The method was based 
on the formation of green colored species with 3-methyl-2-benzothiazolinone 
hydrazone (MBTH) in presence of FeCl3, exhibiting maximum absorption at 623 nm 
[28]. 
2.2.8 A. Salman and C. Suemer have developed method for the spectrophotometric 
assay of ornidazole and nimorazole. Determination of ornidazole (I) and nimorazole 
(II) was presented based on the formation of NO-2 by alkaline hydrolysis of the NO2 
group in I and II.  NO-2 was used to generate the diazonium salt of sulfanilamide 
which was coupled with N-(1-naphthyl)ethylenediamine.  I tablets and ampuls and II 
tablets were assayed.  I was determined via the NH2 group produced by reduction of 
the NO2 group. The resulting NH2 group reacted with p-dimethylaminobenzaldehyde 
[29]. 
2.2.9  N. B. Prakash, S. Birendra, S. Vivake and R. A. Singh have developed a 
validated spectrophotometric method for simultaneous estimation of ofloxacin and 
ornidazole in tablet dosage forms [30]. 
2.2.10  M. I. Toral, C. Soto, P. Jaque, A. E. Tapia and P. Richter have developed 
method for the simultaneous determination of azomycin and ornidazole by first-order 
derivative spectrophotometry. A 1st-order derivative spectrophotometric method for 
the simultaneous determination of azomycin and ornidazole in mixture is reported. 
 The base of method was that the absorption of azomycin and ornidazole, in a medium 
contg. Britton-Robinson buffer at pH 4, depends only on the undissocd. form of 
azomycin and the dissocd. form of ornidazole. And that when the 1st derivative of the 
spectrum is used, azomycin and ornidazole present zero crossing values at 318.4 and 
324.4 nm, respectively.  When both compounds are present together in a sample, it is 
possible to quantify one analyte in the presence of the other.  The best signal/noise 
ratio was found when the 1st derivative of the spectrum was used.  Chemical and 
spectral variables were optimized for the determination of both species.  A good level 
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of repeatability was observed.  The method was applied to the simultaneous of both 
analytes in eggs and poultry feed [31]. 
2.2.11   P. U. Patel, B. N. Suhagia, C. N. Patel, M. M. Patel, G. Y. Patel and G. M. 
Patel  have developed method for the simultaneous spectrophotometric estimation of 
gatifloxacin and ornidazole in mixture. Two simple, rapid, accurate, and economical 
methods were developed for the estimation of gatifloxacin and ornidazole in the 
mixture.  Gatifloxacin has absorbance maxima at 286.2 nm and ornidazole has 
absorbance maxima at 319 nm in distilled water. First method was based on the 
simultaneous equations and second method was based on Q-absorbance ratio. 
 Absorbances at isoabsorptive point 299.2nm and at the λ-max of ornidazole [32]. 
2.2.12   M. F. L. R. Soares, J. L. S. Sobrinho, S. J. Grangeiro, K. E. Ramos da 
Silva, L.D.S. Alves and P. J. Rolim Neto have developed  new dissolution test and 
HPLC-RP method for anti-parasitic ornidazole coated tablets. The dissolution 
conditions were determined after testing Sink conditions, dissolution medium, 
appartus, stirring speed, 24 h stability and medium filtration influence.  The best 
conditions were paddle at a stirring speed of 75 rpm and 900 mL of 0.1 M HCl.  A 
new HPLC quantification method was developed and validated [33]. 
2.2.13     H. Lu, Y. Peng, P. Chen and J. Liao have been developed  method for the 
determination of ornidazole content in ornidazole gel with HPLC. Ornidazole content 
in ornidazole gel was determined with HPLC.  ODS C18 (4.6 mm×150 mm, 5 μm) 
column was adopted, with mobile phase: acetonitrile-water (20:80), detection 
wavelength: 312 nm, flow rate: 1 ml/min and secnidazole as internal standard [34]. 
2.2.14    M. F. L. R. Soares, J. L. Soares-Sobrinho, S. Grangeiro-Junior, K. E. R. 
Silva and P. J. Rolim-Neto have developed methods for the determination of 
ornidazole in coated tablets: development, validation and statistical comparison. The 
antimicrobial drug ornidazole selectively inhibits protozoa and anaerobic bacteria. 
 Official compendia give no method for its quantification.  UV spectrophotometry and 
HPLC methods were developed for ornidazole tablets analysis.  The UV method gave 
the best results when methanol/purified water (45:55) as diluent, sample concentration 
of 10 μg/mL, and absorbance measurement at 320 nm were used.  The HPLC method 
gave the best results when C18 Shim-Pack ODS column (150 × 4.6 mm, 5 μm) , oven 
temp. 30°C, mobile phase methanol/purified water (45:55) acidified to 0.05% 
phosphoric acid, flow rate 1.00 mL/min, sample concentration 40 μg/mL, injection 
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vol. 20.00 μL, and absorbance measurement at 318 nm were used.  The 2 methods 
were statistically equivalent and suitable for ornidazole determination [35]. 
2.2.15 Z. Mu, J. Shang, Q. Zhou and G. Dai have developed method for the 
determination of stability of ornidazole mouthwashes by HPLC. The HPLC seperation 
was carried out on Hypersil ODS column (4.0 mm × 125 mm, 5 μm), using methanol-
water (25:75) as mobile phase. The detection wavelength was 318 nm, the flow rate 
was 1.0 mL/min-1 and the column temperature was 30°C [36]. 
2.2.16  T. Li and L. Chen have developed content determination of ornidazole 
dispersible tablets by HPLC. The separation was performed on a Symmetry C18 
column with methanol-0.01 mol/L monobasic sodium phosphate buffer (45 mL 0.5 
mol/L tetrabutylammonium bromide per 1000 mL buffer, pH 3.5 adjusted by 
phosphoric acid, 40:60 vol./vol.) as mobile phase, flow rate of 1.0 mL/min and 
detection wavelength of 311 nm.  Tinidazole was used as internal standard, and the 
content determination was performed at room temperature [37]. 
2.2.17 L. Guo and Z. Ren have developed method for the determination of 
ornidazole tablets by HPLC. The separation was performed on ODS-C18 column (4.6 
mm × 150 mm, 5 μm) with methanol-purified water (30:70) as mobile phase, flow rate 
of 1.0 mL/min-1 and detection wavelength of 318 nm.  Ornidazole was quantified by 
external standard method [38]. 
2.2.18 S. M.  Ghosh, S. Darbar, P. P. Chowdhury, S. P. Chattopadhyay and 
M. R. Chakraborty have developed method for the simultaneous determination and 
validation of ofloxacin and ornidazole in combined dosage pharmaceutical 
formulation.The method was carried out on an Xterra RP18, 5 μm (4.6 × 250 mm) 
column with a mobile phase consisting of acetonitrile : mixed phosphate buffer 
[0.21012% (w/v) KH2PO4 and 0.10852% (w/v) K2HPO4, in HPLC grade water and 
pH is adjusted to 3.0 with 10% potassium hydroxide soln.] in the ratio 40 : 60.  The flow 
rate was 1.0 mL/min and the effluent was monitored for ofloxacin at 294 nm and for 
ornidazole at 305 nm (Waters 2487 dual absorbance detector) [39]. 
2.2.19 R. Singh, M. Maithani, S. K. Saraf, S. Saraf and R.C. Gupta have 
developed method for the simultaneous estimation of ciprofloxacin hydrochloride, 
ofloxacin, tinidazole and ornidazole by reverse phase - high performance liquid 
chromatography. The separation was achieved by C18 column (Phenomenax, 250 × 4.6 
mm i.d.) coupled with a guard column of same material, in mobile phase 
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acetonitrile:water: Tri ethylamine (25:75).  The pH of mobile phase was adjusted to 6.0 
± 0.1 with 50% ortho phosphoric acid.  The flow rate was 1.0 mL/min-1
2.2.20 D. Nagavalli, R. Rajeev Kumar, P. Rajeev Kumar and T. Devi have 
developed 
 and the 
separated drugs were detected using UV detector at the wavelength of 300 nm [40]. 
RP-HPLC method development and validation for the simultaneous 
estimation of  levofloxacin hemihydrate  and  ornidazole  in tablets. The mobile phase 
was triethylamine (0.5%vol./vol. adjusted to pH 3 using orthophosphoric acid), 
Acetonitrile and MeOH (40:30:30) at a flow rate of 0.5 mL/min.  Detection was carried 
out at 310 nm.  The stationary phase was Phenomenex Luna C18 column (5μ, 150 × 
4.6mm I.D) [41]. 
2.2.21 D. Nagavallai, A. S. K. Sankar, K. Anandakumar, K. Karunambigai 
and M. S. S. N. Raju have developed RP-HPLC method for simultaneous estimation 
of gatifloxacin and ornidazole in tablets.The separation was done using a mobile phase 
consisting of acetonitrile: MeOH: water (50:37.5:12.5).  column used was Hypersil 
C18 (250×4 mm i.d.) 5 μ with a flow rate of 1 mL /min with detection at 280 nm. The 
external standard calibration method was employed for quantification.  An elution 
order of gatifloxacin was 2.58 min and ornidazole was 5.54 min [42]. 
2.2.22 P. N. Ranjane, S. V. Gandhi, S. S. Kadukar and S. S. Ranher have 
developed method for the simultaneous determination of cefuroxime axetil and 
ornidazole in tablet dosage form using reversed-phase high performance liquid 
chromatography. The method was performed with a HiQ-SiL C18 column (250 mm × 
4.6 mm) and photodiode array (PDA) detector, using 0.01 mol/L potassium 
dihydrogen orthophosphate-MeOH (56:44, v/v) as the mobile phase and tinidazole as 
the internal standard [43]. 
 
2.3 Literature Review for Cefixime and Ornidaazole 
 Some method reported for the simultaneous determination of cefixime and 
ornidazole in bulk and pharmaceutical formulation are as under: 
 
2.3.1 R. K. Nanda, J. Gaikwad and A. Prakash have developed method for the 
estimation of cefixime and ornidazole in its pharmaceutical dosage form by 
spectrophotometric method. Two accurate, precise, rapid and economical methods 
were developed for the estimation of cefixime and ornidazole in tablet dosage form. 
 First method was 1st order derivative spectroscopy, wavelengths selected for 
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quantitation were 311.5 nm for cefixime (zero cross for ornidazole) and 290.0 nm for 
ornidazole (zero cross for cefixime).  Second method was area under curve method; 
area under curve in the range of 295.0-285.0 nm (for cefixime) and 317.0-307.0 nm 
(for ornidazole) were selected for the analysis [44]. 
2.3.2 R. K. Nanda, J. Gaikwad, and A. Prakash have developed method for the 
simultaneous spectrophotometric estimation of cefixime and ornidazole in tablet 
dosage form .Two accurate, precise, rapid, and economical methods were developed 
for the estimation of cefixime and ornidazole in tablet dosage form.  First method was 
based on the simultaneous equations and wavelengths selected for analysis were 290.0 
nm (λmax of Cefixime) and 312.0 nm (λmax of Ornidazole) respectively, in methanol. 
 Second method was Q-analysis method based on absorbance ratio at 2 selected 
wavelengths 303.0 nm (iso-absorptive point) and 312.0 nm (λmax of Ornidazole) [45].  
2.3.3 N. Sreekanth, Ch. B. Rao, P. Ramalingam, P. Seetharamaiah and S. 
Ganapaty have developed method for the simultaneous spectrophotometric 
estimation and validation of cefixime and ornidazole in bulk and pharmaceutical 
dosage forms by absorbance ratio method (q-analysis).  A Simple UV 
Spectrophotometric method was developed for the determination of cefixime and 
ornidazole in bulk and its pharmaceutical formulations by absorbance ratio method. 
 In this method, the absorbances of solutions were measured at two wavelengths, one 
being the wave length maxima of one of the component and other being the 
wavelength of equal absorptivity of the two components. Cefixime and ornidazole 
exhibiting maximum absorbance at the wavelength maxima of 289 nm and 310 nm in 
methanol, respectively [46]. 
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3. AIM OF PRESENT WORK 
Various publications are available regarding determination method of cefixime 
and  ornidazole but most of the methods are applicable to alone cefixime or ornidazole in 
pharmaceutical dosage form or in biological fluids. Voltammetric determination, 
fluorescence spectrophotometry, thin-layer chromatography, first-derivative and 
spectrophotometric and HPLC methods are reported. Only three methods are reported for 
the simultaneous determination of Cefixime and Ornidazole.  
It’s methods are UV spectrophotometric determination, which is able to determine 
cefixime and ornidazole in combined dosage form. So far as our knowledge is concern, 
no HPLC analytical method for the determination of cefixime and ornidazole in combine 
dosage forms has been published. The previous published methods are not directly 
applicable for this issue and need more investigation for method development and 
validation.  
Consequently, the focus in the present study was to develop a validated simple, 
accurate and precise HPLC method for the combination.  
 
The aim and scope of the proposed work are as under: 
 To develop suitable HPLC method for simultaneous determination cefixime and 
ornidazole in tablet formulation. 
 Perform the validation for the developed method. 
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4. EXPERIMENTAL 
4.1 Materials 
Cefixime and Ornidazole standard of was provided by Nectar Drugs Ltd. (India). 
Cefixime and Ornidazole tablets containing 200mg cefixime and 500mg ornidazole 
(mahasaif-OZ) and the inactive ingredient used in drug matrix were obtained from 
market. HPLC grade acetonitrile, methanol and water were obtained from Spectrochem 
Pvt. Ltd., Mumbai (India). 
 
4.2 Instrumentation 
The chromatographic system used to perform development and validation of this 
assay method was comprised of a LC-10ATvp binary pump, a SPD-M10Avp photo-diode 
array detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing 
system (Class-VP 6.13 SP2, Shimadzu). 
 
4.3 Mobile phase preparation 
The mobile phase consisted of Water: Acetonitrile: Methanol (50:25:25, 
v/v).Mobile phase was filtered through a 0.45μm nylon membrane (Millipore Pvt. Ltd. 
Bangalore, India) and degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). 
 
4.4 Diluent preparation :  Methanol used as diluents. 
 
4.5 Standard preparation 
Cefixime standard stock solution containing 2000µg/ml was prepared in a 100 ml 
volumetric flask by dissolving 200.00 mg of cefixime and then diluted to volume with 
diluent. Further take 2 ml of this stock solution in 50 ml volumetric flask and make up to 
mark with diluent (this standard solution of 80µg/ml). Ornidazole standard stock solution 
containing 5000µg/ml was prepared in a 100 ml volumetric flask by dissolving 500.00 
mg of ornidazole and then diluted to volume with diluent. Further take 2 ml of this stock 
solution in 50 ml volumetric flask and make up to mark with diluent (this standard 
solution of 200µg/ml). 
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4.6       Test Preparation 
Twenty tablets were weighed and the average weight of tablet was determined. 
From these, five tablets were weighed and transfer into a 500 ml volumetric flask. About 
50 ml of diluent was added and sonicated for a minimum 30 minute with intermittent 
shaking. Then content was brought back to room temperature and diluted to volume with 
diluent. The sample was filtered through 0.45µm nylon syringe filter. Further take 2 ml of 
this stock solution in 50 ml of volumetric flask and make up to mark with diluent. The 
concentration obtained was 80 µg/ml of cefixime and 200 µg/ml of ornidazole. 
 
4.7 Chromatographic Conditions 
Chromatographic analysis was performed on an Aqurasil SS (150mm ×  4.6mm 
i.d., 5 μm particle size) column. The flow rate of the mobile phase was adjusted to 0.6 
ml/min and the injection volume was 20 μl. Detection was performed at 304nm. 
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5. RESULTS AND DISCUSSION 
5.1 Development and Optimization of the HPLC Method 
In the present work, an analytical method based on LC using UV detection was 
developed and validated for assay determination of cefixime and ornidazole in tablet 
formulation. The analytical conditions were selected, keeping in mind the different 
chemical nature of Cefixime and Ornidazole.  
The column selection has been done on the basis of backpressure, resolution, peak 
shape, theoretical plates and day-to-day reproducibility of the retention time and 
resolution between cefixime and ornidazole peak. After evaluating all these factors, an 
Aqurasil SS (150mm ×  4.6mm i.d., 5 μm particle size) column was found to be giving 
satisfactory results. The selection of water, acetonitrile, methanol based on chemical 
structure of both the drugs.These solvent composition was found suitable for solubility, 
resolution, stability, theoretical plates and peak shape of both components. Best results 
were obtained with Water : Acetonitrile : Methanol  solution improved the peak shape of 
cefixime and ornidazole. Finally, by fixing  mobile phase composition consisting of a 
mixture of Water : Acetonitrile : Methanol (50:25:25, v/v). Optimize mobile phase 
proportion was provide good resolution between Cefixime and Ornidazole. Wavelength 
selection and PDA scan graph are given Figure 3 and 4 respectively. Figure 5 and 6 
represents the chromatograms of standard and test preparation respectively. 
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Figure 3: Wavelength scan overlay of standard preparation 
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Figure 4: PDA scan of standard preparation 
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Figure 5: Chromatogram of standard preparation 
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Figure 6: Chromatogram of test preparation 
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5. Method Validation 
 
5.3.1 Specificity 
 
In an assay, demonstration of specificity requires that it can be shown that the 
procedure is unaffected by the presence of impurities or excipients. In practice, this can 
be done by spiking the drug substance or product with appropriate levels of impurities or 
excipients and demonstrating that the assay results is unaffected by the presence of these 
extraneous materials. 
 There should be no interference of the diluents , placebo at retantion time 
of drug substances. 
 
5.3.2 Linearity 
 
For linearity seven points calibration curve were obtained in a concentration range 
from 0.032-0.128 mg/ml for Cefixime and 0.08-0.32 mg/ml for Ornidazole. The response 
of the drug was found to be linear in the investigation concentration range and the linear 
regression equation for Cefixime was y = 7E+07x + 112940 with correlation coefficient 
0.9992 (Figure 7) and for Ornidazole was y = 8E+07x + 73653 with correlation 
coefficient 0.9999 (Figure 8). Where x is the concentration in mg/ml and y is the peak 
area in absorbance unit. Chromatogram obtain during linearity study were shown in 
Figure 9-15. 
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Figure 7: Linearity curve for Cefixime 
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Linearity study for Ornidazole
y = 8E+07x + 73653
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Figure 8: Linearity curve for Ornidazole 
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Figure 9: Linearity study chromatogram of level-1 (40%) 
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Figure 10: Linearity study chromatogram of level-2 (60%) 
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Figure 11: Linearity study chromatogram of level-3 (80%) 
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Figure 12: Linearity study chromatogram of level-4 (100%) 
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Figure 13: Linearity study chromatogram of level-5 (120%) 
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Figure 14: Linearity study chromatogram of level-6 (140%) 
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Figure 15: Linearity study chromatogram of level-7 (160%) 
 
5.3.3 Precision 
Data obtain from precision experiments are given in Table 1 for intraday and 
interday precision study for both Cefixime and Ornidazole. The RSD values for intra day 
precision study and interday precision study was < 2.0 % for Cefixime and Ornidazole. 
Which confirm that the method was precise. 
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Table 1: Results of precision study 
Set 
Cefixime (%Assay) Ornidazole (%Assay) 
Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Intraday 
(n = 6) 
1 101.4 100.7 99.9 98.8 
2 101.5 101.6 100.0 99.2 
3 99.0 101.6 99.1 99.7 
4 100.4 100.8 100.0 99.6 
5 100.7 99.4 101.3 99.5 
6 99.7 100.1 100.8 100.0 
Mean 100.4 100.7 100.2 99.5 
Standard deviation 0.96 0.86 0.77 0.43 
% RSD 0.96 0.85 0.77 0.43 
 
5.3.5 Accuracy 
Recovery of Cefixime and Ornidazole were determined at three different 
concentration levels. The mean recovery for Cefixime was 98.42-99.59 % and 98.20-99.59 
% for Ornidazole (Table 2). The result indicating that the method was accurate. 
Chromatogram obtain during accuracy study were shown in Figure 16-18. 
 
Table 2: Results of accuracy study 
 
 
Level 
(%) 
 
Amount Added 
Concentrationa
Amount Found 
Concentration 
(mg/ml) 
a % 
Recovery  (mg/ml) 
% 
RSD 
Cefixime 
50 0.03995 0.03932 98.42 0.68 
100 0.08027 0.07994 99.59 0.06 
 150 0.12001 0.11903 99.18 0.25 
Ornidazole 50 0.10015 0.09913 98.99 0.73 
100 0.20092 0.20009 99.59 0.43 
 150 0.30052 0.29510 98.20 0.34 
 
 
a Each value corresponds to the mean of three determinations 
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Figure 16: Accuracy study chromatogram of level-1 (50%) 
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  Figure 17: Accuracy study chromatogram of level-2 (100%) 
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Figure 18: Accuracy study chromatogram of level-3 (150%) 
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5.3.6 Solution stability study 
Table 3 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 8˚ C and ambient temperature with the consideration of      < 2.0 % 
in %assay value difference against interval value. 
 
Table 3: Evaluation data of solution stability study 
 
Intervals %Assay for test solution stored at 2-8˚ C 
% Assay for test solution stored 
at ambient temperature 
 Cefixime Ornidazole Cefixime Ornidazole 
Initial 100.98 99.24 100.98 99.24 
12 h 100.82 98.38 100.68 98.72 
24 h 101.24 98.58 100.59 98.30 
36 h 100.49 98.20 100.27 98.05 
48 h 100.68 98.21 100.42 98.03 
 
 
5.3.7 Robustness:  
The result of robustness study of the developed assay method was established in 
Table 4 and Table 5. The result shown that during all variance conditions, assay value of 
the test preparation solution was not affected and it was in accordance with that of actual. 
System suitability parameters were also found satisfactory, hence the analytical method 
would be concluded as robust. Chromatogram obtain during robustness study were shown 
in Figure 19-23.  
 
Table 4: Evaluation data of robustness study of Cefixime  
 
Robust conditions % Assay System suitability parameters Theoretical plates Asymmetry 
Flow 0.5 ml/min 99.7 1950 1.55 
Flow 0.7 ml/min 99.4 1998 1.37 
Water:ACN:MeoH 
 (48:26:26,v/v) 99.3 2015 1.49 
Water:ACN:MeoH 
(52:24:24,v/v) 100.8 1960 1.37 
Column change 100.8 1940 1.39 
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Table 5: Evaluation data of robustness study for Ornidazole  
 
Robust conditions % Assay System suitability parameters Theoretical plates Asymmetry 
Flow 0.5 ml/min 98.3 4520 1.55 
Flow 0.7 ml/min 99.2 4568 1.49 
Water:ACN:MeoH  
(48:26:26,v/v) 99.2 4589 1.66 
Water:ACN:MeoH 
(52:24:24,v/v) 98.8 4734 1.48 
Column change 99.4 4687 1.53 
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Figure 19:  Standard chromatogram (0.5 ml/min flow rate) 
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Figure 20: Standard chromatogram (0.7 ml/min flow rate) 
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Figure 21: Standard chromatogram (Water: ACN: MeoH, 48:26:26,v/v) 
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Figure 22: Standard chromatogram (Water: ACN: MeoH, 52:24:24,v/v) 
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Figure 23: Standard chromatogram (Column change) 
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5.3.8 System suitability:  
A system suitability test of the chromatographic system was performed before 
each validation run. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate, resolution and % RSD of peak area were determined for 
same. Acceptance criteria for system suitability, Asymmetry not more than 2.0, 
theoretical plate not less then 1800 for Cefixime and 4000 for Ornidazole and  % RSD of 
peak area not more then 2.0, were full fill during all validation parameter.  
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6. CALCULATIONS AND DATA 
 
 Calculation formula used: 
 
1. Calculation formula for Cefixime 
 
 
WeightTest
WeightStandard
AreaMean
AreaTestMean
Assay 500
50
2
100Standard
% ×××=  
 
Standard
2
50 ofPotency
ClaimLable
WeightTestMean
×××  
 
2.  Calculation formula for Ornidazole 
 
 
50
2
100Standard
% ××=
WeightStandard
AreaMean
AreaTestMean
Assay  
 
Standard
2
50500 ofPotency
ClaimLable
WeightTestMean
WeightTest
××××  
 
3. Relative standard deviation  
 
100×=
 tsMeasuremenofValueMean
 tsMeasuremenofDeviationStandard
RSD%  
 
4. Recovery  
 
100×=
AddedAmount
FoundAmount
Recovery%  
 
5. Amount Found  
 
ionConcentratStandard
AreaStandardMean
AreaTestMean
(mg/ml)FoundAmount ×=  
 
6. Amount added 
 
Volume
Weight(mg/ml)AddedAmount =  
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Specificity Study for Analytical Method Validation of Cefixime and Ornidazole 
Tablets 
 
 For  Cefixime 
 
Standard weight (mg) 198.1     
Standard dilution 100 2 50   
Standard potency 100.00 %     
Standard concentration(mg/ml) 0.07924     
      
Replicate 1 2 3 4 5 
Standard area 5715893 5738409 5757335 5720794 5698662 
Mean standard area 5726219     
Stdev 22429.04     
% RSD 0.39     
 
 
 
Replicate Test area 
1 5849050 
2 5852208 
Mean test area 5850629 
Test weight (mg) 5240 
Label claim (mg) 200  
Average test weight (mg) 1045 
% Assay 100.9 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
5240
500
50
2
100
1.198
5726219
5850629% ×××=Assay 100
200
1045
2
50
×××  
 
     = 100.9% 
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 For  Ornidazole 
 
Standard weight (mg) 502.1     
Standard dilution 100 2 50   
Standard potency 100.00 %     
Standard concentration (mg/ml) 0.20084     
      
Replicate 1 2 3 4 5 
Standard area 16333449 16463889 16246363 16459996 16587342 
Mean standard area 16418208     
Stdev. 131485.83     
% RSD 0.80     
 
 
 
Replicate Test area 
1 16831702 
2 16142975 
Mean test area  16487339 
Test weight (mg) 5240 
Label claim (mg) 500 
Mean test weight (mg) 1045 
% Assay 100.6 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
5240
500
50
2
100
1.502
16418208
16487339% ×××=Assay 100
500
1045
10
2
×××  
 
     = 100.6 % 
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Linearity Study for Analytical Method Validation of Cefixime and Ornidazole 
Tablets 
 
 For  Cefixime 
 
 
 
Concentration 
level (%) 
Volume of 
linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final concentration 
(mg/ml) Mean area 
40 0.8 50 0.0320 2417693 
60 1.2 50 0.0480 3412559 
80 1.6 50 0.0640 4611500 
100 2 50 0.0800 5582699 
120 2.4 50 0.0960 6816094 
140 2.8 50 0.1120 7850339 
160 3.2 50 0.1280 8835504 
  Correlation co-efficient 0.9996 
  Slope 67708904.02 
  Intercept 229914.18 
Standard weight (mg) 200    
Standard dilution 100 2 50  
Standard potency 100.00 %     
Standard concentration (mg/ml) 0.0800     
Concentration of linearity stock 
solution (mg/ml) 2.0000     
      
 Replicate 1 2 3 4 5 
Standard area 5604344 5641130 5591967 5614212 5580819 
Mean standard area 5606494     
Stdev 23098.06     
% RSD 0.41     
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 For  Ornidazole 
 
Standard weight (mg) 500    
Standard dilution 100 2 50   
Standard potency 100.00%    
Standard concentration 
(mg/ml) 0.2000 
  
Concentration of linearity 
stock solution (mg/ml) 5.0000 
  
     
Replicate 1 2 3 4 5 
Standard area 16311700 16218055 16685585 16676698 16651058 
Mean standard area 16508619  
Stdev 225311.40 
% RSD 1.3648107 
 
 
 
Concentration 
level (%) 
Volume of 
linearity stock 
solution taken (ml) 
Diluted to (ml) 
Final 
concentration 
(mg/ml) 
Mean area 
40 0.8 50 0.0800 6750886 
60 1.2 50 0.1200 9895306 
80 1.6 50 0.1600 13293946 
100 2.0 50 0.2000 16371609 
120 2.4 50 0.2400 19938157 
140 2.8 50 0.2800 23096866 
160 3.2 50 0.3200 26292316 
  Correlation co-efficient 0.9999 
  Slope 81849660.27 
  Intercept 149936.95 
 
 
 
 
 
 
Cefixime and Ornidazole…   Part-A (Section-II) 
 
 
105 
 
Precision Study for Analytical Method Validation of Cefixime and Ornidazole 
Tablets 
 
 For  Cefixime 
 
Standard weight (mg) 200.6     
Standard dilution 100 2 50   
Standard potency 100.00 %     
Label claim (mg) 200     
Mean test weight (mg) 1045     
Standard concentration (mg/ml) 0.08024     
      
Replicate 1 2 3 4 5 
Standard area 5598787 5622040 5665748 5655565 5621650 
Mean standard area 5632758     
Stdev 27389.74      
% RSD 0.49     
 
 
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 5712426 5242.1 101.4 
Set 2 5716156 5239.7 101.5 
Set 3 5578575 5240.5 99.0 
Set 4 5650172 5235.0 100.4 
Set 5 5665756 5237.1 100.7 
Set 6 5603900 5232.0 99.7 
  Mean 100.4 
  Stdev 0.96 
  % RSD 0.96 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
5240
500
50
2
100
6.200
5632758
5712426% ×××=Assay 100
200
1045
2
50
×××  
 
 
       = 101.4 % 
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 For Ornidazole 
 
Standard weight (mg) 504.8    
Standard dilution 100 2 50   
Standard potency 100.00 %    
Label claim (mg) 500   
Mean test weight (mg) 1045   
Standard concentration 
(mg/ml) 0.20192 
  
     
Replicate 1 2 3 4 5 
Standard area 16346562 16446640 16394053 16417685 16496779 
Mean standard area 16420344  
Stdev 56293.55 
% RSD 0.34 
 
 
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 16299547 5242.1 99.9 
Set 2 16309009 5239.7 100.0 
Set 3 16159605 5240.5 99.1 
Set 4 16294706 5235 100.0 
Set 5 16511686 5237.1 101.3 
Set 6 16410562 5232 100.8 
  Mean 100.2 
  Stdev 0.77 
  % RSD 0.77 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
5240
500
50
2
100
8.504
16420344
16299547% ×××=Assay 100
500
1045
2
50
×××  
 
 
       = 99.9 % 
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Intermediate Precision Study for Analytical Method Validation of Cefixime and 
Ornidazole Tablet 
 
 For Cefixime 
 
Standard weight (mg) 199.4     
Standard dilution 100 2 50   
Standard potency 100.00 %     
Label claim (mg) 200     
Mean test weight (mg) 1045     
Standard concentration (mg/ml) 0.07976     
      
Replicate 1 2 3 4 5 
Standard area 5557921 5682898 5586269 5523776 5600687 
Mean standard area 5590310     
Stdev 59523.88     
% RSD 1.06     
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 5665308 5240.1 100.7 
Set 2 5705983 5234.5 101.6 
Set 3 5715111 5240.2 101.6 
Set 4 5664013 5237.2 100.8 
Set 5 5587185 5236.8 99.4 
Set 6 5630968 5244 100.1 
  Mean 100.7 
  Stdev 0.86 
  % RSD 0.85 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
5240
500
50
2
100
4.199
5590310
5665308% ×××=Assay 100
200
1045
2
50
×××  
 
 
       = 100.7 % 
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 For  Ornidazole 
 
Standard weight (mg) 502.9     
Standard dilution 100 2 50   
Standard potency 100.00 %     
Label claim (mg) 500     
Mean test weight (mg) 1045     
Standard concentration (mg/ml) 0.20116     
      
Replicate 1 2 3 4 5 
Standard area 16440515 16390827 16528047 16581902 16602235 
Mean standard area 16508705     
Stdev 90863.74     
% RSD 0.55     
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 16261733 5240.1 98.8 
Set 2 16318324 5234.5 99.2 
Set 3 16411742 5240.2 99.7 
Set 4 16379784 5237.2 99.6 
Set 5 16360534 5236.8 99.5 
Set 6 16480035 5244 100.0 
  Mean 99.5 
  Stdev 0.43 
  % RSD 0.43 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
5240
500
50
2
100
9.502
16508705
16261733% ×××=Assay 100
500
1045
2
50
×××  
 
 
       = 98.8 % 
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Comparison for Precision and Intermediate Precision Study for Analytical Method 
Validation for Cefixime and Ornidazole Tablets 
 
 For Cefixime 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 For  Ornidazole 
  
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Set %Assay 
Precision study 
1 101.4 
2 101.5 
3 99.0 
4 100.4 
5 100.7 
6 99.7 
Intermediate precision 
study 
1 100.7 
2 101.6 
3 101.6 
4 100.8 
5 99.4 
6 100.1 
 Mean 100.6 
 Stdev 0.88 
 % RSD 0.88 
 Set % Assay 
Precision study 
1 99.9 
2 100.0 
3 99.1 
4 100.0 
5 101.3 
6 100.8 
Intermediate precision study 
1 98.8 
2 99.2 
3 99.7 
4 99.6 
5 99.5 
6 100.0 
 Mean 99.8 
 Stdev 0.70 
 % RSD 0.70 
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Accuracy Study for Analytical Method Validation of Cefixime and Ornidazole 
Tablets 
 
 For Cefixime 
 
Standard weight (mg) 200     
Standard dilution 100 2 50   
Standard potency 100.0 %     
Standard concentration (mg/ml) 0.0800     
      
Replicate 1 2 3 4 5 
Standard area 5520509 5525633 5533507 5524643 5533950 
Mean standard area 5527648     
Stdev 5875.77     
% RSD 0.11     
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 For  Ornidazole 
 
Standard weight (mg) 500     
Standard dilution 100 2 50   
Standard potency 100.00 %     
Standard concentration (mg/ml) 0.2000     
      
Replicate 1 2 3 4 5 
Standard area 16398847 16272029 16471102 16457597 16404760 
Mean standard area 16400867     
Stdev 78691.99     
% RSD 0.48     
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Solution Stability Study for Analytical Method Validation of Cefixime and 
Ornidazole Tablets 
 
 For  Cefixime 
 
System suitability of standard preparation for solution stability 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours After 48 hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 5605893 5655882 5665783 5565543 5605477 
2 5637408 5630508 5651528 5551578 5591570 
3 5636335 5636335 5639324 5609327 5600386 
4 5633794 5643294 5643284 5600379 5624982 
5 5592862 5700662 5639673 5599677 5598657 
Mean 5621258 5653336 5647918 5585301 5604214 
Stdev. 20540.85 28094.60 11129.93 25193.67 12632.39 
%RSD 0.37 0.50 0.20 0.45 0.23 
 
 
 
 
 
 
 
 
 
 
 
 
 
Solution stability for standard preparation at 2-8°C 
 After 12 hours After 24 hours After 36 hours After 48 hours Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 5605893 5605893 5605893 5605893 
2 5637408 5637408 5637408 5637408 
3 5636335 5636335 5636335 5636335 
4 5633794 5633794 5633794 5633794 
5 5592862 5592862 5592862 5592862 
1 5719853 5734754 5706054 5691094 
2 5711262 5726233 5710253 5660243 
Mean 5648201 5652468 5646086 5636804 
Stdev 49037.27 55931.75 45613.08 32641.55 
%RSD 0.87 0.99 0.81 0.58 
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Solution stability for standard preparation at room temperature 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 5605893 5605893 5605893 5605893 
2 5637408 5637408 5637408 5637408 
3 5636335 5636335 5636335 5636335 
4 5633794 5633794 5633794 5633794 
5 5592862 5592862 5592862 5592862 
1 5731451 5755453 5745447 5710487 
2 5744872 5749675 5749675 5729075 
Mean 5654659 5658774 5657345 5649408 
Stdev 59583.42 66250.32 63882.33 51197.62 
%RSD 1.05 1.17 1.13 0.91 
Solution stability for test preparation at 2-8°C 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 5605893 5655882 5665783 5565543 5605477 
2 5637408 5630508 5651528 5551578 5591570 
3 5636335 5636335 5639324 5609327 5600386 
4 5633794 5643294 5643284 5600379 5624982 
5 5592862 5700662 5639673 5599677 5598657 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 5713873 5709518 5704417 5677516 5632696 
2 5710862 5711332 5701302 5671314 5639304 
Mean 5712368 5710425 5702860 5674415 5636000 
% Assay 100.98 100.82 101.24 100.49 100.68 
Standard weight (mg) 199.3 200.2 201.1 198.4 200.8 
Test weight (mg) 5240 5240 5240 5240 5240 
% Difference compare 
to that of Initial  0.16 -0.26 0.49 0.30 
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Solution stability for test preparation at room temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 5605893 5655882 5665783 5565543 5605477 
2 5637408 5630508 5651528 5551578 5591570 
3 5636335 5636335 5639324 5609327 5600386 
4 5633794 5643294 5643284 5600379 5624982 
5 5592862 5700662 5639673 5599677 5598657 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 5713873 5703194 5673493 5663479 5613009 
2 5710862 5701651 5658991 5659631 5629303 
Mean 5712368 5702423 5666242 5661555 5621156 
% Assay 100.98 100.68 100.59 100.27 100.42 
Standard weight (mg) 199.3 200.2 201.1 198.4 200.8 
Test weight (mg) 5240 5240 5240 5240 5240 
% Difference 
compare to that of 
Initial 
 0.30 0.39  
0.71 
 
0.56 
 
 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
5240
500
50
2
100
3.199
5621258
5712368% ×××=Assay 100
200
1045
2
50
×××  
 
       = 100.98 % 
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 For Ornidazole 
 
System suitability of standard preparation for solution stability 
 
Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 16393465 16540524 16393244 16511362 16410525 
2 16466879 16390827 16307876 16519895 16390827 
3 16406769 16518040 16504809 16485080 16528037 
4 16389095 16581982 16455889 16410097 16581902 
5 16587342 16617285 16501942 16553150 16602235 
Mean 16448710 16529732 16432752 16495917 16502705 
Stdev 83537.34 86520.75 83171.04 53785.74 97254.74 
%RSD 0.51 0.52 0.51 0.33 0.59 
 
 
Solution stability for standard preparation at 2 -8°C 
 After 12 hours After 24 hours After 36 hours After 48 hours Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 16393465 16393465 16393465 16393465 
2 16466879 16466879 16466879 16466879 
3 16406769 16406769 16406769 16406769 
4 16389095 16389095 16389095 16389095 
5 16587342 16587342 16587342 16587342 
1 16238195 16202275 16348420 16232192 
2 16294274 16232170 16295016 16281272 
Mean 16396574 16382571 16412427 16393859 
Stdev 113323.99 132232.68 93433.10 116739.85 
%RSD 0.69 0.81 0.57 0.71 
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Solution stability for standard preparation at room temperature 
 After 12 hours After 24 hours After 36 hours After 48 hours Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 16393465 16393465 16393465 16393465 
2 16466879 16466879 16466879 16466879 
3 16406769 16406769 16406769 16406769 
4 16389095 16389095 16389095 16389095 
5 16587342 16587342 16587342 16587342 
1 16373456 16291874 16231001 16173456 
2 16293191 16372458 16192935 16178191 
Mean 16415742 16415412 16381069 16370742 
Stdev 91428.70 91800.89 134601.44 149614.31 
%RSD 0.56 0.56 0.82 0.91 
Solution stability for test preparation at 2-8°C 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 16393465 16540524 16393244 16511362 16410525 
2 16466879 16390827 16307876 16519895 16390827 
3 16406769 16518040 16504809 16485080 16528037 
4 16389095 16581982 16455889 16410097 16581902 
5 16587342 16617285 16501942 16553150 16602235 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 16303534 16279876 16202275 16144309 16236400 
2 16314484 16199854 16232170 16185361 16186682 
Mean 16309009 16239865 16217223 16164835 16211541 
% Assay 99.24 98.38 98.58 98.20 98.21 
Standard weight (mg) 501.9 502.1 500.9 502.5 501.3 
Test weight (mg) 5240 5240 5240 5240 5240 
% Difference compare 
to that of Initial  
0.86 
 
0.66 
 
1.04 
 
1.03 
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Calculation: 
 
Prototype calculation for one set: 
 
5240
500
50
2
100
9.501
16448710
16309009% ×××=Assay 100
500
1045
2
50
×××  
 
       = 99.24 % 
Solution stability for test preparation at room temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 16393465 16540524 16393244 16511362 16410525 
2 16466879 16390827 16307876 16519895 16390827 
3 16406769 16518040 16504809 16485080 16528037 
4 16389095 16581982 16455889 16410097 16581902 
5 16587342 16617285 16501942 16553150 16602235 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 16303534 16309147 16203898 16104132 16202301 
2 16314484 16285335 16136710 16175920 16160425 
Mean 16309009 16297241 16170304 16140026 16181363 
% Assay 99.24 98.72 98.30 98.05 98.03 
Standard weight (mg) 501.9 502.1 500.9 502.5 501.3 
Test weight (mg) 5240 5240 5240 5240 5240 
% Difference 
compare to that of 
Initial 
 0.52  
0.94 
 
1.19 
 
1.21 
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SECTION III: HPLC METHOD DEVELOPMENT AND VALIDATION OF 
COMBINED DOSAGE FORM OF ATENOLOL AND INDAPAMIDE IN 
TABLETS 
 
1. INTRODUCTION OF DRUGS 
 
1.1 Introduction to Atenolol 
Atenolol (Tenormin) is a selective β1 receptor antagonist, a drug belonging to the 
group of beta blockers (sometimes written β-blockers), a class of drugs used primarily in 
cardiovascular diseases. Introduced in 1976, atenolol was developed as a replacement for 
propranolol in the treatment of hypertension. The chemical works by slowing down the 
heart and reducing its workload. Unlike propranolol, atenolol does not pass through the 
blood-brain barrier thus avoiding various central nervous system side effects [1].  
Atenolol is one of the most widely used β-blockers in the United Kingdom and was 
once the first-line treatment for hypertension. The role for β-blockers in hypertension was 
downgraded in June 2006 in the United Kingdom to fourth-line, as they perform less 
appropriately or effectively than newer drugs, particularly in the elderly. Some evidence 
suggests that even in normal doses the most frequently used β-blockers carry an 
unacceptable risk of provoking type 2 diabetes [2]. 
1.1.1 Description 
Atenolol is chemically (RS)-2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy] 
phenyl}acetamide [Figure 1] and its molecular formula is C14H22N2O3
hypertension
, and molecular 
weight is 266.34 gm/mole. Atenolol can be used to treat cardiovascular diseases and 
conditions such as , coronary heart disease, arrhythmias, angina and to treat 
and reduce the risk of heart complications following myocardial infarction. 
NH2
O
O
OH
NH CH3
CH3
 
 
Figure: 1    (RS)-2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy] phenyl}acetamide 
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1.2 Introduction to Indapamide 
Indapamide is a non-thiazide sulphonamide diuretic drug marketed by Servier, 
generally used in the treatment of hypertension, as well as decompensated cardiac failure. 
The US trade name for indapamide is Lozol [3]. Indapamide is marketed as Natrilix 
outside of the US. Combination preparations with perindopril (an ACE inhibitor 
antihypertensive) are also available.It is described as a thiazide-like diuretic [4]. 
1.2.1 Description 
Indapamide is chemically 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-
sulfamoyl-benzamide [Figure 2]. Its molecular formula is C16H16ClN3O3S  having 
molecular weight 365.84 gm/mole.  Indapamide is a non-thiazide sulphonamide diuretic 
drug. generally used in the treatment of hypertension, as well as decompensated cardiac 
failure. 
N
CH3
NH
O
Cl
S
O
O NH2
 
 
Figure 2 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoyl-benzamide 
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2. LITERATURE REVIEW 
2.1 Literature Review of Atenolol 
The literature reviews regarding atenolol suggest that various analytical methods 
were reported for its determination as drug, in pharmaceutical formulation and in various 
biological fluids. The literature reviews for analysis of atenolol are as under:  
 
2.1.1   L. Dong and J. Huang have developed method for the determination of atenolol 
in human plasma by pseudo reversed phase liquid chromatography-tandem mass 
spectrometry. Previous HPLC determination of atenolol on reversed-phase packings has 
often required a mobile phase contg. 3 components: organic modifier, buffer, and ion-
pairing reagent or organic amine.  In addition to the complexity of the eluents employed, 
alkyl sulfonates and organic  amines in the mobile phase can reduce the life of silica-
based bonded columns [5]. 
2.1.2  J. Petri, A. Kaunzinger, A. Niemoeller and M. Karas have developed method 
for the quality control of tablets by near infrared (NIR)-spectroscopy. With respect to 
enalapril tablets simultaneous analysis by HPLC, according to USP 26 was carried out.  It 
was investigated if such methods allow a determination of active ingredients in tablets 
within limits of +/- 10% of declaration.  It was shown that it is possible to set up 
calibration models to quantify active ingredients in tablets independent of adjuvants or 
optical appearance.  Additional it could be shown that NIR-spectroscopy is also 
applicable to determine the concentration of active ingredients in blister-packed tablets 
[6]. 
2.1.3   K. Basavaiah and U. Chandrashekar have been developed method for the  
determination of atenolol in pharmaceuticals by HPLC and spectrophotometry. Two rapid 
assay procedures using HPLC and visible light spectrophotometry were developed for the 
determination of atenolol in pharmaceutical formulations.  The HPLC determination was 
carried out on a reversed-phase Hypersil ODS 5 µ column using a mobile phase 
consisting of ammonium acetate (pH 4.5)-acetonitrile (50:50) at a flow rate of 0.8 
mLmin-1 
2.1.4  A. Weich, D. Carvalho de Oliveira, J. de Melo, K. Goebel and C. M. B. Rolim 
have 
with UV-detection at 225 nm.  The spectrophotometric method was based on the 
formation of a stable donor-acceptor complex between atenolol and chloro-anilic acid in 
acetonitrile medium.  The resulting intensive red color was  measured at 520 nm.  [7]. 
validated of UV spectrophotometric and HPLC methods for quantitative 
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determination of atenolol in pharmaceutical preparations .A rapid and sensitive RP-HPLC 
method with UV detection and UV spectrophotometric method for routine control of 
atenolol in tablets was developed.  Chromatography was performed with mobile phase 
contg. a mixture of 10 mM ammonium acetate buffer (pH 7.0) and acetonitrile (80:20 
vol./vol.).  The samples were injected onto Purospher RP-18 (250 mm × 4.6 mm, 5 μm) 
column.  The flow rate was 0.8 mL.min-1
2.1.5  Y. Tang and L. Gu have developed method for the 
.  The samples were detected at 275 nm [8]. 
determination of atenolol in 
human plasma by RP-HPLC-FLD.A RP-HPLC-FLD method for the determination of 
atenolol in human plasma was established.  Atenolol was extracted by organic solvent 
(acetoacetate-isopropanol = 4:1), and then was determined and quantified with internal 
standard.  The separation was performed on Phenomenex C18 (4.6 mm × 250 mm, 5 μm) 
with a mobile phase consisting of water (25 mmol/L-1 sodium dihydrogen phosphate and 
5 mmol/L-1
2.1.6  O. H. Weddle, E. N. Amick and W.D. Mason have developed method for 
 sodium laurylsulfate) and acetonitrile (70:30, vol./vol.).  The detective 
wavelength was as follows: λex = 226 nm and λem = 310 nm [9]. 
rapid 
determination of atenolol in human plasma and urine by HPLC. A rapid, specific, HPLC 
determination of atenolol (I) [29122-68-7] in plasma and urine was developed. The 
method employed selective extraction with 10% butanol in hexane, reversed-phase liquid 
chromatography with heptanesulfonic acid, and fluorescence detection to measure 
concentrations as low as 20 ng I/mL of plasma.  The assay was valid in the presence of 
plasma and urine substances.  The detection limit was 3 ng/mL [10]. 
2.1.7  L. Vlase, S. Leucuta and S. Imre have developed an HPLC method and 
validated for determination of atenolol in human plasma. An HPLC method with 
fluorescence detection for atenolol determination in human plasma was developed and 
validated, using metoclopramide as internal standard  After protein pptn. with perchloric 
acid, atenolol was separated at 30 °C on a C18 column, 150 mm x 4.6 mm, 5 /m.  The 
mobile phases consisted of a mixture of acetonitrile:sodium dihydrogen phosphate 40 
mM, pH3 with phosphoric acid 85%, 10:90 (solvent A), and acetonitrile (solvent B).  The 
elution was made in gradient mode: 0-4 min 0%B, 4-8 min 30% B, 8-13 min 0%B, at I 
ml/min.  The excitation and emission wavelengths were Ex/Em = 235/315 nm for 7.5 
min, and 309/356 until 13 minute [11]. 
2.1.8  X. Guo, J. Zhao L. Wang  and  Y.Cai have developed method for the 
determination of atenolol in atenolol tablets by HPLC. The separation was performed on a 
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Dinamonsil-C18 and column, methanol-water (550:470) 1000 mL. C7H15SO3Na  960 mg 
and CH3COONa 82 mg were add HOAc 0.57 mL as the mobile phase; the flow rate was 
1.0 mL/min-1
2.1.9  D. Radulovic, L. Zivanovic, G. Velimirovic and D. Stevanovic have developed 
method for 
; the detection wavelength was 276 nm, and the column temperature  was 
28° [12]. 
high -performance liquid chromatographic determination of atenolol in 
tablets. A reversed-phase HPLC method was developed for the determination of atenolol 
in four oral 100 mg atenolol preparations.  An aliquot of the sample is dissolved in a 
mobile phase consisting of 0.0612M K2HPO4
2.1.10  L. Gong and Y. Liu have developed method for an 
-iso-PrOH-THF (84:10:6, by vol.).  The pH 
was adjusted to 6.7 with phosphate buffer.  Nicotinamide was used as internal standard 
and chromatographed on a Pinkerton column ISRP (GFF-S5-80) 5 μm, 150 × 4.6 mm i.d. 
 The applied column is convenient for the assay at least 90 samples of atenolol without 
degrading column performance.  The detection was performed at 272 nm [13]. 
HPLC analysis of compound 
atenolol tablets. Atenolol (I) and chlorthalidone (II) in compound tablets were dissolved 
in MeOH-0.02 M(NH4)2HPO4 
2.1.11  T. Jiang, W. Wang and X. Zhang have developed method for the 
(9:1) as the mobile phase and determined by HPLC with 
detection at 275 nm.  The recovery was 99.8 and 101.4%, respectively, and the relative 
standaed deviation was 0.69 and 1.9%, respectively, for I and II [14]. 
determination 
the content of atenolol in atenolol injections by HPLC. The studied was established a 
method for determination the content of atenolol in atenolol injections by an ion-pair high 
performance liquid chromatography.  The Betasil C18 column (250 mm × 4.6 mm, 10 m) 
was used; the mobile phase consisted of phosphate buffer-methanol-sodium 
octanesulfonate (800:200:0.5); the detection wavelength was 275 nm; the flow rate was 
1.0 mL/min-1
2.1.12   R. Ceresole, M. A. Moyano, M. T. Pizzorno, and A. I. Segall have developed  
 [15]. 
validated reversed-phase HPLC method for the determination of atenolol in the presence 
of its major degradation product. A reversed-phase liquid chromatography (RP-LC) assay 
method, developed for the quantitative determination of atenolol in the presence of its 
degradation products was described.  The assay involved an isocratic elution of atenolol 
in a Waters μBondapak C18 column using a mobile phase consisting of acetonitrile-
sodium phosphate monobasic (0.08 M, pH 3.0) (10:90, vol./vol.).  The flow rate was 1.0 
mL/min and the analyte monitored at 284 nm [16]. 
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2.1.13  Y. G. Yee, P. Rubin and T. F. Blaschke have developed method for atenolol 
determination by high-performance liquid chromatography and fluorescence detection. A 
high-performance liquid chromatography procedure using a fluorescence detector for the 
analysis of atenolol (I) [29122-68-7] in plasma and whole blood is described.  It 
employed a simple and rapid method of preparation I and metoprolol as the internal 
standard are chromatographed as ion pairs with heptanesulfonic acid [17]. 
2.1.14   S. V. Erram and H. P. Tipnis have been developed method for the simultaneous 
determination of atenolol and nifedipine in solid dosage forms by RP-HPLC. A 
spherisorb ODS surface column was used with a mobile phase of MeOH-aqueous 0.1M 
Na2HPO4 (75:25), pH adjusted to 3 with acetic acid and detection at 238 nm [18]. 
2.1.15  S. Saraf, S. Saraf and  G. Gargl  have developed  new procedure for the 
determination of atenolol and hydrochlorothiazide by spectrophotometry, HPLC and 
HPTLC in combined dosage forms. The invention relates to developing determination 
methods for atenolol and hydrochlorothiazide in combined dosage forms by UV 
spectrophotometry, HPLC and HPTLC [19]. 
2.1.16   D. Durga Rao, N. V. Satyanarayana, S. S. Sait, Y. Ramakoti Reddy and K. 
Mukkanti  have been developed method for the simultaneous determination of losartan 
potassium, atenolol and hydrochlorothiazide in pharmaceutical preparations by stability-
indicating UPLC. A stability-indicating UPLC method was developed for the 
simultaneous quantitative determination of losartan potassium, atenolol, and 
hydrochlorothiazide in pharmaceutical dosage forms in the presence of degradation 
products.  The seperation was achieved on a simple isocratic method (water: acetonitrile: 
tri-Et amine: ortho phosphoric acid (60:40:0.1:0.1, vol./vol.) at 0.7 mL min-1
2.1.17   K. Abdussaleem, D. Boopathy and P. Perumal have developed an 
, a detection 
wavelength of 225 nm) [20]. 
analytical 
method  and validated of losartan potassium and atenolol in combined dosage form by 
RP-HPLC. A simple, specific, accurate, and precise reverse phase high pressure liquid 
chromatography method was developed for the simultaneous determination of losartan 
potassium and atenolol from combined dosage form by reverse phase C18 column 
(Phenomenex C18, 5 μ, 250 mm × 4.6 mm).  The sample was analyzed using 
Triethylamine:Acetonitrile:MeOH in the ratio of 50:30:20 (pH adjusted to 4.0 with 
phosphoric acid) as a mobile phase at a flow rate of 1.2 mL/min and detection at 235 nm 
[21]. 
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2.1.18   J. Kavitha and  and S. Muralidharan  have developed  and validated of new 
method for atenolol, hydrochlorothiazide and losartan potassium by RP-HPLC: its 
application to routine quality control analysis.Simple, rapid, and sensitive UV, HPLC and 
dissolution methods was developed and validated for the analysis of atenolol, 
hydrochlorothiazide, and losartan potassium in tablet formulation.  Best chromatographic 
resolution was achieved on a reverse-phase Phenomenex C18 column using acetonitrile: 
50 mM potassium dihydrogen ortho phosphate (pH 3.5) ratio 50:50 as mobile phase with 
a flow rate of 1 mL/min and isocratic elution with a total run time of 14 minute 
 Sulfadoxine was selected as internal standard.  The retention time of Atenolol, 
hydrochlorothiazide, losartan potassium, and internal stdandard was found to be 5.550, 
3.280, 7.370, and 12.397 respectively.  Detection of the multicompounds was carried out 
at 270 nm [22] 
2.1.19   A. B. Thomas, U. B. Chavan, R. K. Nanda, L. P. Kothapalli, S. N. Jagdale, S. 
B. Dighe and A. D. Deshpande have developed method for the simultaneous RP-HPLC 
analysis of atenolol, hydrochlorothiazide, and losartan potassium in a tablet formulation. 
Simultaneous analysis of atenolol (Atn), hydrochlorothiazide (Hctz) and losartan 
potassium (Los) in solid dosage forms was achieved by reversed-phase HPLC on a C18 
column with a 0.035 M potassium dihydrogen orthophosphate-acetonitrile gradient as 
mobile phase and UV detection at 225 nm [23]. 
2.1.20  El-Walili and M. K. Abdel-Fattah have developed first-derivative UV 
spectroscopy capillary gas liquid and high performance liquid chromatographic methods 
for the simultaneous assay of nifedipine and atenolol in pharmaceutical capsules. The 
drugs in combined preparation have been quantified using the first-derivative spectra of 
their solution in methanol.  The analytical procedure was based on the linear relationship 
between the nifedipine concentration and the min. peak at 390 nm and that between the 
atenolol concentration and min. peak at 282 nm. No spectral interferences from tablet 
excipients were found. For validation of the derivative procedure, a newly gas-liquid 
chromatography (GLC) and high performance liquid chromatography (HPLC) methods 
were developed [24]. 
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2.2 Literature Review of Indapamide 
  The literature reviews regarding indapamide suggest that various analytical 
methods were reported for its determination as drug, in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of indapamide are as under: 
 
2.2.1  C. Xia, X. Wang, Y. Xiong and X. Zhang have developed method for the 
determination of indapamide in human plasma by HPLC-MS and studied on its 
pharmacokinetics. An HPLC-MS assay for determination of indapamide in human 
plasma was development and the bioavailability in healthy volunteers was evaluated. 
 Plasma was extracted with di-Et and separated by a C18 column with a mobile phase of 
methanol-water (include 0.04 tri-Et amine and 0.5 mmol/L-1
2.2.2  L. Tong, D. Qi, K. Bi and X. Chen have developed method for the 
 ammonium acetate). 
 HPLC-MS was performed in the selected ion monitoring mode using target ions at m/z 
364 for indapamide and m/z 275 for chlorpropamide (IS).  The fragmentor voltage was 
25 V [25]. 
determination 
of indapamide in human plasma with high performance LC-MS method and 
bioequivalence study. Plasma concentrations were detected by HPLC-MS method after a 
single oral dose of 2.5 mg individually of test indapamide tablets or the ref. ones, resp. 
 The mobile phase consisted of methanol-1% formic acid (75:25, V/V), and detection 
was performed on a single quadrupole mass spectrometer in pos. selected ion monitoring 
(SIM) mode via atmospheric pressure chemical ionization (APCI) source.  The plasma 
concentrations, pharmacokinetics and bioequivalence of the two preparations were 
measured and calculated [26]. 
2.2.3  Y. Liang, H. Li, W. Chen, X. Liu, G. Wang and L. Xie have developed simple, 
sensitive, and rapid LC-MS method for the quantitation of indapamide in human plasma-
application to pharmacokinetic studies. A sensitive and specific liquid chromatographic 
electrospray ionization mass spectrometry (LC-ESI-MS) method was developed and 
validated for the identification and quantification of indapamide in human plasma.  After 
the addition of the internal standard (IS) and 0.1M NaOH solution, plasma samples were 
extracted with Et2O.  The organic layer was evaporated under a stream of N at 40°.  The 
residue was reconstituted with 200 μL MeOH.  The compounds were separated on a 
stainless-steel column (C18 Shim-pack 5 μm 150 mm × 2.0 mm I.D., Shimadzu) at a 
flow rate of 0.2 mL/min by a gradient elution.  Detection was performed on a single 
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quadrupole mass spectrometer by selected ion monitoring (SIM) mode via an 
electrospray ionization (ESI) source [27]. 
2.2.4  J. Zou, C. Zhao and X. Dai have developed RP-HPLC method for the 
determination of indapamide concentration in human plasma. An RP-HPLC method for 
the determination of indapamide in human plasma was established.  Chromatography 
was conducted on an ULTRON VX-ODS column (5 μm, 4.6 mm × 250 mm) at room 
temperature and detected at 242 nm.  The mobile phase was methanol-acetonitrile-water 
(50:5:45) at a flow rate of 1 mL/min-1
2.2.5  M. J. Legorburu, R. M. Alonso, R. M. Jimenez and E. Ortiz have developed  
method for the 
 [28]. 
quantitative determination of indapamide in pharmaceuticals and urine by 
high-performance liquid chromatography with amperometric detection. A high-
performance liquid chromatography method with amperometric detection for the 
determination of the diuretic indapamide using a μBondapak C18 column is developed. 
 The mobile phase consists of an acetonitrile-water mixture. (45:55, 5mM) in 
KH2PO4K2HPO4 (pH 4.0).  The compound is monitored at +1200 mV with an 
amperometric detector equipped with a glassy carbon working electrode [29]. 
2.2.6  X. Leng, X. Liu and J. Xu have developed HPLC method for the determination 
of indapamide in indapamide sustained-release tablets. Indapamide content in 
indapamide sustained-release tablets was determined.  An HPLC method was adopted. 
 C18 column was used.  The mobile phase consisted of 0.05 mol/L-1 K2H2PO4 solution 
(pH 6.8)-methanol-dichloromethane (9:10:1).  UV detective wavelength was set at 242 
nm [30]. 
2.2.7  Y. Zhu, J. Zhang and D. Tian have developed  method for the determination of 
indapamide by RP-HPLC. A Kromasil C18 column was used with the mobile phase 
composed of water-acetonitrile-methanol-glacial acetic acid (at a ratio of 65:17.5:17.5:0.1). 
 The flow rate was 1.0 mL/min and the detection wavelength was 240 nm [31]. 
2.2.8  L. Li and X. Zhang have developed method for the determination of indapamide 
content in indapamide tablets by HPLC. HPLC was conducted with C18 column and 
methonal-water-glacial acetic acid (40:60:0.1) at flow rate of 1.0 mL/min-1
2.2.9  W. Lin, R. R. Chen and S. Suen have developed method for the 
, detection 
wavelength of 240 nm, column temperature of room temperature and sample volume of 20 
μL  [32]. 
stability studied of 
indapamide in aqueous solutions. The decomposition of indapamide in aqueous solutions 
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followed apparent first-order kinetics.  One hydrolysis product, 4-chloro-3-sulfamoylbenzoic 
acid (CSBA), was efficiently and completely separated from indapamide by HPLC.  The 
pH-log rate plot showed a sigmoidal profile above pH 7 which indicated dissociation of 
indapamide at a pH near its pKa.  Acid-and base-catalyzed hydrolysis of indapamide were 
observed in solutions at pH < 3.25 and pH>7.  The decomposition of indapamide in basic 
solutions was faster than in acidic solutions.  Raising the temparature from 25°Cto 50° C 
increased the hydrolysis rate about 5-7 fold.  The activation energy obtained from an 
Arrhenius plot was in the range of 12-16 kcal/mol which indicated that hydrolysis dominated 
the degradation process.  The ionic strength, buffer concentration and buffer species showed 
no significant effect on the hydrolysis of indapamide around pH 3.25 [33]. 
2.2.10   M. V. Padval and H. N. Bhargava have developed method for the liquid 
chromatographic determination of indapamide in the presence of its degradation products. 
Indapamide (I) and its degradation products were determined by HPLC using an 
octadecylsilane column RP-18 and MeOH-aq. AcOH (1%) with triethylamine (0.2%) as 
mobile phase in order to study I solution stability.  The degradation of I was pH-dependent 
and the pH-rate profile was biphasic.  Maximum stability of the drug was observed at pH 5.0 
and 9.5.  The degradation showed weak temperature dependency at both pH's and no 
significant effect of light or dissolved air was observed on the degradation of I [34]. 
2.2.11   B. A. Moussa, A. H. Abadi, H. E. Abou-Youssef and  M. A. Mahrouse  have 
developed method for the simultaneous determination of indapamide and captopril in binary 
mixtures by derivative spectrophotometry and TLC densitometry. Binary mixtures made up 
of indapamide and captopril were simultaneously assayed by 1st- and 2nd-deriv. 
spectrophotometry, 1st derivative ratio spectrophotometry, and TLC densitometry.  In the 1st 
and 2nd derivative spectrophotometric methods, the measurements were taken at 246.4 nm 
and 251.4 nm for indapamide, respectively and at 208.2 nm and 222 nm for captopril, 
respectively.  In the TLC densitometric method, separation of the components of the binary 
mixture was carried out on TLC silica gel F254 plates, using chloroform - glacial acetic acid 
(6.5: 1, vol./vol.) as mobile phase, the chromatograms were scanned at 242 nm and 212 nm 
for indapamide and captopril, respectively [35]. 
2.2.12   N. Erk   has studied comparison of spectrophotometric and an LC method for the 
determination perindopril and indapamide in pharmaceutical formulations.  The 1st method 
was based on HPLC on a reversed-phase column using a mobile phase of phosphate buffer 
pH 2.4 and acetonitrile (7:3 vol./vol.) was used.   In the 2nd method, the 1st derivative 
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spectrophotometry with a zero-crossing technique of measurement was used for the 
simultaneous quantitative determination of perindopril and indapamide in binary mixturs 
without previous separation step.  Linear calibration graphs of 1st derivative values at 225.7 
and 255.4 nm for perindopril and indapamide, respectively.  The 3rd method was based on 
ratio derivative spectrophotometry, the amplitudes in the 1st derivative of the ratio spectra at 
226.5 and at 255.3 nm were selected to determination perindopril and indapamide in the 
binary mixture [36]. 
2.2.13   J. N. Harlikar, A. M. Amlani, R. Pol and S. R. Sharma have developed  method 
for the simultaneous determination of perindopril, indapamide, ramipril, trandolapril in 
pharmaceutical formulations using reverse phase liquid chromatography. They were using a 
mobile phase consisting of 0.05M ammonium acetate (pH 2.5) and acetonitrile in volume 
ratio of 70:30 at a flow rate of 1.0 mL/min.  A Supelco C-18, (3μ, 33 × 4.6 mm) column was 
used as stationary phase.  Quantitation was performed using UV detector at 215 nm [37]. 
2.2.14   H. Jogia, U. Khandelwal, T. Gandhi, S. Singh and D. Modi  have developed    
and validated of a stability-indicating assay method for simultaneous determination of 
perindopril and indapamide in combined dosage form by reversed-phase HPLC. Separation 
was achieved on an XTerra RP18, 5 μm, 150 × 4.6 mm id column at 55° C by using the 
mobile phase NaH2PO4 buffer (pH 2.0; 0.005 M)-acetonitrile (75/25, vol./vol.) at a flow 
rate of 1 mL/min and UV detection at 215 nm [38]. 
 
2.3     Literature Review for Atenolol and Indapamide 
 Some method reported for the simultaneous determination of atenolol and 
indapamide  in bulk and pharmaceutical formulation are as under: 
 
2.3.1 N. Fernandes,   M. S. Nimdeo, V. P. Choudhari, R. R. Kulkarni, V. V. Pande  
and  A. G. Nikalje  have developed dual wavelength and simultaneous equation 
spectrophotometric methods for estimation of  atenolol  and  indapamide  in their combined 
dosage form. Two simple, accurate, and precise UV spectroscopic methods were developed 
for the simultaneous esttmation of atenolol and indapamide in their combined dosage form.  
First method employed  formation and solving of simultaneous equation using 246.4 nm and 
266 nm as 2 wavelengths for formation of simultaneous equations. Second method being dual 
wavelength method, in which 2 wavelengths were selected for each drug in a way so that the 
difference in absorbance is zero for another drug.  Atenolol has equal absorbance at 246.4 nm 
and 254.2 nm, where the differences in absorbance were measured for the determination of 
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indapamide; similarly differences in absorbance at 266 nm and 270.2 nm were measured for 
the determination of atenolol [39]. 
2.3.2 K. R. Gupta, S. B. Wankhede, M. R. Tajne and S. G. Wadodkar have developed 
method for the high performance thin layer chromatographic estimation of  atenolol  and  
indapamide  from pharmaceutical dosage form.  Atenolol and indapamide in combination is 
available as tablet dosage forms in the ratio of 20:1.  HPTLC method was developed for 
analysis of above formulation.  Atenolol and indapamide were separeted on the plate coated 
with silica gel 60G F254 using a mixure of toluene:ethanol:acetone:acetic acid (7:2.5:3:0.3 
vol./vol.) as mobile phase.  Quantification was carried out by the use of densitometer in 
absorbance mode at 266 nm [40].   
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3. AIM OF PRESENT WORK 
In recent time, there is increased tendency towards the development of stability-
indicating assays [41-43], using the approach of stress testing as enshrined in the 
International Conference on Harmonization (ICH) guideline Q1A (R2) [44]. Even this 
approach is being extended to drug combinations [45, 46] to allow accurate and precise 
quantitation of multiple drugs in presence of their degradation products and interaction 
product if any. 
Various publications are available regarding determination method ofAtenolol and 
Indapamide but most of the methods are applicable to alone Atenolol or Indapamide in 
pharmaceutical dosage form or in biological fluids. Thin-layer chromatography, 
fluorometrically, first-derivative and spectrophotometric, Near IR, LC-MS and HPLC 
methods are reported. Only two methods are reported for the simultaneous determination 
of atenolol and indapamide. One is Dual wavelength and simultaneous equation 
spectrophotometric methods for estimation of atenolol and indapamide in their combined 
dosage form. Second is high performance thin-layer chromatography (HPTLC). Which is 
able to determine atenolol  and indapamide in combined dosage form. As far as our 
knowledge is concern, no stability-indicating analytical method for the determination of 
atenolol and indapamide in combine dosage forms has been published. The previous 
published methods are not directly applicable for this issue and need more investigation 
for method development and validation.  
Consequently, the focus in the present study was to develop a validated stability 
indicating HPLC method for the combination, by degrading the drugs together under 
various stress conditions like acid hydrolysis, base hydrolysis, oxidation, thermal and 
photolytic stress which is recommended by ICH guideline. 
 
The aim and scope of the proposed work are as under: 
 To develop suitable HPLC method for simultaneous determination atenolol and 
indapamide  in tablet formulation. 
 Forced degradation study of atenolol and indapamide under stress condition. 
 To resolve all major impurities generated during the force degradation studies of 
atenolol and indapamide. 
 Perform the validation for the developed method. 
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4. EXPERIMENTAL 
4.1 Materials 
Atenolol and Indapamide standard of was provided by Hetero Drugs Ltd., H.P. 
(India). Atenolol and indapamide tablets containing 50mg atenolol and 2.5mg indapamide 
and the inactive ingredient used in drug matrix were obtained from market. HPLC grade 
acetonitrile and water were obtained from Spectrochem Pvt. Ltd., Mumbai (India). 
Analytical grade ammonium acetate, hydrochloric acid, glacial acetic acid, sodium 
hydroxide pellets and 30% v/v hydrogen peroxide solution were obtained from Ranbaxy 
Fine Chemicals, New Delhi (India). 
4.2 Instrumentation 
The chromatographic system used to perform development and validation of this 
assay method was comprised of a LC-10ATvp binary pump, a SPD-M10Avp photo-diode 
array detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing 
system (Class-VP 6.13 SP2, Shimadzu). 
4.3 Mobile phase preparation 
The mobile phase consisted of acetonitrile – 0.02M potassium di hydrogen 
orthophosphate buffer pH 3.0 (50: 50, v/v). To prepare the buffer solution, 2.7218 g 
potassium dihydrogen orthophosphate were weighed and dissolve in 1000 ml HPLC 
grade water and then adjusted to pH 3.0 with phosphoric acid. Mobile phase was filtered 
through a 0.45μm nylon membrane (Millipore Pvt. Ltd. Bangalore, India) and degassed in 
an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). 
4.4 Diluent preparation 
Use Acetonitrile: Buffer (50:50 v/v) used as a diluents. 
4.5 Standard preparation 
Atenolol standard stock solution containing 5000µg/ml was prepared in a 100 ml 
volumetric flask by dissolving 500.00 mg of Atenolol and then diluted to volume with 
diluent. Further take 5 ml of this stock solution in 50 ml volumetric flask and make up to 
mark with diluent (this standard solution of 500µg/ml). Indapamide standard stock 
solution containing 250µg/ml was prepared in a 100 ml volumetric flask by dissolving 
25.00 mg of  indapamide and then diluted to volume with diluent. Further take 5 ml of 
this stock solution in 50 ml volumetric flask and make up to mark with diluent (this 
standard solution of 25µg/ml). 
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4.6 Test Preparation 
 
Twenty tablets were weighed and the average weight of tablet was determined. 
From these, five tablets were weighed and transfer into a 500 ml volumetric flask. About 
50 ml of diluent was added and sonicated for a minimum 30 minute with intermittent 
shaking. Then content was brought back to room temperature and diluted to volume with 
diluent. The sample was filtered through 0.45µm nylon syringe filter. The concentration 
obtained was 500 µg/ml of atenolol and 25 µg/ml of isndapamide. 
4.7 Chromatographic Conditions 
Chromatographic analysis was performed on a Phenomenex make Gemini C18 
column (250mm ×  4.6mm i.d., 5 μm particle size) column. The flow rate of the mobile 
phase was adjusted to 0.8 ml/min and the injection volume was 20 μl. Detection was 
performed at 241nm. 
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5. RESULTS AND DISCUSSION 
5.1 Development and Optimization of the HPLC Method 
In the present work, an analytical method based on LC using UV detection was 
developed and validated for assay determination of atenolol and indapamide in tablet 
formulation. The analytical conditions were selected, keeping in mind the different 
chemical nature of atenolol and indapamide. The development trials were taken by using 
the degraded sample of each component was done, by keeping them in various extreme 
conditions. 
The column selection has been done on the basis of backpressure, resolution, peak 
shape, theoretical plates and day-to-day reproducibility of the retention time and 
resolution between atenolol and indapamide peak. After evaluating all these factors, 
Phenomenex make Gemini C18 column (250mm ×  4.6mm i.d., 5 μm particle size) 
column was found to be giving satisfactory results. The selection of buffer based on 
chemical structure of both the drugs. The acidic pH range was found suitable for 
solubility, resolution, stability, theoretical plates and peak shape of both components. 
Best results were obtained with 0.02M potassium dihydrogen orthophosphate pH 3.0 with 
phospharic acid solution improved the peak shape of atenolol and indapamide. Finally, by 
fixing 0.02M potassium di hydrogen orthophosphate pH 3.0  and mobile phase 
composition consisting of a mixture of 0.02M potassium dihydrogen orthophosphate pH 
3.0  (v/v)-acetonitrile (50:50, v/v). Optimize mobile phase proportion was provide good 
resolution between atenolol and indapamide and also for degradation product which is 
generated during force degradation study. For the selection of organic constituent of 
mobile phase, acetonitrile was chosen to reduce the longer retention time and to attain 
good peak shape. Figure 3 and 4 represent the wavelength selection and PDA scan 
overlay graph of standard preparation respectively. Figure 4 and 5 represent the 
chromatograms of standard and test preparation respectively. 
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Figure 3:  Wavelength scan overlay of standard preparation 
 
 
 
Figure 4: PDA scan of standard preparation 
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   Figure 5: Chromatogram of standard preparation 
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Figure 6: Chromatogram of test preparation 
 
5.2 Degradation Study 
In order to determine the analytical method and assay for the study of stability 
indicating method in tablets of Atenolol combined with Indapamide studies under various 
stressed conditions to conduct forced degradation studies. Regulatory guidance in ICH 
Q2A, Q2B, Q3B and FDA 21CFR section 211 all require the development and validation 
of stability-indicating potency assays. Unfortunately, the current guidance documents do 
not indicate detailed degradation conditions in stress testing. However, the used forced 
degradation conditions, stress agent concentration and times of stress, were found to 
effect degradation, preferably not more than 10% and not complete degradation of active 
materials. The discovery of such conditions was based on trial and error. 
The degradation samples were prepared by transferring powdered tablets, 
equivalent to 50 mg atenolol and 2.5 mg indapamide into a 100 ml round bottom flask. 
Then prepared samples were employed for acidic, alkaline and oxidant media and also for 
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thermal and photolytic stress conditions. After the degradation treatments were 
completed, the stress content solutions were allowed to equilibrate to room temperature 
and diluted with mobile phase to attain 500 µg/ml of atenolol and 25 µg/ml 
5.2.1 Acidic condition 
of indapamide 
concentration. Specific degradation conditions were described as follows. 
 
Acidic degradation study was performed by taking the drug content in 0.1 N HCl 
at room temperature for 1.0 hour and mixture was neutralized. The drug content was 
found to be degrading up to 2-3 % in acidic condition (Figure 7).   
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Figure 7: Chromatogram of acidic forced degradation study 
 
5.2.2 Alkaline condition 
Alkaline degradation study was performed by taking the drug content in 0.1 N 
NaOH at room temperature for 1.0 hour and mixture was neutralized. In alkali 
degradation, it was found that around 1-2 % of the drug degraded (Figure 8).  
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Figure 8: Chromatogram of alkali forced degradation study 
 
 
5.2.3 Oxidative condition 
Oxidation degradation study was performed by taking the drug content in 3.0% 
v/v H2O2
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 at room temperature for 1 hour. In oxidative degradation, it was found that 
around 8-9 % of the drug degraded (Figure 9). 
 
 
Figure 9: Chromatogram of oxidative forced degradation study 
 
5.2.4 Thermal condition 
Thermal degradation was performed by exposing solid drug at 80˚  C for 72 hour. 
Resultant chromatogram of thermal degradation study indicate that atenolol and 
indapamide is found slightly degradation . (Figure 10) 
 
Atenolol and Indapamide…   Part-A (Section-III) 
 
 
145 
 
 
Figure 10: Chromatogram of thermal degradation study 
 
 
5.2.5 Photolytic condition 
Photolytic degradation study was performed by exposing the drug content in UV-
light for 72 h.There is slightly degradation observed in above specific photolytic 
condition. (Figure 11) 
 
 
 
Figure 11: Chromatogram of UV-light degradation study 
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5. Method Validation 
 
5.3.1 Specificity 
 
The specificity of the method was determined by checking the interference of 
placebo with analyte and the proposed method were eluted by checking the peak purity of 
Atenolol and Indapamide during the force degradation study. The peak purity of the 
Atenolol and Indapamide were found satisfactory under different stress condition. There 
was no interference of any peak of degradation product with drug peak. 
 
5.3.2 Linearity 
 
For linearity seven points calibration curve were obtained in a concentration range 
from 0.2-0.8 mg/ml for Atenolol and 0.01-0.04 mg/ml for Indapamide. The response of 
the drug was found to be linear in the investigation concentration range and the linear 
regression equation for Atenolol was y = 7E+06x + 69390 with correlation coefficient 
0.9995(Figure 12) and for Indapamide was y = 1E+08x + 13559 with correlation 
coefficient 0.9989 (Figure 13). Where x is the concentration in mg/ml and y is the peak 
area in absorbance unit. Chromatogram obtain during linearity study were shown in 
Figure 14-20.  
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Figure 12: Linearity curve for Atenolol 
 
 
Atenolol and Indapamide…   Part-A (Section-III) 
 
 
147 
 
 
Linearity study for Indapamide
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Figure 13: Linearity curve for Indapamide 
 
Minutes
0 2 4 6 8 10 12 14
m
AU
0
50
100
150
At
en
ol
ol
In
da
pa
m
id
e
 
Figure 14: Linearity study chromatogram of level-1 (40%) 
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Figure15: Linearity study chromatogram of level-2 (60%) 
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Figure16: Linearity study chromatogram of level-3 (80%) 
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Figure 17: Linearity study chromatogram of level-4 (100%) 
 
 
Minutes
0 2 4 6 8 10 12 14
m
AU
0
200
400
At
en
ol
ol
In
da
pa
m
id
e
 
Figure 18: Linearity study chromatogram of level-5 (120%) 
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Figure 19: Linearity study chromatogram of level-6 (140%) 
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Figure 20: Linearity study chromatogram of level-7 (160%) 
 
 
5.3.3 Precision 
Data obtain from precision experiments are given in Table 1 for intraday and interday 
precision study for both Atenolol and Indapamide. The RSD values for intraday precision 
study and interday precision study was < 2.0 % for Atenolol and Indapamide. Which 
confirm that the method was precise. 
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Table 1: Results of precision study  
 
Set 
Atenolol (%Assay) Indapamide (%Assay) 
Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Intraday 
(n = 6) 
1 99.1 99.9 100.9 101.2 
2 98.9 99.5 100.4 101.8 
3 98.5 99.2 99.8 100.7 
4 99.1 99.7 101.5 101.5 
5 99.2 99.6 100.1 101.7 
6 99.1 100.0 100.5 101.0 
Mean 99.0 99.6 100.5 101.3 
Standard deviation 0.26 0.27 0.60 0.43 
% RSD 0.26 0.28 0.59 0.42 
 
 
5.3.5 Accuracy 
Recovery of Atenolol and Indapamide were determined at three different 
concentration levels. The mean recovery for Atenolol was 98.83-99.06 % and 98.02-100.51 
% for Indapamide (Table 2). The result indicating that the method was accurate. 
Chromatogram obtain during accuracy study were shown in Figure 21-23. 
 
Table 2: Results of accuracy study 
 
 
Level 
(%) 
 
Theoretical 
concentrationa
Observed 
concentration 
(mg/ml) 
a % 
Recovery  (mg/ml) 
%  
RSD 
Atenolol 
50 0.25007 0.24666 98.63 0.49 
100 0.50093 0.49240 98.30 1.68 
150 0.75017 0.74428 99.09 1.38 
Indapamide 
50 0.01250 0.01256 100.51 0.13 
100 0.02510 0.02454 98.02 0.16 
150 0.03753 0.03697 98.50 0.29 
 
a Each value corresponds to the mean of three determinations 
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Figure19: Accuracy study chromatogram of level-1 (50%) 
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 Figure 20: Accuracy study chromatogram of level-2 (100%) 
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Figure 21: Accuracy study chromatogram of level-3 (150%) 
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5.3.6 Solution stability study 
Table 3 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 8˚ C and at ambient temperature with the consideration of      < 2.0 
% in %assay value difference against interval value. 
 
Table 3: Evaluation data of solution stability study 
 
 Intervals 
% Assay for test solution 
stored at 2 -8˚ C 
% Assay for test solution 
stored at ambient 
temperature 
Atenolol Indapamide Atenolol Indapamide 
Initial 99.76 99.44 99.76 99.44 
12 h 99.51 99.26 99.21 99.05 
24 h 99.30 99.38 98.77 98.68 
36 h 98.67 98.59 98.40 98.23 
48 h 98.25 98.47 98.33 98.11 
 
 
 
5.3.7 Robustness:  
The result of robustness study of the developed assay method was established in 
Table 4 and Table 5. The result shown that during all variance conditions, assay value of 
the test preparation solution was not affected and it was in accordance with that of actual. 
System suitability parameters were also found satisfactory; hence the analytical method 
would be concluded as robust. Chromatogram obtain during robustness study were shown 
in Figure 24-30. 
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Table 4: Evaluation data of robustness study of Atenolol 
  
Robust conditions % Assay 
System suitability parameters 
Theoretical plates Asymmetry 
Flow 0.7 ml/min 99.7 1825 1.55 
Flow 0.9 ml/min 100.2 1798 1.37 
Buffer pH 2.8 101.6 1814 1.35 
Buffer pH 3.2 101.3 1920 1.34 
Buffer-ACN (48:52,v/v) 100.1 1805 1.37 
Buffer-ACN (52:48,v/v) 99.5 1886 1.33 
Column change 98.8 1940 1.39 
 
 
 
Table 5: Evaluation data of robustness study for Indapamide  
 
 
Robust conditions % Assay 
System suitability parameters 
Theoretical plates Asymmetry 
Flow 0.7 ml/min 99.0 4857 1.62 
Flow 0.9 ml/min 98.8 4765 1.49 
Buffer pH 2.8 99.5 4813 1.46 
Buffer pH 3.2 99.2 4920 1.63 
Buffer-ACN (48:52,v/v)       100.1 4794 1.48 
Buffer-ACN (52:48,v/v) 98.9 4874 1.63 
Column change 100.5 4890 1.53 
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Figure 24:  Standard chromatogram (0.7 ml/min flow rate) 
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Figure 25: Standard chromatogram 0.9 ml/min flow rate) 
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Figure 26: Standard chromatogram (Buffer: ACN: 48: 52) 
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Figure 27: Standard chromatogram (Buffer: ACN: 52: 48) 
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Figure 28: Standard chromatogram (pH2.8) 
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Figure 29: Standard chromatogram (pH 3.2) 
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Figure 30: Standard chromatogram (Column change) 
 
5.3.8 System suitability:  
A system suitability test of the chromatographic system was performed before 
each validation run. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate, resolution and % RSD of peak area were determined for 
same. Acceptance criteria for system suitability, Asymmetry not more than 2.0, 
theoretical plate not less than 1700 for Atenolol and 4000 for Indapamide and  % RSD of 
peak area not more then 2.0, were full fill during all validation parameter.  
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6. CALCULATIONS  AND DATA 
 
 Calculation formula used: 
 
1. Calculation formula for Atenolol 
 
WeightTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay 500
50
5
100
% ×××=  
 
StandardofPotency
ClaimLable
WeightTestMean
××  
 
2.  Calculation formula for Indapamide 
 
50
5
100
% ××=
WeightStandard
AreaStandardMean
AreaTestMean
Assay  
 
Standard500 ofPotency
ClaimLable
WeightTestMean
WeightTest
×××  
 
3. Relative standard deviation  
 
100×=
 tsMeasuremenofValueMean
 tsMeasuremenofDeviationStandard
RSD%  
 
4. Recovery  
 
100×=
AddedAmount
FoundAmount
Recovery%  
 
5. Amount Found  
 
ionConcentratStandard
AreaStandardMean
AreaTestMean
(mg/ml)FoundAmount ×=  
 
6. Amount added 
 
Volume
Weight(mg/ml)AddedAmount =  
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Specificity Study for Analytical Method Validation of Atenolol and Indamapide 
Tablets 
 
 For Atenolol 
 
Standard weight (mg) 504.1     
Standard dilution 100 5 50   
Standard potency 100.00 %     
Standard concentration (mg/ml) 0.5041     
      
Replicate 1 2 3 4 5 
Standard area 3732471 3711509 3740976 3757018 3753511 
Mean standard area 3739097     
Stdev 18285.64     
% RSD 0.49     
 
 
 
Replicate Test Area 
1 3688425 
2 3695123 
Mean test area 3691774 
Test weight (mg) 934 
Label claim (mg) 50 
Average test weight (mg) 186 
% Assay 99.1 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
934
500
50
5
100
1.504
3739097
3691774% ×××=Assay 100
50
186
××  
 
     = 99.1% 
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 For Indapamide 
 
Standard weight (mg) 24.8      
Standard dilution 100 5 50   
Standard potency 100.00 %     
Standard concentration (mg/ml) 0.0248     
      
Replicate 1 2 3 4 5 
Standard area 2479600 2523433 2497005 2462931 2417787 
Mean standard area 2476151     
Stdev. 39571.13     
% RSD 1.60     
 
 
 
Replicate Test Area 
1 2511048 
2 2510563 
Mean test area 2510806 
Test weight (mg) 934 
Label claim (mg) 2.5 
Mean test weight (mg) 186 
% Assay 100.2 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
934
500
50
5
100
8.24
2476151
2510806% ×××=Assay 100
5.2
186
××  
 
     = 100.2 % 
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Linearity Study for Analytical Method Validation of Atenolol and Indapamide 
Tablets 
 
 For Atenolol 
 
 
 
Standard weight (mg) 500    
Standard dilution 100 5 50  
Standard potency 100.00 %     
Standard concentration (mg/ml) 0.5000     
Concentration of linearity stock 
solution (mg/ml) 1.0000     
      
 Replicate 1 2 3 4 5 
Standard area 3732471 3741509 3739976 3757018 3760911 
Mean standard area 3746377     
Stdev 12067.68     
% RSD 0.32     
Concentration 
level (%) 
Volume of linearity 
stock solution taken 
(ml) 
Diluted to (ml) 
Final 
concentration 
(mg/ml) 
Mean area 
40 2.0 50 0.2000 1577226 
60 3.0 50 0.3000 2294502 
80 4.0 50 0.4000 3027869 
100 5.0 50 0.5000 3676944 
120 6.0 50 0.6000 4436798 
140 7.0 50 0.7000 5181536 
160 8.0 50 0.8000 5869790 
  Correlation co-efficient 0.9999 
  Slope 7164530.71 
  Intercept 141258.00 
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 For Indapamide 
 
 
 
Standard weight (mg) 25.0    
Standard dilution 100 5 50  
Standard potency 100.00%    
Standard concentration (mg/ml) 0.0250     
Concentration of linearity stock 
solution (mg/ml) 0.2500     
      
Replicate 1 2 3 4 5 
Standard area 2479600 2523433 2497005 2462931 2417787 
Mean standard area 2476151     
Stdev 39571.13     
% RSD 1.60     
Concentration 
level (%) 
Volume of linearity 
stock solution taken 
(ml) 
Diluted to 
(ml) 
Final 
concentration 
(mg/ml) 
Mean area 
40 2.0 50 0.0100 992888 
60 3.0 50 0.0150 1427581 
80 4.0 50 0.0200 1966347 
100 5.0 50 0.0250 2505710 
120 6.0 50 0.0300 2864855 
140 7.0 50 0.0350 3434400 
160 8.0 50 0.0400 3847945 
  Correlation co-efficient 0.9991 
  Slope 96266550 
  Intercept 27582.54 
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Precision Study for Analytical Method Validation of Atenolol and Indapamide 
Tablets 
 
 For Atenolol 
 
 
Standard weight (mg) 505.1     
Standard dilution 100 5 50   
Standard potency 100.00 %     
Label claim (mg) 50     
Mean test weight (mg) 186     
Standard concentration (mg/ml) 0.5051     
      
Replicate 1 2 3 4 5 
Standard area 3701935 3714672 3707394 3717855 3722328 
Mean standard area 3712837     
Stdev 8171.70     
% RSD 0.22     
 
 
 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
930
500
50
5
100
1.505
3712837
3640857% ×××=Assay 100
50
186
××  
 
       = 99.1 % 
 
 
 
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 3640857 930 99.1 
Set 2 3661746 937 98.9 
Set 3 3631807 933 98.5 
Set 4 3666983 936 99.1 
Set 5 3649594 931 99.2 
Set 6 3662724 935 99.1 
  Mean 99 
  Stdev 0.26 
  % RSD 0.26 
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 For Indapamide 
 
Standard weight (mg) 25.2     
Standard dilution 100 5 50   
Standard potency 100.00 %     
Label claim (mg) 2.5     
Mean test weight (mg) 186     
Standard concentration (mg/ml) 0.0252     
      
Replicate 1 2 3 4 5 
Standard area 2507402 2523414 2481805 2527691 2496707 
Mean standard area 2507404     
Stdev 18957.96     
% RSD 0.76     
 
Description Mean area Test weight (mg) % Assay 
Set 1 2508955 930 100.9 
Set 2 2515780 937 100.4 
Set 3 2491141 933 99.8 
Set 4 2541280 936 101.5 
Set 5 2492558 931 100.1 
Set 6 2512341 935 100.5 
  Mean 100.5 
  Stdev 0.60 
  % RSD 0.59 
 
 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
930
500
50
5
100
2.25
2507404
2508955% ×××=Assay 100
5.2
186
××  
 
       = 100.9 % 
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Intermediate Precision Study for Analytical Method Validation of Atenolol and 
Indapamide Tablet 
 
 For Atenolol 
 
Standard weight (mg) 504.7     
Standard dilution 100 5 50   
Standard potency 100.00 %     
Label claim (mg) 50     
Mean test weight (mg) 186     
Standard concentration (mg/ml) 0.5047     
      
Replicate 1 2 3 4 5 
Standard area 3723543 3713369 3731098 3700223 3699245 
Mean standard area 3713496     
Stdev 14053.93     
% RSD 0.38     
 
 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
935
500
50
5
100
7.504
3713496
3694345% ×××=Assay 100
50
186
××  
 
       = 99.9 % 
  
 
Description Mean area Test weight (mg) % Assay 
Set 1 3694345 935 99.9 
Set 2 3662681 931 99.5 
Set 3 3658391 932 99.2 
Set 4 3690442 936 99.7 
Set 5 3681086 934 99.6 
Set 6 3697797 935 100.0 
  Mean 99.6 
  Stdev 0.27 
  % RSD 0.28 
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 For Indapamide 
 
Standard weight (mg) 25.3     
Standard dilution 100 5 50   
Standard potency 100.00 %     
Label claim (mg) 2.5     
Mean test weight (mg) 186     
Standard concentration (mg/ml) 0.0253     
      
Replicate 1 2 3 4 5 
Standard area 2517432 2524531 2471652 2537653 2566334 
Mean standard area 2523520     
Stdev 34500.56     
% RSD 1.37     
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 2536558 935 101.2 
Set 2 2541545 931 101.8 
Set 3 2516129 932 100.7 
Set 4 2547402 936 101.5 
Set 5 2546290 934 101.7 
Set 6 2532297 935 101.0 
  Mean 101.3 
  Stdev 0.43 
  % RSD 0.42 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
935
500
50
5
100
3.25
2523520
2536558% ×××=Assay 100
5.2
186
××  
 
       = 10 1.2% 
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Comparison for Precision and Intermediate Precision Study for Analytical Method 
Validation for Atenolol  and Indapamide Tablets 
 
 For Atenolol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 For Indapamide  
 
 
  
   
 
 
 
 
 
 
 Set %Assay 
Precision study 
1 99.1 
2 98.9 
3 98.5 
4 99.1 
5 99.2 
6 99.1 
Intermediate precision 
study 
1 99.9 
2 99.5 
3 99.2 
4 99.7 
5 99.6 
6 100.0 
 Mean 99.3 
 Stdev 0.43 
 % RSD 0.44 
 Set % Assay 
Precision study 
1 100.9 
2 100.4 
3 99.8 
4 101.5 
5 100.1 
6 100.5 
Intermediate precision study 
1 101.2 
2 101.8 
3 100.7 
4 101.5 
5 101.7 
6 101 
 Mean 100.9 
 Stdev 0.64 
 % RSD 0.64 
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Accuracy Study for Analytical Method Validation of Atenolol and Indapamide 
Tablets 
 
 For Atenolol  
 
Standard weight (mg) 500.0     
Standard dilution 100 5 50   
Standard potency 100.0 %     
Standard concentration (mg/ml) 0.500     
      
Replicate 1 2 3 4 5 
Standard area 3683408 3781274 3740772 3718028 3646933 
Mean standard area 3714083     
Stdev 51702.45     
% RSD 1.39     
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 For Indapamide 
 
Standard weight (mg) 25.0     
Standard dilution 100 5 50   
Standard potency 100.00 %     
Standard concentration (mg/ml) 0.0250     
      
Replicate 1 2 3 4 5 
Standard area 2475469 2527270 2506546 2522764 2495910 
Mean standard area 2505592     
Stdev 21017.01     
% RSD 0.84     
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Solution Stability Study for Analytical Method Validation of Atenolol and 
Indapamide Tablets 
 
 For Atenolol 
 
System suitability of standard preparation for solution stability 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 3722471 3731935 3743264 3745354 3730267 
2 3701509 3730672 3717251 3710534 3718622 
3 3719976 3721394 3724929 3744576 3743371 
4 3727018 3717855 3729431 3760345 3744411 
5 3710911 3692328 3759908 3733521 3720765 
Mean 3716377 3718837 3734957 3738866 3731487 
Stdev 10176.63 15983.23 16853.48 18488.62 12147.19 
%RSD 0.27 0.43 0.45 0.49 0.33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Solution stability for standard preparation at 2-8°C 
 After 12 hours After 24 hours After 36 hours 
After 48 
hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 3722471 3722471 3722471 3722471 
2 3701509 3701509 3701509 3701509 
3 3719976 3719976 3719976 3719976 
4 3727018 3727018 3727018 3727018 
5 3710911 3710911 3710911 3710911 
1 3698922 3681093 3657554 3594761 
2 3688356 3690476 3644873 3601981 
Mean 3709880 3707636 3697759 3682661 
Stdev 14193.13 17297.77 33067.55 58214.79 
%RSD 0.38 0.47 0.89 1.58 
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Solution stability for standard preparation at room temperature 
 After 12 hours After 24 hours After 36 hours After 48 hours Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 3722471 3722471 3722471 3722471 
2 3701509 3701509 3701509 3701509 
3 3719976 3719976 3719976 3719976 
4 3727018 3727018 3727018 3727018 
5 3710911 3710911 3710911 3710911 
1 3649378 3656935 3626763 3608972 
2 3656736 3642243 3619364 3689834 
Mean 3698286 3697295 3689716 3697242 
Stdev 32065.22 33898.18 46333.54 41011.11 
%RSD 0.87 0.92 1.26 1.11 
Solution stability for test preparation at 2-8°C 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 3722471 3731935 3743264 3745354 3730267 
2 3701509 3730672 3717251 3710534 3718622 
3 3719976 3721394 3724929 3744576 3743371 
4 3727018 3717855 3729431 3760345 3744411 
5 3710911 3692328 3759908 3733521 3720765 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 3688826 3682675 3681093 3656987 3649438 
2 3678475 3689736 3690476 3669340 3638354 
Mean 3683651 3686206 3685785 3663164 3643896 
% Assay 99.76 99.51 99.30 98.67 98.25 
Standard weight (mg) 505.4 504.1 505.3 505.7 505.2 
Test weight (mg) 934 934 934 934 934 
% Difference compare to 
that of Initial  0.25 0.46 1.09 1.51 
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Solution stability for test preparation at room temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 3722471 3731935 3743264 3745354 3730267 
2 3701509 3730672 3717251 3710534 3718622 
3 3719976 3721394 3724929 3744576 3743371 
4 3727018 3717855 3729431 3760345 3744411 
5 3710911 3692328 3759908 3733521 3720765 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 3688826 3672849 3659763 3652861 3644345 
2 3678475 3677530 3663845 3656232 3649357 
Mean 3683651 3675190 3661804 3654547 3646851 
% Assay 99.76 99.21 98.77 98.40 98.33 
Standard weight (mg) 505.4 504.1 505.9 505.5 505.2 
Test weight (mg) 934 934 934 934 934 
% Difference 
compare to that of 
Initial 
 0.55 0.99 1.36 1.43 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
934
500
50
5
100
4.505
3683651
3716377% ×××=Assay 100
50
186
××  
 
       = 99.76 % 
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 For Indapamide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
System suitability of standard preparation for solution stability 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 2537402 2510324 2513273 2533024 2557365 
2 2523414 2512442 2522378 2541783 2528348 
3 2531805 2507833 2509402 2551805 2519298 
4 2527691 2521622 2517341 2549321 2557793 
5 2536707 2516237 2513243 2526227 2534567 
Mean 2531404 2513692 2515127 2540432 2539474 
Stdev 5955.78 5398.98 4930.55 10803.30 17396.92 
%RSD 0.24 0.21 0.20 0.43 0.69 
Solution stability for standard preparation at 2-8°C 
 After 12 hours After 24 hours After 36 hours After 48 hours Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 2537402 2537402 2537402 2537402 
2 2523414 2523414 2523414 2523414 
3 2531805 2531805 2531805 2531805 
4 2527691 2527691 2527691 2527691 
5 2536707 2536707 2536707 2536707 
1 2521805 2512811 2471223 2442423 
2 2514693 2502224 2476844 2448328 
Mean 2527645 2524579 2515012 2506824 
Stdev 8310.51 12993.63 28459.37 42292.61 
%RSD 0.33 0.51 1.13 1.69 
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Solution stability for standard preparation at room temperature 
 After 12 hours After 24 hours After 36 hours After 48 hours Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 2537402 2537402 2537402 2537402 
2 2523414 2523414 2523414 2523414 
3 2531805 2531805 2531805 2531805 
4 2527691 2527691 2527691 2527691 
5 2536707 2536707 2536707 2536707 
1 2518354 2485383 2458153 2443376 
2 2503874 2479822 2465930 2450365 
Mean 2525607 2517461 2511586 2507251 
Stdev 11795.68 24357.02 34266.52 41582.66 
%RSD 0.47 0.97 1.36 1.66 
Solution stability for test preparation at 2-8°C 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 2537402 2510324 2513273 2533024 2557365 
2 2523414 2512442 2522378 2541783 2528348 
3 2531805 2507833 2509402 2551805 2519298 
4 2527691 2521622 2517341 2549321 2557793 
5 2536707 2516237 2513243 2526227 2534567 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 2519247 2517987 2508338 2493343 2494652 
2 2516663 2513739 2512390 2497687 2488387 
Mean 2517955 2515863 2510364 2495515 2491520 
% Assay 99.44 99.26 99.38 98.59 98.47 
Standard weight (mg) 25.1 24.9 25 25.2 25.2 
Test weight (mg) 1071.5 1070.5 1071.3 1070.4 1071.4 
% Difference compare 
to that of Initial  0.18 0.06 0.85 0.97 
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Calculation: 
 
Prototype calculation for one set: 
 
934
500
50
5
100
1.25
2531404
2517955% ×××=Assay 100
5.2
186
××  
 
       = 99.44 % 
Solution stability for test preparation at room temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 2537402 2510324 2513273 2533024 2557365 
2 2523414 2512442 2522378 2541783 2528348 
3 2531805 2507833 2509402 2551805 2519298 
4 2527691 2521622 2517341 2549321 2557793 
5 2536707 2516237 2513243 2526227 2534567 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 2519247 2507894 2496329 2483353 2484225 
2 2516663 2513387 2489043 2489265 2480287 
Mean 2517955 2510641 2492686 2486309 2482256 
% Assay 99.44 99.05 98.68 98.23 98.11 
Standard weight (mg) 25.1 24.9 25.0 25.2 25.2 
Test weight (mg) 934 934 934 934 934 
% Difference 
compare to that of 
Initial 
 0.39 0.76 1.21 1.33 
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Rs  =  N 
 4 ( 
α -1 
  α )       k     k+1 (     ) 
Retentivity Selectivity 
 
System 
Efficiency 
DEVELOPMENT AND VALIDATION OF A STABILITY INDICATING UPLC 
ASSAY METHOD FOR DETERMINATION OF LEFLUNOMIDE IN TABLET 
FORMULATION 
 
1. INTRODUCTION TO UPLC 
History of chromatography can give an idea about improvement in technology 
from conventional column chromatography to high performance liquid chromatography 
and finally at this stage an ultra performance liquid chromatography or in other way a 
combination of pressurized chromatographic technology and sub 2 (two) micron particle 
size of stationary phase technology leads to advance Ultra Performance Liquid 
Chromatography (UPLC) or Rapid Resolution Liquid Chromatography (RRLC) 
technology. 
Technology of sub 2 (two) micron particle size leads many modifications in 
hardware part of the system like reduction of system volume, higher pump pressure 
capacity, injector and needle part, and cell volume of detector as well as in software area, 
data acquisition rate or capacity was increased for sufficient data collection. 
In brief detail, small particle size columns leads to increase in pump pressure so 
that area was improved and for accurate and precise injection volume needle in needle 
technology with teflon material was came into the picture. Detector cell volume was 
reduced for better signals and resolution. 
Smaller particle size of 2 micron technology altered the machine and its 
application for faster way of analysis in current scenario of separation science. 
Requirement of this technology can be explained by van deemeter equation [1, 4] and plot 
as shown in fig 1. From this plot it reveals that there is minimum HETP against the linear 
velocity with the almost constant relation or maximum the theoretical plates can be 
achieved with particle size less than 2 micron. Finally as a known fact increasing in N 
leads to increase in Resolution as shown in formula; 
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Figure1: Van Deemter plots-influence of particle size 
Now, for method conversion from HPLC to UPLC or for comparison of both the 
technology following aspects needs to take in consideration [2-3]. 
 
 Ratio of column length to particle size (L/dp) needs to keep constant. 
        i.e. 150 mm/5 µm = 30,000 is closest to 50mm/1.7 µm = 29,500 
 Column selection should be based on same basic column chemistry 
        i.e. C18 column should be replaced by C18 
 5 µm to 1.7 µm particle size leads to increase in speed of 9X along with 9X pressure 
column 
 3 µm to 1.7 µm particle size leads to increase in speed of 3X along with 3X pressure 
 5 µm to 1.7 µm particle size leads to increase in peak height of 1.7X 
 3 µm to 1.7 µm particle size leads to increase in peak height of 1.3X 
 5 µm to 1.7 µm particle size leads to decrease in peak width of 0.6X 
 3 µm to 1.7 µm particle size leads to decrease in peak width of 0.8X 
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 Column efficiency (N) is inversely proportional to dp 
 
 
 
i.e. 5 µm to 1.7 µm particle size leads to increase in column efficiency (N) 3X but 
  
 
So, resolution also increase by 1.7X 
Based on above fact practically an example for chromatogram comparison against 
column dimension for rune time and resolution is shown in fig 2. 
 
Remark 
Here, X is used to express the mathematical relation in multi fold. 
e.g. pressure increased by 3X i.e. pressure increase by three times 
 
Method Development 
 
Method development in UPLC remains same as of HPLC but few areas of 
chromatographic conditions are different e.g. for gradient elution column equilibration 
time is very less as compare to HPLC due to lower column volume. 
 
Advance technology in column filled material for HPLC as well as UPLC allows 
higher pH and temperature stability for column for wider choice of mobile phase for 
different applications. e.g. pH of mobile phase or its buffer can selected based on 
compound chemical nature and that can be explain by fig.3 for reversed phase retention 
plot. 
 
 
 
dp
N 1∝
NRs ∝
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Figure 2: Chromatogram comparison against column dimension 
 
  
 
Figure 3: Reversed phase retention plot 
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From the above plot and fundamental theory of solvent gives following 
information for development consideration. 
 
Facts for basic compound  
Alkaline pH increases retention of basic analytes 
Methanol increases retention of all components compared to acetonitrile 
 Similar basic analytes differ little in selectivity, respective to one another, when they 
are either fully charged or uncharged 
 Largest selectivity differences between bonded phases occur with methanol and 
analytes in their unionized state 
 
Facts for acid compound  
1. Acidic pH increases retention of acidic analytes 
Methanol increases retention of all components compared to acetonitrile 
Large differences in selectivity are observed when change in pH alters charge state 
Largest selectivity differences between bonded phases occur with methanol and 
analytes in their unionized state 
Column chemistry for known columns UPLC are shown in fig 4. 
 
 
 Figure 4: Column chemistry of UPLC column 
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By many recent research and development, UPLC presents the ability to extend 
and expand the utility of separation science at a time when many scientists have reached 
separation barriers, pushing the limits of conventional HPLC. New chemistry and 
instrumentation technology can provide more information per unit of work as UPLC 
begins to fulfil the promise of increased speed, resolution, and sensitivity predicted for 
liquid chromatography. As this is the concept for the scientist many of industries may 
take time to use in routine but it can be the future of the liquid chromatography. Hence 
present research work includes the extended area of HPLC to UPLC as a part of 
technology updating or a balance form of present HPLC and improved LC or UPLC for 
future scope for separation science. 
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2. LITERATURE REVIEW 
Literature review for methods developed for leflunomide is mentioned in the 
section I, page number 38. 
 
3. AIM OF PRESENT WORK 
As per discussion in the literature review, UV, TLC, LC-MS and HPLC methods 
for the determination of leflunomide in pharmaceutical dosage forms or in metabolite and 
plasma are reported. HPLC methods applied to the determination of leflunomide. So far 
to our present knowledge, no validated stability indicating UPLC assay method for the 
determination of leflunomide in pharmaceutical formulation was available in literature. 
Our work deals with the forced degradation of leflunomide under stress condition like 
acid hydrolysis, base hydrolysis, and oxidation, thermal and photolytic stress. This work 
also deals with the validation of the developed method for the assay of leflunomide from 
its dosage form (tablets). Hence, the method is useful for routine quality control analysis 
and also for determination of stability. 
 
The aim and scope of the proposed work are as under: 
 To develop suitable UPLC method for leflunomide, 
 Forced degradation study of leflunomide under stress condition, 
 To resolve all major impurities generated during the force degradation studies of 
leflunomide, 
 Perform the validation for the developed method. 
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4. EXPERIMENTAL 
4.1 Materials  
Detail of materials for methods developed for leflunomide is mentioned in the 
section 1, page number 43. 
 
4.2 Instrumentation 
The LC system of Waters Acquity UPLC with PDA was used for this entire study 
and chromatographic separation was achieved on Water Acquity BEH C18, 2.4mm x 
4.6mm 1.7µm column as stationary phase with binary gradient mode.  
 
4.3 Mobile phase Preparation 
The mobile phase consisted of acetonitrile – 0.02M ammonium acetate buffer (60: 
40, v/v). To prepare the buffer solution, 1.5416 g ammonium acetate was weighed and 
dissolve in 1000 ml HPLC grade. Mobile phase was filtered through a 0.45 μm nylon 
membrane (Millipore Pvt. Ltd. Bangalore, India) and degassed in an ultrasonic bath 
(Spincotech Pvt. Ltd., Mumbai).  
 
4.4 Diluent Preparation  
Use acetonitrile-buffer (50:50, v/v) used as diluents. 
 
4.5 Standard Preparation  
Standard solution containing leflunomide (100 µg/mL) was prepared by 
dissolving accurately about 10.0 mg in 100 mL volumetric flask by diluent [acetonitrile-
buffer (50:50, v/v)] (stock standard solution). 10 mL of stock solution was pipetted out 
into 50 mL volumetric flask and dilute up to mark with diluent (standard solution). The 
concentration obtain was 20 µg/mL of leflunomide. 
 
4.6 Test Preparation  
Twenty tablets were weighed and the average weight of tablet was determined. 
From these, five tablets were weighed and transfer into a 500 ml volumetric flask. About 
50 ml diluent was added and sonicated for a minimum 30 min. with intermittent shaking. 
Then content was brought back to room temperature and diluted to volume with diluents. 
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The sample was filtered through 0.45μm nylon syringe filter. 10 mL of filtrate stock 
solution was pipetted out into 50 mL volumetric flask and dilute up to mark with diluents. 
The concentration obtained was 20 μg/ml of Lelunomide.  
 
4.7 Chromatographic Conditions  
Chromatographic analysis was perfomed on Water Acquity BEH C18, 2.4 x 
50mm, 1.7µ column. The mobile phase was consisted of acetonitrile and 0.02M 
ammonium acetate buffer (60:40, v/v). The flow rate of the mobile phase was adjusted to 
0.4 mL/min and the injection volume was 5 µl. Detection was performed at 260nm. 
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5. RESULTS AND DISCUSSION 
5.1 Development and Optimization of the UPLC Method 
Proper selection of the methods depends upon the nature of the sample (ionic or 
ionisable or neutral molecule) its molecular weight and solubility. Leflunomide is 
dissolved in polar solvent hence RP-UPLC was selected to estimate them. To develop a 
rugged and suitable UPLC method for the quantitative determination of leflunomide, the 
analytical condition were selected after testing the different parameters such as diluents, 
buffer, buffer concentration, organic solvent for mobile phase and mobile phase 
composition and other chromatographic conditions. Our preliminary trials using different 
composition of mobile phases consisting of water with methanol or acetonitrile, did not 
give good peak shape.  
 The mobile phase consisted of acetonitrile – 0.02M ammonium acetate buffer (60: 
40, v/v). To prepare the buffer solution, 1.5416 g ammonium acetate was weighed and 
dissolves in 1000 ml HPLC grade water. Mobile phase was filtered through a 0.22 μm 
nylon membrane (Millipore Pvt. Ltd. Bangalore, India) and degassed in an ultrasonic bath 
(Spincotech Pvt. Ltd., Mumbai). 
 By using 0.02M Ammonium acetate buffer in 1000 ml of buffer and keeping 
mobile phase composition as acetonitrile-ammonium acetate buffer (60: 40, v/v), best 
peak shape was obtained. For the selection of organic constituent of mobile phase, 
acetonitrile was chosen to reduce the longer retention time and to attain good peak shape. 
Figure 2 and Figure 3 represent the chromatograms of standard and test preparation 
respectively. 
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Figure 2: Chromatogram of standard preparation 
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Figure 3: Chromatogram of test preparation 
5.2 Degradation Study 
The degradation samples were prepared by transferring powdered tablets, 
equivalent to 10.0 mg leflunomide into a 250 mL round bottomed flask. Then drug 
content were employed for acidic, alkaline and oxidant media and also for thermal and 
photolytic stress conditions. After the degradation treatments were completed, the stress 
content solutions were allowed to equilibrate to room temperature and diluted with 
diluent to attain 20 µg/ mL leflunomide concentrations. Specific degradation conditions 
were described as follows.  
5.2.1 Acidic condition  
Acidic degradation study was performed by heating the drug content in 1 N HCl at 
60° C for 2 hours and mixture was neutralized. In acidic degradation, it was found that 
around 10 % of the drug degraded. (Figure 4) 
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Figure 4: Chromatogram of acidic forced degradation study 
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5.2.2 Alkaline condition 
Alkaline degradation study was performed by ambient temperature in 0.005N 
NaOH for 2 hours and mixture was neutralized. In alkali degradation, it was found that 
around 8-9 % of the drug degraded.  (Figure 5) 
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Figure 5: Chromatogram of alkali forced degradation study 
 
5.2.3 Oxidative condition 
Oxidation degradation study was performed by heating the drug content in 30% 
v/v H2O2
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 at 80° C for 45 min. Major degradation was found in oxidative condition that 
product was degraded up to 22 %. The major impurity peaks was found at 0.5 min.  
(Figure 6) 
 
Figure 6: Chromatogram of oxidative forced degradation study 
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5.2.4 Thermal condition 
Thermal degradation was performed by exposing solid drug to dry heat of 80˚ C in 
a conventional oven for 72 hr. In thermal degradation, it was found that around 0.60% of 
the drug degraded. (Figure 7) 
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Figure 7: Chromatogram of thermal degradation study 
 
5.2.5 Photolytic condition 
Photolytic degradation study was performed by exposing the drug content in UV-
light for 72 hours. In photolytic degradation, it was found that around 1.12 % of the drug 
degraded. (Figure 8) 
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Figure 8: Chromatogram of UV-light degradation study 
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5.3 Method Validation 
5.3.1 Specificity 
 The specificity of the method was determined by checking the interference 
of placebo with analyte and the proposed method was eluted by checking the peak purity 
of Leflunomide during the force degradation study. The peak purity of the leflunomide 
was found satisfactory (0.9999) under different stress condition. There was no 
interference of any peak of degradation product with drug peak. 
 
5.3.2 Linearity 
Five points calibration curve were obtained in a concentration range from 10-30 
μg/ml for leflunomide. The response of the drug was found to be linear in the 
investigation concentration range and the linear regression equation was 
y=56906771.42857x- 2237.10714 with correlation coefficient 0.9998. (Figure 9) 
Chromatogram obtain during linearity study were shown in figure 10-14. 
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Figure 9: Linearity curve for leflunomide 
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Figure 10: Linearity study chromatogram of level-1 (50%) 
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Figure 11: Linearity study chromatogram of level-2 (75%) 
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Figure 12: Linearity study chromatogram of level-3 (100%) 
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Figure 13: Linearity study chromatogram of level-4 (125%) 
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Figure 14: Linearity study chromatogram of level-5 (150%) 
 
 
5.3.3 Precision 
The result of repeatability and intermediate precision study are shown in Table 1. 
The developed method was found to be precise as the %RSD values for the repeatability 
and intermediate precision studies were <1.16 % and < 0.60 %, respectively, which 
confirm that method was precise. 
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Table 1: Evaluation data of precision study 
Set Intraday (n = 6) Interday (n = 6) 
1 101.8 100.2 
2 100.6 99.9 
3 101.2 99.5 
4 100.4 99.4 
5 101.0 98.7 
6 98.4 100.3 
Mean 100.6 99.7 
Standard deviation 1.17 0.60 
% RSD 1.16 0.60 
 
  
5.3.4 Accuracy 
The UPLC area responses for accuracy determination are depicted in Table 2. The 
result shown that best recoveries (99.44-100.24 %) of the spiked drug were obtained at 
each added concentration, indicating that the method was accurate. Chromatogram obtain 
during accuracy study were shown in figure 15-17. 
 
Table 2: Evaluation data of accuracy study 
Level (%) 
 
Amount added 
concentration a
Amount found 
concentration 
(mg/ml) 
 a % Recovery  
(mg/ml) 
% RSD 
50 0.00987 0.00989 100.24 1.09 
100 0.02000 0.01989 99.44 1.24 
150 0.02987 0.02978 99.72 1.31 
 
  a Each value corresponds to the mean of three determinations 
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Figure 15: Accuracy study chromatogram of level-1 (50%) 
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Figure 16: Accuracy study chromatogram of level-2 (100%) 
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Figure 17: Accuracy study chromatogram of level-3 (150%) 
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5.3.5 Solution stability study  
Table 3 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 8˚ C and ambient temperature, as during this time the result was 
not decrease below the minimum percentage. 
Table 3: Evaluation data of solution stability study 
Intervals 
% Assay for Test 
Preparation Solution Stored 
at 2-8 ˚C 
% Assay for Test  
Preparation Solution Stored 
at Ambient Temperature 
Initial 99.6 99.6 
12 h 100.3 100.0 
24 h 98.4 98.3 
36 h 98.6 98.1 
48 h 97.8 97.7 
 
 
5.3.6 Robustness 
The result of robustness study of the developed assay method was established in 
Table 4. The result shown that during all variance conditions, assay value of the test 
preparation solution was not affected and it was in accordance with that of actual. System 
suitability parameters were also found satisfactory; hence the analytical method would be 
concluded as robust. Chromatogram obtain during robustness study were shown in Figure 
18-22. 
Table 4: Evaluation data of robustness study 
Robust conditions % Assay System suitability parameters Theoretical plates Asymmetry 
Flow 0.35 ml/min 99.5 4546 1.45 
Flow 0.45 ml/min 102.0 4456 1.20 
ACN-Buffer (62: 38,v/v) 98.8 4490 1.35 
ACN-Buffer (58: 42,v/v) 98.2 4520 1.58 
Column change 99.1 4430 0.58 
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Figure 18: Standard chromatogram (0.35 ml/min flow rate) 
 
 
Figure 19: Standard chromatogram (0.45 ml/min flow rate) 
 
 
Figure 20: Standard chromatogram (Buffer-ACN (62:38 v/v) 
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Figure 21: Standard chromatogram (Buffer-ACN (58:42 v/v) 
 
 
Figure 22: Standard chromatogram (Column change) 
 
5.3.7 System suitability 
A system suitability test of the chromatographic system was performed before 
each validation run. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate and % RSD of peak area were determined for same. 
Acceptance criteria for system suitability, Asymmetry not more than 2.0, theoretical plate 
not less then 4000 and % RSD of peak area not more then 2.0, were full fill during all 
validation parameter.  
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6. CALCULATIONS AND DATA 
 
Calculation formula used: 
 
     
1. Calculation formula for % assay of   Leflunomide 
 
 
WeightTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay 500
50
10
100
% ×××=  
 
Standard
10
50 ofPotency
ClaimLable
WeightTestMean
×××  
 
 
2. Relative standard deviation 
 
100×=
sMeasurmentofValueMean
sMeasurmentofDeviationStandard
RSD%  
 
 
3. Recovery 
 
100×=
AddedAmount
foundAmount
Recovery%  
 
 
4. Amount found  
 
ionConcentratStandard
AreaStandardMean
AreaTestMean
(mg/ml)FoundAmount ×=  
 
 
5. Amount added 
 
Volume
Weight(mg/ml)AddedAmount =  
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Specificity Study for Analytical Method Validation of Leflunomide Tablets 
 
 
Standard weight (mg) 10.2     
Standard dilution 100 10 50   
Standard potency 100 %     
Standard concentration (mg/ml) 0.0204     
      
Replicate 1 2 3 4 5 
Standard area 1109463 1104667 1103821 1108382 1109695 
Mean standard area 1107206     
Stdev. 2764.82     
% RSD 0.25     
 
 
Replicate Test Area 
1 1088033 
2 1089272 
Mean test area 1088653 
Test weight (mg) 520.6 
Label claim (mg) 10 
Mean test weight (mg) 104.1 
% Assay 100.3 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
6.520
500
50
10
100
2.10
1107206
1088653% ×××=Assay 100
10
1.104
10
50
×××  
 
              
     = 100.3 % 
  
 
 
 
 
 
 
 
 
 
    
UPLC…   Part-B 
 
 
 
 
205 
 
Linearity Study for Analytical Method Validation of Leflunomide Tablets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard weight (mg) 10    
Standard dilution 100 10 50  
Standard potency 100.0 %    
Standard concentration (mg/ml) 0.02     
Concentration of linearity stock 
solution (mg/ml) 0.1     
      
Replicate 1 2 3 4 5 
Standard area 1104650 1114310 1103652 1112850 1100472 
Mean standard area 1107187     
Stdev 5419.05     
% RSD 0.49     
Concentration 
level (%) 
Volume of 
linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final concentration 
(mg/ml) Mean area 
25 5 50 0.0100 563042 
50 6 50 0.0150 843909 
75 7 50 0.0200 1141704 
100 8 50 0.0250 1432920 
150 9 50 0.0300 1695680 
  Correlation co-efficient 0.9998 
  Slope 57085740 
  Intercept -6263.90 
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Precision Study for Analytical Method Validation of Leflunomide Tablets 
 
 
Standard weight (mg) 10.8     
Standard dilution 100 10 50   
Standard potency 100.0 %     
Label claim (mg) 10     
Mean test weight (mg) 104.1     
Standard concentration (mg/ml) 0.0216     
      
Replicate 1 2 3 4 5 
Standard area 1140917 1141408 1140459 1141200 1142979 
Mean standard area 1141393     
Stdev. 955.48     
% RSD 0.08     
 
 
 
Description Mean area Wt. (mg) % Assay 
Set 1 1025342 496 101.8 
Set 2 1023250 501 100.6 
Set 3 1026058 499.5 101.2 
Set 4 1025136 503 100.4 
Set 5 1022628 498.5 101.0 
Set 6 1021204 511 98.4 
 
Mean 100.6 
Stdev 1.17 
% RSD 1.16 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
496
500
50
10
100
8.10
1141393
1025342% ×××=Assay 100
10
1.104
10
50
×××  
 
     
= 101.8 % 
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Intermediate precision study for Analytical Method Validation of Leflunomide 
Tablets 
 
Standard weight (mg) 10.9     
Standard dilution 100 10 50   
Standard potency 100.0 %     
Label claim (mg) 10     
Mean test weight (mg) 104.1     
Standard concentration (mg/ml) 0.0218     
      
Replicate 1 2 3 4 5 
Standard area 1149905 1169289 1159991 1169119 1168277 
Mean standard area 1163316     
Stdev. 8439.10     
% RSD 0.73     
 
 
 
Description Mean area Wt. (mg) % Assay 
Set 1 1039067 505.5 100.2 
Set 2 1026061 501 99.9 
Set 3 1040481 510 99.5 
Set 4 1030206 505.5 99.4 
Set 5 1033177 510.5 98.7 
Set 6 1032629 502 100.3 
 Mean 99.7 
Stdev 0.60 
% RSD 0.60 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
505.5
500
50
10
100
9.10
1163316
1039067% ×××=Assay 100
10
1.104
10
50
×××  
 
 
    = 100.2 % 
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Comparison for Precision and Intermediate Precision Study for Analytical Method 
Validation for Leflunomide Tablets 
 
 
 Set %Assay 
Precision study 
1 101.8 
2 100.6 
3 101.2 
4 100.4 
5 101 
6 98.4 
Intermediate precision study 
1 100.2 
2 99.9 
3 99.5 
4 99.4 
5 98.7 
6 100.3 
 Mean 100.1 
 Stdev 1.00 
 % RSD 1.00 
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Accuracy study for Analytical Method Validation of Leflunomide Tablets 
 
 
Standard weight (mg) 10     
Standard dilution 100 10 50   
Standard potency 100.0 %     
Standard concentration (mg/ml) 0.0200     
      
Replicate 1 2 3 4 5 
Standard area 1144121 1143841 1144407 1144872 1144353 
Mean standard area 1144319     
Stdev 381.575     
% RSD 0.03     
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Solution Stability Study for Analytical Method Validation of Leflunomide Tablets 
 
 
 
 
 
 
  
 
Solution stability for standard preparation at 2 -8°C 
 After 12 hours After 24 hours After 36 hours After 48 hours Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1141121 1141121 1141121 1141121 
2 1143841 1143841 1143841 1143841 
3 1144507 1144507 1144507 1144507 
4 1143872 1143872 1143872 1143872 
5 1142353 1142353 1142353 1142353 
1 1135991 1128014 1116282 1110143 
2 1133119 1127493 1117107 1111054 
Mean 1140686 1138743 1135583 1133842 
Stdev 4415.41 7592.55 12954.62 15920.01 
%RSD 0.39 0.67 1.14 1.40 
 
 
 
 
 
 
 
System suitability of standard preparation for solution stability 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1141121 1149917 1101050 1109463 1138408 
2 1143841 1141408 1104390 1104667 1130459 
3 1144507 1140459 1104832 1103821 1131200 
4 1143872 1140200 1104970 1108382 1130905 
5 1142353 1145979 1103335 1109695 1139272 
Mean 1143139 1143593 1103715 1107206 1134049 
Stdev 1377.65 4236.58 1622.11 2764.82 4392.33 
%RSD 0.12 0.37 0.15 0.25 0.39 
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Solution stability for test preparation at 2 -8°C 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1141121 1149917 1101050 1109463 1138408 
2 1143841 1141408 1104390 1104667 1130459 
3 1144507 1140459 1104832 1103821 1131200 
4 1143872 1140200 1104970 1108382 1130905 
5 1142353 1145979 1103335 1109695 1139272 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 1096429 1070519 1057443 1050958 1046080 
2 1094254 1075383 1054519 1049857 1049734 
Mean 1095892 1072951 1055981 1050408 1047907 
% Assay 99.6 100.3 98.4 98.6 97.8 
Standard weight (mg) 10.4 10.7 10.3 10.4 10.6 
Test weight (mg) 521.1 521.1 521.1 521.1 521.1 
% Difference compare 
to that of Initial  -0.7 1.2 1.0 1.8 
Solution stability for standard preparation at room temperature 
 After 12 hours After 24 hours After 36 hours After 48 hours Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1141121 1141121 1141121 1141121 
2 1143841 1143841 1143841 1143841 
3 1144507 1144507 1144507 1144507 
4 1143872 1143872 1143872 1143872 
5 1142353 1142353 1142353 1142353 
1 1132105 1169289 1112686 1104407 
2 1131575 1167432 1115628 1102979 
Mean 1139911 1150345 1134858 1131869 
Stdev 5628.91 12369.85 14211.73 19284.83 
%RSD 0.49 1.08 1.25 1.70 
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Calculation: 
 
Prototype calculation for one set: 
 
1.521
500
100
4.10
1143139
1095892% ××=Assay 100
10
1.104
10
50
×××
 
 
                 = 99.6 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Solution stability for test preparation at room temperature 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1141121 1149917 1101050 1109463 1138408 
2 1143841 1141408 1104390 1104667 1130459 
3 1144507 1140459 1104832 1103821 1131200 
4 1143872 1140200 1104970 1108382 1130905 
5 1142353 1145979 1103335 1109695 1139272 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 1096829 1070028 1056383 1046033 1044387 
2 1094954 1069396 1052028 1044272 1047443 
Mean 1095892 1069712 1054206 1045153 1045915 
% Assay 99.6 100.0 98.3 98.1 97.7 
Standard weight (mg) 10.4 10.7 10.3 10.4 10.6 
Test weight (mg) 521.1 521.1 521.1 521.1 521.1 
% Difference 
compare to that of 
Initial 
 -0.4 1.3 1.5 1.9 
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Robustness Study for Analytical Method Validation of Leflunomide Tablets 
 
 
 
 
Calculation: 
 
Prototype calculation for one set:  
 
5.520
500
50
10
100
5.10
1341884
1270362% ×××=Assay 100
10
1.104
10
50
×××
 
    
                 = 99.4 % 
 
 
Flow rate 
at 
0.35ml/min 
Flow rate 
at 
0.45ml/min 
Buffer-ACN 
38: 62 
Buffer- ACN 
58: 42 
Column 
change 
Standard Replicate Standard Area 
Standard 
Area 
Standard 
Area 
Standard 
Area Area 
1 1339878 1008918 1102325 1170918 1124805 
2 1342058 1006247 1104472 1172058 1118285 
3 1340459 1010052 1100487 1170459 1123791 
4 1341050 1011253 1102384 1176200 1119118 
5 1345973 1012854 1110234 1177379 1122379 
Mean 1341884 1009865 1103980 1173403 1121676 
Stdev 2423.86 2494.11 3769.68 3173.45 2863.58 
% RSD 0.18 0.25 0.34 0.27 0.26 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 1266469 981089 1036895 1098524 1059058 
2 1274255 981895 1039983 1095978 1058060 
Mean 1270362 981492 1038439 1097251 1058559 
Standard 
Weight (mg) 10.5 10.5 10.5 10.5 10.5 
Test Weight 
(mg) 520.5 520.5 520.5 520.5 520.5 
Label Claim 
(mg) 10 10 10 10 10 
Mean Test 
Weight (mg) 104.1 104.1 104.1 104.1 104.1 
% Assay 99.4 102.0 98.8 98.2 99.1 
UPLC…   Part-B 
 
 
 
 
215 
 
Referencess 
 
1. Dao T.-T. Nguyen, Davy Guillarme, Serge Rudaz, Jean-Luc Veuthey, Journal of 
Chromatography A, 1128 (2006) 105-113. 
2. UPLC waters seminar presentation at Singapore (2006). 
3. http://www.waters.com. 
4. Michael E. Swartz, Journal of Liquid Chromatography and Related Technologies, 28 
(2005) 1253-1263. 
PART-C 
 
STUDIES OF 
SIMULTANEOUS 
ESTIMATION OF 
FUROSEMIDE AND 
SPIRONOLACTONE FROM 
DRUG PRODUCT BY HIGH 
PERFORMANCE THIN 
LAYER 
CHROMATOGRAPHY 
(HPTLC) 
Furosemide and Spironolactone…   Part-C  
 
 
 
216 
 
STUDIES OF SIMULTANEOUS ESTIMATION OF FUROSEMIDE AND 
SPIRONOLACTONE FROM DRUG PRODUCT BY HIGH PERFOMANCE 
THIN LAYER CHROMATOGRAPHY (HPTLC) 
 
1. Introduction to HPTLC Methods of Analysis for Drugs[1,3] 
 
 Thin   layer   chromatography   (TLC);   also   know   as   planar-chromatography   
or   flat   bed chromatography is like all other chromatographic techniques, a multi-
stage distribution process. 
 HPTLC   is   the   most   simple   separation   technique   today   available   to   
the   analyst.   It   can   be considered a time machine that can speed your work and 
allows you to do many things at a time usually not possible with other analytical 
techniques.  
 
 
 HPTLC TLC 
Layer of sorbent 100µm 250µm 
Efficiency High due to particle size analyzer generated Less 
Separations 3-5 cm 10-15 cm 
Analysis time 
Shorter migration distance 
and the analysis time is 
greatly reduce 
Slower 
Solid support 
Wide choice of stationary 
phase like silica gel for 
normal phase and C-8,C-18 
for reversed phase modes 
Silica gel, 
Alumina 
and                    
Kiesulguhr 
Development chamber New type that require less amount of mobile phase More amount 
Sample spotting Auto sampler Manual spotting 
Scanning 
Use of UV/Visible/Fluore- 
scence scanner scans the 
entire chromatogram 
qualitatively and 
quantitatively and the 
scanner is an advance type 
of densitometer 
Not possible 
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 TLC / HPTLC are often found more troublesome than GLC / HPLC as uantitative 
TLC is an off-line technique, hence automation is difficult and because of its open 
character, is highly influenced by environmental factors. It is, therefore, essential that 
each step which may require specific approach must be carefully validated to determine 
potential source of error. 
 
Factors influencing the TLC / HPTLC separation and resolution of spots:  
 
 Type of stationary phase(sorbent), 
 Type of pre-coated plates(TLC / HPTLC);for quantitative analysis, use of 
HPTLC pre-coated is absolutely essential, 
 Layer thickness / Binder in the layer, 
 Mobile phase(solvent system), 
 Solvent purity, 
 Size of the developing chamber, 
 Saturation of chamber(pre-equilibrium), 
 Sample volume to be spotted, 
 Size(diameter) of the initial spot, 
 Solvent level in the chamber, 
 Gradient, 
 Relative humidity, 
 Temperature(RF
 Flow rate of solvent, 
 values usually increase with rise in temperature), 
 Separation distance, 
 Mode of development. 
 
 Greater the distance between different spots and smaller the initial spot diameter 
of the sample, better the resolution. While describing the result of any TLC / HPTLC 
procedure, various parameters and conditions under which results for a specific 
analysis have been obtained must be documented. This is absolutely essential for 
possible results. 
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Features of HPTLC 
 
1. Simultaneous   processing   of   sample   and   standard   -   better   analytical  precision   
and accuracy less need for Internal Standard. 
2. Several analysts work simultaneously. 
3. Lower analysis time and less cost per analysis. 
4. Low maintenance cost. 
5. Simple sample preparation - handle samples of divergent nature. 
6. No prior treatment for solvents like filtration and degassing. 
7. Low mobile phase consumption per sample. 
8. No interference from previous analysis - fresh stationary and mobile phases for each 
 analysis - no contamination. 
9. Visual detection possible - open system. 
10. Non UV absorbing compounds detected by post-chromatographic derivatization. 
 
Steps involved in HPTLC:  
1. Selection of chromatographic layer  
2. Sample and standard preparation  
3. Layer pre-washing 
4. Layer pre-conditioning  
5. Application of sample and standard 
6. Chromatographic development  
7. Detection of spots  
8. Scanning  
9. Documentation of chromatic plate  
 
Selection of chromatographic layer: 
 Precoated plates-different support material-different sorbents available, 
 80 % of analysis : Basic substances, alkaloids and steroids, Aluminum oxide- 
silica gel GF, 
 Amino acids, dipeptidees, sugars and alkaloids- cellulose, 
 Non-polar substances, fatty acids, caratenoids, cholesterol-RP-2,RP-8 and RP-18, 
 Preservatives, barbiturates, analgesic and phenothiazines-Hybrid plates-           RP-
WF254s. 
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Sample and standard preparation: 
  To avoid interference from impurities and vapours, 
  Low signal to noise ratio-straight base line-Improvement of LOD, 
  Solvents used are Methanol, Chloroform : Methanol (1:1), Ethyl acetate :   
Methanol   (1:1), Chloroform : Methanol : ammonia (90:10:1), Methylene 
chloride : Methanol (1:1), 1 % Ammonia or 1 % Acetic acid, 
 Dry the plates and store in dust free atmosphere. 
 
Activation of pre-coated plates: 
 Freshly open box of plates do not require activation, 
 Plates exposed to high humidity or kept on hand for long time to be activated, 
 By placing in an oven at 110-120º C for 30 minutes prior to spotting, 
 Aluminum sheets should be kept in between two glass plates and placing in oven 
at 110-120º C for 15 minutes. 
 
Application of sample and standard: 
 Usual concentration range is 0.1-1 μg / μl, 
 Above this cause poor separation, 
 Linomat  IV(automatic   applicator)   –   nitrogen   gas   sprays   sample   and   
standard   from syringe on TLC plates as bands, 
 Band wise application-better separation-high response to densitometer. 
  
Selection of mobile phase: 
 Trial and error, 
 One’s own experience and Literature, 
 3-4 component mobile phase should be avoided, 
 Multi component mobile phase once used not recommended for further use and 
solvent  
 composition is expressed by volume (v / v) and sum of volumes is  usually 100, 
 Twin trough chambers are used only 10-15 ml of mobile phase is required, 
 Components of mobile phase should be mixed introduced into the twin-trough 
chamber. 
 
Furosemide and Spironolactone…   Part-C  
 
 
 
220 
 
 Stationary phase is polar, 
Normal phase : 
 Mobile phase is non polar, 
 Non-polar compounds eluted first because of lower affinity with stationary phase, 
 Polar compounds retained because of higher affinity with the stationary phase. 
 
 Stationary phase is non polar, 
Reversed phase :  
 Mobile phase is polar, 
 Polar compounds eluted first because of lower affinity with stationary phase, 
 Non-Polar compounds retained because of higher affinity with the stationary 
phase. 
 
Pre- conditioning (Chamber saturation): 
 Un- saturated chamber causes high RF
 Saturated   chamber   by   lining   with   filter   paper   for   30   minutes   prior   to   
development-uniform distribution of solvent  vapours- less solvent for the sample 
to travel- lower  RF  values. 
 values, 
 
Chromatographic development and drying: 
 After   development,  the   plate  and  mobile   phase   is   removed   from  the  
plate-   to  avoid contamition of lab atmosphere, 
 Dry   in   vacuum  desicator  (avoid   hair   drier)   because   essential   oil   
components   may evaporate. 
 
Detection and visualization: 
 Detection under UV light is first choice- non destructive, 
 Spots of fluorescent compounds can be seen at 254 nm (short wave length) or at 
366 nm (long wave length), 
 Spots of non fluorescent compounds like ethambutol, dicylomine etc-dipping the 
plates in 0.1 % iodine solution, 
 When   individual   component   does   not   respond   to   UV-  derivatisation  
required   for detection. 
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Quantification: 
 Sample   and   standard   should   be  chromatographed  on   same   plate-after   
development chromatogram is scanned, 
 Camag TLC scanner III scan the chromatogram in reflectance or in transmittance 
mode  
 by absorbance or by fluorescent mode-scanning speed selectable up to 100 mm/s –  
 spectra recording is fast-36 tracks with up to 100 peak windows can be evaluated, 
 Calibration of single and multiple levels with linear or non-linear regressions are 
possible when target values are to be verified such as stability testing and 
dissolution profile, single level calibration is suitable, 
Statistics such as RSD or CV report automatically, 
 Concentration of analyte in the sample is calculated by considering the sample 
initially taken and dilution factors. 
 
Documentation: 
 E-Merck   introduced   plates   with   imprinted   identification  code,   supplier   
name,   item number, batch number and individual plate number, 
 Avoid manipulation of data at any stage, 
 All work performed is documentated in a project worksheet. 
 
 Retention factor (R
Parameters that are affected by the changes in chromatographic conditions are: 
 
F
 Peak purity. 
), 
  
1. Retention factor (RF): 
2. Peak purity: The null hypothesis “these spectra are identical” can in this case (purity) 
with two sided significance.   During the purity  test the spectrum  taken at the  first peak 
Retention factor (RF) is defined as the amount of separation due 
to the solvent migration through the sorbent layer as shown in the formula.   It depends on 
time of development and velocity coefficient or solvent front velocity.  
Migration distance of substance 
RF        =   ---------------------------------------------------------------- 
Migration distance of solvent front from origin 
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slope is correlated with the spectrum of peak maximum [r (s, m)] and the correlation of 
the spectra taken at the peak maximum with the one from the down slope or peak end     
[r (m, e)] which is used as a reference spectra for statistical calculation.  An error 
probability of 1 % only be rejected if the test value is greater than or equal to 2.576. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic procedure for HPTLC  
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HPTLC Method design and development (Figure 1) 
Set   the   analytical   objective   first   that   may   be   quantification   or   
qualitative   identification   or separation of two components/multicomponent mixtures or 
optimization of analysis time before starting   HPTLC.   Method   for   analyzing   drugs   
in   multicomponent   dosage   forms   by   HPTLC demands   primary   knowledge   
about   the   nature   of   the   sample,   namely,   structure,   polarity, volatility, stability 
and the solubility parameter.  An exact recipe for HPTLC, however, also same like HPLC 
cannot be provided because method development involves considerable trial and error 
procedures.   The most difficult problem usually is where to start, with what kind of 
mobile phase. 
Selection of stationary phase is quite easy that is to start with silica gel which is 
asonable and nearly suits all kind of drugs.   Mobile phase optimization is carried out by 
using three level techniques.   First level involves use of neat solvents and then by finding 
some such solvents which   can   have   average   separation   power   for   the   desired   
drugs.   Second   level   involves decreasing or increasing solvent strength using hexane 
or water for respective purposes.  Third level involves trying of mixtures instead of neat 
solvents from the selected solvents of first and second level which can further be 
optimized by the use of modifier like acids or bases. Analytes are detected using 
fluorescence mode or absorbance mode.  But if the analytes are not detected perfectly 
than it need change of stationary phase or mobile phase or need the help of pre or post 
chromatographic derivatization.  
Optimization can be started only after a reasonable chromatogram which can be 
done by slight change in mobile phase composition.  This leads to a reasonable 
chromatogram which has all the desired peaks in symmetry and well separated.  
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2. INTRODUCTION OF DRUGS 
2.1 Introduction to Furosemide 
Furosemide (INN) or Frusemide (former BAN) is a loop diuretic used in the 
treatment of congestive heart failure and edema. It is most commonly marketed by 
Sanofi-Aventis under the brand name Lasix. It has also been used to prevent 
thoroughbred and standardbred race horses from bleeding through the nose during races. 
Along with some other diuretics, furosemide is also included on the World Anti-
Doping Agency's banned drug list due to its alleged use as a masking agent for other 
drugs. 
 
2.1.1 Description 
Furosemide is chemically 4-Chloro-2-(furan-2-ylmethylamino)-5-sulfa 
moylbenzoic acid (Figure 2). Its CAS number is 54-31-9. Its molecular formula is 
C12H11ClN2O5S  having molecular weight 330.74gm/mole. Furosemide, an anthranilic 
acid derivative, is a potent diuretic that inhibits the active reabsorption of chloride in the 
diluting segment of the loop of Henle, thus preventing the reabsorption of sodium, which 
passively follows chloride [4]. This loop diuretic is commonly used for the treatment of 
renal diseases, congestive heart failure and hypertension [5]. 
 
Cl
S
O
NH2
O
O OH
NH
O
 
 
 
Figure: 2    4-Chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid 
 
2.1.2    Mechanism of action 
The name of Lasix is derived from lasts six (hours) -- referring to its duration of 
action. Like other loop diuretics, furosemide acts by inhibiting the Na-K-2Cl symporter in 
the thick ascending limb of the loop of Henle. The action on the distal tubules is 
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independent of any inhibitory effect on carbonic anhydrase or aldosterone; it also 
abolishes the corticomedullary osmotic gradient and blocks negative as well as positive 
free water clearance. 
Due to the large NaCl absorptive capacity of the loop of Henle and the fact that 
diuresis is not limited by development of acidosis, as it is with the carbonic anhydrase 
inhibitors. 
By inhibiting the transporter, the loop diuretics reduce the reabsorption of NaCl 
and also diminish the lumen-positive potential that derives from K+ recycling. This 
electrical potential normally drives divalent cation reabsorbtion in the loop, and by 
reducing this potential loop diuretics cause an increase in Mg2+ and Ca2+
hypomagnesemia
 excretion. 
Prolonged use can cause significant  in some patients. Since Ca2+
Additionally, furosemide is a noncompetitive subtype-specific blocker of GABA-
A receptors 
 is 
actively reabsorbed in the distal convoluted tubule, loop diuretics do not generally cause 
hypocalcemia. 
[6, 8]. Furosemide has been reported to reversibly antagonize GABA-evoked 
currents of α6 β2 γ2 receptors at micromole concentrations, but not alpha1 β2 γ2 
receptors [6, 7]. During development, the alpha6 beta2 gamma2 receptor increases in 
expression in cerebellar granule neurons, corresponding to increased sensitivity to 
furosemide [7]. 
 
2.2 Introduction to Spironolactone 
Spironolactone (marketed under the trade names Aldactone, Novo-Spiroton, 
Aldactazide, Spiractin, Spirotone, Verospiron or Berlactone) is a diuretic and is used as 
an antiandrogen. 
It is a synthetic 17-lactone drug that is a renal competitive aldosterone antagonist 
in a class of pharmaceuticals called potassium-sparing diuretics, used primarily to treat 
heart failure, ascites in patients with liver disease, low-renin hypertension, hypokalemia 
and Conn's syndrome. On its own, spironolactone is only a weak diuretic, but it can be 
combined with other diuretics. About one person in one hundred with hypertension has 
elevated levels of aldosterone; in these persons the antihypertensive effect of 
spironolactone may exceed that of complex combined regimens of other 
antihypertensives. Due to its anti-androgen effect, it can also be used to treat hirsutism, 
and it is a common component in hormone therapy for male-to-female transsexual and 
Furosemide and Spironolactone…   Part-C  
 
 
 
226 
 
transgender people. It is commonly used to treat symptoms of Polycystic Ovary 
Syndrome (PCOS) such as excess facial hair and acne. 
 
2.2.1  Description 
Spironolactone is chemically 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-
carbolactone (Figure 3). Its molecular formula is C24H32O4
aldosterone receptors
S having molecular weight 
416.58 gm/mole. Spironolactone inhibits the effect of aldosterone by competing for 
intracellular  in the distal tubule cells (it actually works on 
aldosterone receptors in the collecting duct). This increases the excretion of water and 
sodium, while decreasing the excretion of potassium. Spironolactone has a fairly slow 
onset of action, taking several days to develop, and similarly the effect diminishes slowly. 
Spironolactone has anti-androgen activity by binding to the androgen receptor and 
preventing it from interacting with dihydro testosterone [8]. 
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Figure: 3      7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone 
 
2.2.2 Mechanism of action 
Spironolactone inhibits the effect of aldosterone by competing for intracellular 
aldosterone receptors in the distal tubule cells (it actually works on aldosterone receptors 
in the collecting duct). This increases the excretion of water and sodium, while decreasing 
the excretion of potassium. Spironolactone has a fairly slow onset of action, taking 
several days to develop, and similarly the effect diminishes slowly. Spironolactone has 
anti-androgen activity by binding to the androgen receptor and preventing it from 
interacting with dihydrotestosterone[9]. 
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2.2.3 Pharmacokinetics 
Spironolactone is a synthetic steroid that acts as a competitive antagonist to 
aldosterone. Its onset and duration of action are determined by the kinetics of the 
aldosterone response in the target tissue. Substantial inactivation of spironolactone occurs 
in the liver. Over all, spironolactone has a rather slow onset of action, requiring several 
days before full therapeutic effect is achieved. 
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3. LITERATURE REVIEW 
3.1 Literature review of furosemide 
The literature reviews regarding furosemide suggest that various analytical 
methods were reported for its determination as drug, in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of furosemide are as under:  
 
3.1.1 A. O. Santini, H. R. Pezza, R. Sequinel, J. L. Rufino, L. Pezza have studied the 
use of potentiometric sensor for furosemide determination in pharmaceuticals, urine, 
blood serum and bovine milk. The construction, evaluation, and analytical application of 
a potentiometric sensor, namely, Pt|Hg|Hg2(Fur)2|Graphite, where Furosemide 4-chloro-
N-furfuryl-5-sulphamoyl-anthranilate ion, are described.  This electrode has a linear 
dynamic range between 5.0 x 10-7-1.0 x 10-2 mol L-1 with a near-nernstian slope of (-
58.4 ± 0.9) mV decade-1 and a detection limit of 3.8 x 10-7 mol L-1.  The potentiometric 
response is independent of the pH of the solution in the pH range 7.0-9.0.  The electrode 
shows easy construction, low-cost, fast response time (within 10-20 s), and can be used 
for 6 month without significant change in its performance characteristics. The proposed 
sensor displayed good selectivities over a variety of other anions (carboxylates and inorg. 
anions) [10].   
3.1.2 I. L. T. Dias, J. L. S. Martins, G. de Oliveira Neto have developed furosemide 
determination by first-derivative spectrophotometric method.  Furosemide was analyzed 
in tablet and liquid pharmaceutical preparations entirely and after photolytic degradation, 
by direct UV 1st derivative spectrophotometry 1D at 262 nm.  At this wavelength, it was 
possible to eliminate the decomposition product interference.  A linear response range 
between 1.0 and 10.0 µg mL-1
3.1.3 E. F. Salim, A. Haussler, J. B. Vaughan have studied qualitative and quantiative 
tests for furosemide. Physical properties, identity tests, purity tests, and assay procedure 
are described for furosemide [12]. 
 was obtained in optimized conditions.  The estimation of 
relative standard deviation was within the range 0.37-2.4% (n = 10).  The method was 
applied in pharmaceutical samples, and the results were compared with those obtained 
with normal spectrophotometric method to determine furosemide with advantages as high 
selective, accuracy, and precision [11]. 
3.1.4 J. Xie, F. Yang, Y. Zhai, J. Yao, W. Zhang  have developed determination of 
the related substances in furosemide for injection by HPLC. The samples were separated 
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on Hypersil ODS column.  The mobile phase was water-tetrahydrofuran-acetic acid 
(70:30:1) at a flow rate of 1.0 mL/min-1 at the wavelength of 254 nm and the injection 
volume was 20 µL.  The contents of the related substances were computed by a self 
control method.  the linear range of furosemide was 50-2000 µg/mL-1
3.1.5 B. Wesley-Hadzija, A. M. Mattocks, have developed thin-layer chromatographic 
determination of furosemide and 4-chloro-5-sulfamoylanthranilic acid in plasma and 
urine. A method is described for the assay of furosemide [54-31-9] based on thin-layer 
chromatography and measurement of fluorescence directly on the plates.  As little as 10 
ng can be accurately measured and fluorescence is linear up to 160 ng.  The metabolite or 
decomposed product 4-chloro-5-sulfamoylanthranilic acid  [3086-91-7] is well separated 
and measured quantity in the procedure.  Application of the method to the assay in human 
plasma and urine is demonstrated [14]. 
 (r = 0.999 7).  The 
avrage content of the related substances in samples was 0.78%.  The method is simple, 
rapid, accurate and reproducible, and it can be used as the quality control of furosemide 
for injection [13]. 
3.1.6 Shu-hua He, Chao-yin Li, have developed flow injection chemiluminescence’s 
method for the determination of furosemide based on KMnO4-Na2S2O4
3.1.7 F. S. Semaan, E. T. G. Cavalheiro have developed spectrophotometric 
determination of furosemide based on its complexation with Fe (III) in ethanolic medium 
using a flow injection procedure. The proposed method was applied to tablets and 
ampoules and urine sample spiked with the analyte without an effect from the other 
substances present in the formulation [16]. 
 reaction.  A 
novel flow injection chemiluminescence (FI-CL) system for determination of furosemide 
was presented.  It was based on the chemiluminescence reaction of sodium hydrosulfite 
with potassium permanganate in the vitriol acid solution. The emission intensity can be 
enhanced greatly by furosemide.  The chemiluminescence intensity was proportional to 
furosemide concentration over the range 0.01-5.0 mg/L.  The detection limit is 5.7μg/L 
and the relative standard deviation is 3.7% for the furosemide concentration 0.5 mg/L 
(times measuring n = 11).  This method had been successfully applied to determination of 
furosemide in injections [15]. 
3.1.8 P. Mishra, D. Katrolia, R. K.  Agrawal have developed  Simple colorimetric 
estimation of furosemide in dosage forms, tablets and injections by treatment with 
Cu(OAc)2 and measurement of the Cu complex obtained at 742 and 730 nm in MeOH 
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and Ethyl acetate respectively. The metal to ligand ratio in the complex was 1:2 and the 
structure was proposed.  The recovery was 98-100% and the sensitivity was 1-5 mg/mL 
[17]. 
3.1.9 C. Dreux, D. Halter, S. B. Hop, F. P. St.-Louis have developed 
spectrofluorimetric determination of furosemide in biological fluids and application to 
pharmaco- and biokinetic studies. The method is described for the determination of 
furosemide [54-31-9] in blood serum and urine.  For blood serum samples, first is 
extracted with a slightly acidic EtOA soln. followed by a second extraction with borate 
buffer (pH 10).  The pH of the second extracted is adjusted to 2 with formic acid and first 
was determined fluorometrically at 345 and 413 nm.  The sensitivity of this method is 
0.02 and 0.5 μg/ml for serum and urine, respectively [18].   
3.1.10   L. O. Guerello, J. Dobrecky have developed spectrophotometric determination 
of triamterene and furosemide in pharmaceutical mixtures. Triamterene and furosemide in 
tablets are determined by spectrophotometry at 275 and 370 nm., using 50% EtOH as a 
solvent [19]. 
3.1.11   A. Goelcue has developed spectrophotometric method was developed for the 
assay of furosemide (FUR), which is based on the complexation of the drug with 
copper(II) at pH 3.2 using Mclivaine buffer solution to produce a green adduct.  The latter 
has maximum absorbance at 790 nm and obeys Beer's law within the concentration range 
5-30 μg/mL.  Regression analysis of the calibration data showed a good correlation 
coefficent (r = 0.9997) with min. detection limit of 0.23 μg/mL.  The proposed procedure 
was successfully applied to the determination of this drug in tablets [20]. 
3.1.12   H. M. Abdel-Hay has developed stability-indicating derivative 
spectrophotometric determination of frusemide.  The development of a first- and second-
derivative spectrophotometric determination of frusemide in pharmaceutical formulations 
in the presence of its acid-hydrolysis product saluamine, is described. The procedure 
involves measurements of first-derivative amplitudes at 254 and 262 nm and second-
derivative amplitudes at 265 and 272 nm for the assay of frusemide and saluamine, 
respectively. Kinetic investigation of the acid degrdation rate of frusemide revealed that 
the proposed method is stability indicating [21]. 
3.1.13  G. M. Hanna, C. A. Lau-Cam have developed stability-indicating proton 
nuclear magnetic resonance spectroscopic assay method for furosemide in tablets and 
injections. This method was developed for the identification and assay for furosemide and 
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its degradation product, 4-chloro-5-sulfamoylanthranilic acid (CSA), in tablets and 
injections. Dissolution of the sample in D2
 
O-NaOD resulted in a solution yielding the 
required separation among the resonance signals of furosemide, CSA, and tert-BuOH, the 
internal standard.  The mean standard deviation recovery values of furosemide and CSA 
from 10 synthetic formulations were 99.6 and 98.9%, respectively [22]. 
3.2 Literature Review of Spironolactone 
The literature reviews regarding spironolactone suggest that various analytical 
methods were reported for its determination as drug, in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of spironolactone are as 
under : 
 
3.2.1   Z. Tang, F. Liu, Y.  Go, Y.  Guo, Y.  Ren have developed nondestructive 
quantitative analysis method of spironolactone pharmaceutical powder by artificial neural 
network and near- infrared spectrometry. An artificial neural network model to predict 
unknown samples was based on the data from near-IR diffuse reflectance spectra of 
spironolactone pharmaceutical powders [23]. 
3.2.2 M. S. Mahrous, A. S Issa, N. S. Soliman have developed colorimetric methods 
for the determination of spironolactone in tablets. Three different methods were 
developed for the colorimetric determination of spironolactone, either in its pure form or 
in tablets.  The methods utilize either the alkaline picrate reagent, isonicotinic acid 
hydrazide solution or hydroxamic acid formation for the evaluation of spironolactone.  
The sensitivity of the proposed procedures was discussed and the results obtained were 
compared with the pharmacopeial methods [24]. 
3.2.3 B. A. Moussa, N. M. El Kousy have developed colorimetric analysis method of 
some diuretic drugs: hydrochlorothiazide and spironolactone.  Hydrochlorothiazide [58-
93-5] and spironolactone [52-01-7] were determined inbulk and tablets by colorimetry.  
Hydrochlorothiazide reacted with BuNH2 [109-73-9] and CoCl2 in anhydride medium, 
giving a blue-violet color. The absorbance at 570 nm of 0.2-1.12 mg/mL 
hydrochlorothiazide obeyed Beer's law. Spironolactone determination was dependent on 
the reaction with isoniazid [54-85-3].  The absorbance was measured at 450 nm.  Beer's 
law was obeyed over the concentration range 4-20 µg/mL [25]. 
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3.2.4 D. M. Shingbal, V. R. Rao have developed colorimetric analysis method for 
spironolactone and its dosage forms. Spironolactone [52-01-7] was determined in tablets 
by a colorimetric method based on spironolactone dissolution in EtOH and mixing of an 
aliquot of this solution with p-dinitrobenzene [100-25-4] and NaOH solution and 
measurement of the absorbance of the yellow solution at 400 nm.  The color was stable 
for 6 hour at room temperature. Common tablet excipients did not interfere in the 
determination. The recovery was 98.8-99.76% [26]. 
3.2.5 V. Nevrekar has developed spectrophotometric estimation of spironolactone. 
Spironolactone [52-01-7] was determined in tablets by dissolving in EtOH, diluted with 
MeOH, mixing with 2,3,5-triphenyltetrazolium chloride [298-96-4] and Me4
3.2.6 D. M. Shingbal, J. S. Prabhudesai have developed a spectrophotometric 
estimation method for spironolactone in pharmaceutical dosage form, based on reaction 
with isoniazid  [54-85-3] in CHCl
NOH in 
MeOH, heating the solution at 45°C for 55 min, and measuring the absorbance at 480 nm.  
Beer's law held for 10-70 µg/mL, and recoveries were 99.9-100.1% [27].  
3
3.2.7 P. Parimoo, A. Bharathi, K. Padma  have developed a method for simultaneous 
determination of spironolactone with hydroflumethiazide and spironolactone with 
frusemide in combination formulations by UV absorption method. The λ max for SPN 
was found at 238 nm, for HFT at 273 nm and for FRU at 276 for SPN was found at 238 
nm, for HFT at 273 nm and for FRU at 276 nm respectively. There were no interferences 
in their estimations [29]. 
 and MeOH in acid medium and measuring the 
absorbance of the resulting yellow solution at 375 nm.  Beer's law was obeyed in the 
concentration range 5-40 µg/mL. The standard deviation was 0.613-0.652 and the 
recovery 99% [28].   
3.2.8 H. Salem, M. El-Maamli, M. El-Sadek, A. A. Kheir have developed UV and 
UV derivative spectrophotometric determination of two-component mixtures. Two-
component mixtures (spironolactone with hydrochlorothiazide, captopril with 
hydrochlorothiazide, and spironolactone with furosemide) were assayed by UV (A), first 
derivative (dA/dλ) and second derivative (d2A/dλ) spectrophotometric methods, applying 
"Zero-Crossing" technique of measurement. The methods were proved using laboratory 
prepared mixtures.  The utility of the methods in assay of dosage forms is also presented 
[30].       
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3.2.9 J. Chamberlain has developed, a gas chromatographic determination method for 
levels of aldadiene in human plasma and urine following therapeutic doses of 
spironolactone. Aldadiene was extracted from the samples into dichloroethane and 
dissolved in EtOH for electron-capture gas chromatography on a 2% OV-1
3.2.10  F. Belal has studied polarographic behavior and determination of spironolactone. 
The polarogaphic behavior of spironolactone in Britton-Robinson buffers content 40% 
MeOH as a solubilizer was studied. Over the pH range 3-12 a cathodic wave was 
produced. The wave was characterized as irreversible, diffusion-controlled and partially 
affected by adsorption phenomena. The number of electrons involved in the reduction 
was found by coulometric measurements at a controlled potential [32].   
/CQ column at 
250°with N carrier gas and with androst-4-ene-3, 6, 17-trione as the internal standard.  
The mean recovery was 96% with < 4% standard deviations, and the detector response 
(relative peak height) was linear for 15 mg aldadiene/1 ml urine and 150 μg 
aldadiene/100 ml plasma. Aldadiene levels in plasma reached a maximum of 10-15 
µg/100 ml. approximately 3 hour after administration of 100-mg spironolactone, and 
approximately 4 mg aldadiene was excreted 24-hr following the spironolactone dose [31]. 
3.2.11  G. K. Dyade, A. K. Sharma have developed two methods for simultaneous 
spectrophotometric determination of spironolactone and hydroflumethiazide in tablet 
formulations. The methods were multi-wavelength spectroscopy and the isoabsorptive 
point method.  Spironolactone and hydroflumethiazide had absorption maxima at 238.0 
and 273.0 nm, respectively in MeOH. Both the drugs obeyed Beer's law in the 
concentration ranges employed for these methods [33].  
3.2.12 Hong-Yan Ma, Guang-Cai Qi have developed method for determination of 
spironolactone by micellar enhanced spectrofluorimetry. In the presence of sodium 
dodecyl sulfate (SDS), the detection limit is 1.2 x 10-9 mol-L-1, the linear range of 1.4 x 
10-9 - 4.3 x 10-6 mol-L-1
3.2.13  P. Parimoo, A. Bharathi, K. Padma  have developed fluorimetric determination 
of spironolactone in the presence of frusemide and hydroflumethiazide in drug 
formulations. Spironolactone was determined in pharmaceuticals from its strong 
fluorescence in 62% H
 is obtained. This method was successfully applied to the 
determination of spironolactone in tablets with satisfactory results [34].  
2SO4 and ethanol (excitation 324 nm, emission 530 nm).  The 
presence of HFT did not affect the fluorescence of SPN, however FRU caused a slight 
decrease in fluorescence intensity.  The limit of detection for SPN was 8.3 µg/mL [35]. 
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4. AIM OF PRESENT WORK 
Various publications are available regarding determination method of Furosemide 
and Spironolactone but most of the methods are applicable to alone Spironolactone or 
Furosemide in pharmaceutical dosage form or in biological fluids. Potentiometric, 
colorimetric estimation, thin-layer chromatography, fluorometrically, complexation, first-
derivative and spectrophotometric, flow injection chemiluminescence method, proton 
nuclear magnetic resonance spectroscopic and HPLC methods are reported. Only few 
methods are reported for the simultaneous determination of spironolactone and 
furosemide. Two methods are UV and UV derivative spectrophotometric determination 
of two-component mixtures (spironolactone with hydrochlorothiazide, captopril with 
hydrochlorothiazide, and spironolactone with furosemide, spironolactone with 
hydroflumethiazide), which is able to determine spironolactone and furosemide in 
combined dosage form and fourth fluorimetric determination of spironolactone in the 
presence of frusemide and hydroflumethiazide in drug formulations. As far as our 
knowledge is concern, No reported HPTLC method estimation of these drugs in tablet, 
taking into consideration the simplicity, cost effectiveness and reliability of HPTLC in the 
analysis of Drugs, an attempt was made to develop a new, simple and validated HPTLC 
method for simultaneous estimation of furosemide and spironolatone dosage form tablets.  
The HPTLC method was subjected to statistical validation and was applied for the 
determination of  furosemide and spironolactone from its combined dosage form. 
 
The aim and scope of the proposed work are as under: 
 To develop simple HPTLC method for simultaneous determination furosemide and 
spironolactone in tablet formulation. 
 Perform the validation for the developed method. 
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5. EXPERIMENTAL 
5.1 Materials 
Furosemide and Spironolactone standard of was provided by Aarti Drugs Ltd., 
Boisar (India). Furosemide and Spironolactone tablets containing 50mg spironolactone 
and 20mg furosemide and the inactive ingredient used in drug matrix were obtained from 
market. Ethyl acetate, hexane and methanol were purchased from Spechtrochem Ltd. 
5.2 Instrumentation 
Traditional Thin Layer Chromatography and its modern instrumental quatintative 
analysis version HPTLC are very popular for many resons sich as visual chramatogram, 
simplicity, multiple sample handling, low running and maintenance costs,disposable layer 
etc. HPTLC is the fastet of all chromatographic methods. Very few HPTLC plates are 
required to handle a very large number of samples. Important scientific reasons for 
HPTLC’s modest popularity are that it is an open system due to which atmospheric 
conditions can affect the chromatographic process during development i.e. during 
separation.Humidity is found to be variable affecting reproduction of results. Most 
HPTLC’s done today are perfomed on silica gel, a strongly hydrophilic substance. The 
nature of silica gel is such that it separates both by adsorption throughout its structural 
OH group as well as partition though its absorbed moisture content. 
The HPTLC comprises of three sections. The lower section holds the 20 x 10 cm 
twin through chamber.The upper half is robotic where the plate is held for pre-
conditionning the layer before development specified in the method as well as for drying 
the plate uniformly after development. The top section contains the electronics. 
The chromatographic system used to perform development and validation of this 
assay method was Camag Linomat V Sample applicator, Camag Twin trough glass 
chamber and Camag TLC scanner III equipped with Cats 3 Version softeware. 
5.3 Mobile phase preparation 
The mobile phase comprising of Ethyl acetate: Haxane in the volume ratio of  (80: 
20, v/v) was employed for the elution. 
5.4 Diluent preparation 
Use  Methanol  used as a diluent. 
5.5 Standard preparation 
Furosemide standard stock solution containing 200µg/ml was prepared in a 100 
ml volumetric flask by dissolving 20.00 mg of Furosemide and then diluted to volume 
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with diluent. Further take 10 ml of this stock solution in 50 ml volumetric flask and make 
up to mark with diluent (this standard solution of 40µg/ml).Spironolactone standard stock 
solution containing 500µg/ml was prepared in a 100 ml volumetric flask by dissolving 
50.00 mg of Spironolactone and then diluted to volume with diluent. Further take 10 ml 
of this stock solution in 50 ml volumetric flask and make up to mark with diluent (this 
standard solution of 100µg/ml).  
5.6 Test preparation 
 
Twenty tablets were weighed and the average weight of tablet was determined. 
From these, five tablets were weighed and transfer into a 500 ml volumetric flask. About 
50 ml of diluent was added and sonicated for a minimum 30 minute. with intermittent 
shaking. Then content was brought back to room temperature and diluted to volume with 
diluent. The sample was filtered through 0.45µm nylon syringe filter. Further take 10 ml 
of this stock solution in 50 ml of volumetric flask and make up to mark with diluent. The 
concentration obtained was 40 µg/ml of Furosemide and 100 µg/ml of Spironolactone. 
5.7 Chromatographic conditions 
Chromatographic analysis was performed on a HPTLC   plates precoated with 
0.25 mm layer of chromatographic silica gel mixture(Silica GF254) on aluminum sheets. 
After development of the Cromplate, The detection was carried out using an UV scanning 
densitometer set at a wavelength of 254nm. 
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6. RESULTS AND DISCUSSION 
6.1 Development and Optimization of the HPTLC Method 
Selection of Chromatographic Condition: In the present work, an analytical 
method based on HPTLC was developed and validated for assay determination of 
Furosemide and Spironolactone in tablet formulation. The various steps involved in 
TLC/HPTLC are Sample preparation, TLC plate pretreat men, and Sample application, 
Drying, Evalution and Documentation. Thin layer chromatography is an off-line 
technique as compared to HPLC/GC but the properties that govern the selection of a 
method and its components are essentially same. 
Following are the factors or steps involved in method development by TLC, 
which results in good separation, which is one of the most critical steps in qualitative and 
quantitative analysis 1)selection of stationary phase, 2)Selection of vapour phase, 3) 
Selection of suitable solvent, 4) Optimisation of mobile phase, 5)Selection of 
development mode ,6)Selection of other operating parameters. 
Traditionaly TLC is inexpensive, simple to use and requires minimal 
instrumentation, laboratory space and maintenance. However, to achieve good precision, 
accuracy and reproducibility, a certain degree of instrumentation is required and 
dansitometric detection is necessary for quantification. 
Standardization of experimental condition: The extent of separation of various 
components of a mixture by a   given Thin layer chromatography method depends on the 
separation efficiency and selectivity of the separating system. The various factors 
influencing the separation are: 
 Type of stationary phase 
 Type of pre-coated plate(TLC/HPTLC) 
 Layer thickness 
 Binder in the layer 
 Mobile phase 
 Solvent purity 
 Size of the developing chamber 
 Saturation of the chamber (pre-equilibrium) 
 Relative humidity 
 Temperature 
 Separation distance 
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Mobile phase optimization: The mobile phase in TLC is generally selected by 
controlled trial and error method. In normal phase, TLC separation is carried out on a 
non-aqueous mobile phase(silica gel) using a non-aqueous mobile phase. Developing 
solvent usually, is a mixture of non-polar organic solvent with a polar modifier such as 
methanol, ethyl acetate, acetone, acetonitrile to control the solvent strength and 
selectivity. 
Sometimes small amounts of third component such asacetic acid, ammonia, 
triethylamine and formic acid are added to mobile phase because they partially modify 
the surface of silica gel. Keeping the acidic and the basic centers in a molecule 
nonionised; leads to decrease in the tailing of polar sample components. 
The selection of the mobile phase is of prime importance in the development of a 
chromatographic technique for proper elution, resolution, spot definition, symmetrical 
peak shapes and Rf reproducibility of the analytes.  
In present research work, initial trials were done using mobile phase with  used 
these solvent like chloroform, methanol, ethyl acetate and hexane.it was observed that 
resolution between the two actives was good but the Rf value was not meeting the 
acceptance criteria. Hence, the final method set was by using Ethyl acetate: Hexane 
(80:20) for better separation as well as reproducibility of Rf value. 
Thus, optimized mobile phase used for separation was Ethyl acetate: Hexane 
in volume ratio of 80:20(v/v). 
Both components i.e. Furosemide and Spironolactone are found to be soluble in 
methanol was choosen as diluents for standard as well as sample preparation. Recovery of 
actives in accuracy was good with the use of methanol as solvent. 
Selection of the most suitable wavelength for densitometric scanning: In case 
of multi component pharmaceuticals preparations,containing more than one active 
ingredient with variable concentrations, if the TLC plate is scanned at maximum 
absorbance of each component the purpose of using TLC, as a high throughput device is 
lost. Hence, in such cases one has to explore the possibility of selecting a wave length at 
which the entire chromatogram can be scanned without losing any vital information about 
different components in the formulation. The single wavelength referred   to as “most 
suitable wavelength” In the present research work the most suitable wavelength was 
found to be 254 nm as can be seen from the UV spectrum where in all both actives 
showed good absorption. (Figure- 4) 
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Figure 4: UV Scan Spectrum of standards 
 
OPTIMIZED CHROMATOGRAPHIC CONDITIONS FOR HPTLC: 
 
Optimized chromatographic conditions for HPTLC method as under, 
       
          Parameters        Chromatographic Conditions 
Development chamber CAMAGE Twin Trough Chamber 
Stationary phase Silica gel GF254 precoated on aluminum sheet  
Mobile phase Ethyl acetate: Hexane(80:20) 
Chamber saturation 45 mins 
Sample applicator CAMAGE LINOMAT V 
Band 6mm 
Space 9 mm 
Scanning speed 20mm/sec 
Development distance 8 cm 
Drying of plate Room temperature 
Densitometric scanner CAMAGE TLC SCANNER 
Lamp Deuterium  
Wavelenth 254 nm 
Volume 5µl 
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Figure 5 and 6 represent the densitometry chromatograms of standard and test preparation 
respectively. 
 
   Figure 5: Chromatogram of standard preparation 
 
Figure 6: Chromatogram of test preparation 
Furosemide and Spironolactone…   Part-C  
 
 
 
241 
 
6.2 Method Validation 
 
6.2.1 Specificity 
In an assay, demonstration of specificity requires that it can be shown that the 
procedure is unaffected by the presence of impurities or excipients. In practice, this can 
be done by spiking the drug substance or product with appropriate levels of impurities or 
excipients and demonstrating that the assay results is unaffected by the presence of these 
extraneous materials. 
 There should be no interference of the diluents / placebo at Rf value of 
drug substances. 
 
6.2.2 Linearity 
 
For linearity seven points calibration curve were obtained in a concentration range 
from 0.016-0.064 mg/ml for Furosemide and 0.040-0.160 mg/ml for Spironolactone. The 
response of the drug was found to be linear in the investigation concentration range and 
the linear regression equation for Furosemide was y = 28661x + 38.477 with correlation 
coefficient 0.9958(Figure 7) and for Spironolactone was y = 38237x + 47.754 with 
correlation coefficient 0.9975 (Figure 8). Where x is the concentration in mg/ml and y is 
the peak area in absorbance unit.  
 
Linearity study for Furosemide
y = 28661x + 38.477
R2 = 0.9958
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Figure 7: Linearity curve for Furosemide  
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Linearity study for Spironolactone
y = 38237x + 47.754
R2 = 0.9975
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Figure 8: Linearity curve for Spironolactone 
 
6.2.3 Precision 
Data obtain from precision experiments are given in Table 1 for intraday and 
interday precision study for both furosemide and spironolactoned. The RSD values for 
intra day precision study and interday precision study was < 2.0 % for furosemide and 
spironolactone. Which confirm that the method was precise. 
Table 1: Results of precision study  
 
Set 
Furosemide(%Assay) Spironolactone(%Assay) 
Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Interday 
(n = 6) 
1 98.0 97.1 97.9 98.5 
2 99.9 100.3 97.6 99.2 
3 100.7 98.7 97.2 98.1 
4 98.0 98.6 99.3 100.7 
5 96.6 97.2 100.2 99.5 
6 100.1 100.3 96.5 97.6 
Mean 98.9 98.7 98.1 98.9 
Standard deviation 1.58 1.42 1.35 1.10 
% RSD 1.60 1.44 1.37 1.11 
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6.2.4 Accuracy 
Recovery of Furosemide and Spironolactone were determined at three different 
concentration levels. The mean recovery for Furosemide was 98.51- 98.81 % and 98.20-
98.98 % for Spironolactone (Table 2). 
 
Table 2: Results of accuracy study 
 
 
 
Level 
(%) 
 
Theoretical 
concentrationa
Observed 
concentration 
(µg/ml) 
a % 
Recovery  (µg/ml) 
% RSD 
Furosemide  
50 20.73 20.43 98.53 0.59 
100 40.00 39.40 98.51 1.01 
150 40.60 59.68 98.81 0.14 
Spironolactone 
50 50.47 49.94 98.95 0.32 
100 100.40 99.59 99.20 1.23 
150 150.33 148.80 98.98 1.37 
 
a
6.2.5 Solution stability study 
 Each value corresponds to the mean of three determinations 
 
Stability of sample solution was checked by using sample preparation from 
preparation from precision study stored at room temperature for 24 hours; withdrawn in 
the intervals of 2 hrs, 4hrs, 12hrs and 24hrs and applied on the chromatoplate. After 
development, the chromatogram was evaluated for additional spots if any. There was no      
indication of compound instability in the sample solution. 
Stability on the sorbent layer prior to development (spot stability): The time 
wherein the sample is left to stand on the sorbent prior to chromatographic development 
can influence the stability of separated spots and are required to be investigated for 
validation. Two- dimensional chromatography using same solvent system was used to 
find out any decomposition occurs during spotting and development. Incase, if 
decomposition occurs during development, peaks of decomposition products are obtained 
for the analyte both in the first and second direction of run. No decomposition was 
observed during spotting and development.  
 
 
 
Furosemide and Spironolactone…   Part-C  
 
 
 
244 
 
6.2.6 Robustness:  
The result of robustness study of the developed assay method was established in 
Table 4 and Table 5. The result shown that during all variance conditions, assay value of 
the test preparation solution was not affected and it was in accordance with that of actual. 
System suitability parameters were also found satisfactory; hence the analytical method 
would be concluded as robust.  
Table 4: Evaluation data of robustness study of Furosemide  
 
 
Robust conditions % Assay System suitability parameters Area Rf value 
Ethyl acetate.:Hexan(82:18) 99.4 1042 35 
Ethyl acetate.:Hexan(78:22) 98.3 1243 31 
Analyst Change 98.5 1144 33 
 
 
Table 5: Evaluation data of robustness study for Spironolactone 
 
 
Robust conditions % Assay System suitability parameters Area Rf value 
Ethyl acetate :Hexan(82:18) 98.1 3986 86 
Ethyl acetate :Hexan(78:22) 98.3 4289 82 
Analyst Change 98.5 4123 84 
  
 
5.2.7 System suitability:  
A system suitability test of the chromatographic system was performed before 
each validation run to confirm the suitability and reproducibility of the system. The 
system suitability experiment as carried out using 40 ppm of Furosemide and 100 ppm of 
Spironolactone. This solution was spotted five times on the chromatographic plate under 
the optimized conditions. Parameters  that were studied to evaluate the suitability of the 
system where:-  
1. % RSD of peak area 
2. % RSD of retention factor of drug peak 
 
The Rf value of indivisual spotted should be comparable with the corresponding 
Rf value of system suitability solution.(Table 6) 
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Table 6: System suitability 
 
 
   No. 
100% Level 
Furosemide Spironolactone 
 Peak area Rf value Peak area Rf value 
1 1220 34 4033 84 
2 1243 33 4071 85 
3 1236 33 4129 84 
4 1205 32 4181 81 
5 1280 31 4210 83 
Mean 1237 32.6 4125 83.4 
S.D. 28.27897 1.14 73.750932 1.52 
%RSD 2.29 3.50 1.79 1.82 
 
 
The value of %Relative standard deviation of 5 replicates of peak area of bands 
should be well less than 5.0%. Whereas %Relative standard deviation of Rf value should 
be less than 10.0 %.From the above results, it can be seen that the %Relative standard 
deviation for all parameter is well below the required limit for all the parameters. 
To demonstrated that that the proposed method is adequated for its intended use,the 
method was subjected to statistical validation to determine linearity, accuracy and 
precision. 
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7. CALCULATIONS AND DATA 
 
Calculation formula used: 
 
1. Calculation formula for furosemide 
 
 
WeightTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay 500
50
10
100
% ×××=  
 
Standard
10
50 ofPotency
ClaimLable
WeightTestMean
×××  
 
2.  Calculation formula for spironolactone 
 
 
50
10
100
Standard
Standard
% ××=
Weight
AreaMean
AreaTestMean
Assay  
 
Standard
10
50500 ofPotency
ClaimLable
WeightTestMean
WeightTest
××××  
 
3. Relative standard deviation  
 
100×=
 tsMeasuremenofValueMean
 tsMeasuremenofDeviationStandard
RSD%  
 
4. Recovery  
 
100×=
AddedAmount
FoundAmount
Recovery%  
 
5. Amount Found  
 
ionConcentratStandard
AreaStandardMean
AreaTestMean
(mg/ml)FoundAmount ×=  
 
6. Amount added 
 
Volume
Weight(mg/ml)AddedAmount =  
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Specificity Study for Analytical Method Validation of Furosemide and 
Spironolactone Tablets 
 
 For Furosemide 
 
Standard weight (mg) 20.4     
Standard dilution 100 10 50   
Standard potency 100.00 %     
Standard concentration (mg/ml) 0.0408     
      
Replicate 1 2 3 4 5 
Standard area 1220 1243 1236 1205 1280 
Mean standard area 1237     
Stdev. 28.28     
% RSD 2.29     
 
 
 
Replicate Test area 
1 1180 
2 1158 
Mean test area 1169 
Test weight (mg) 1071.3 
Label claim (mg) 20 
Mean test weight (mg) 217.8 
% Assay 98.0 
 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
3.1071
500
50
10
100
4.20
1237
1169% ×××=Assay 100
20
8.217
10
50
×××  
 
     =  98.0 % 
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 For Spironolactone 
 
Standard weight (mg) 50.4     
Standard dilution 100 10 50   
Standard potency 100.00 %     
Standard concentration (mg/ml) 0.1008     
      
Replicate 1 2 3 4 5 
Standard area 4033 4071 4129 4181 4210 
Mean standard area 4125     
Stdev 73.75     
% RSD 1.79     
 
 
 
Replicate Test area 
1 3998 
2 3961 
Mean test area 3980 
Test weight (mg) 1071.3 
Label claim (mg) 50  
Average test weight (mg) 217.8 
% Assay 98.9 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
3.1071
500
50
10
100
4.50
4125
3980% ×××=Assay 100
50
8.217
10
50
×××  
 
     =  98.9 % 
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Linearity Study for Analytical Method Validation of Furosemide and 
Spironolactone Tablets 
 
 For Furosemide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard weight (mg) 40.0    
Standard dilution 100 10 50  
Standard potency 100.00%    
Standard concentration (mg/ml) 0.0400     
Concentration of linearity stock solution (mg/ml) 0.4000     
      
Replicate 1 2 3 4 5 
Standard area 1190 1234 1251 1198 1268 
Mean standard area 1228     
Stdev 33.57     
% RSD 2.73     
Concentration level 
(%) 
Volume of 
linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final 
concentration 
(mg/ml) 
Mean area 
40 2.0 50 0.0160 487 
60 3.0 50 0.0240 768 
80 4.0 50 0.0320 998 
100 5.0 50 0.0400 1164 
120 6.0 50 0.0480 1460 
140 7.0 50 0.0560 1694 
160 8.0 50 0.0640 1878 
  Correlation co-efficient 0.9971 
  Slope 27853.57565 
  Intercept 76.73 
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 For Spironolactone 
 
 
  
 
 
Standard weight (mg) 100    
Standard dilution 100 10 50  
Standard potency 100.0 %     
Standard concentration (mg/ml) 0.1000     
Concentration of linearity stock solution (mg/ml) 1.0000     
      
 Replicate 1 2 3 4 5 
Standard area 4123 4067 4149 4184 4222 
Mean standard area 4149     
Stdev 59.06     
% RSD 1.42     
Concentration level 
(%) 
Volume of 
linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final 
concentration 
(mg/ml) 
Mean area 
40 2.0 50 0.0400 1476 
60 3.0 50 0.0600 2443 
80 4.0 50 0.0600 3178 
100 5.0 50 0.0800 4019 
120 6.0 50 0.1000 4501 
140 7.0 50 0.1400 5437 
160 8.0 50 0.1600 6096 
  Correlation co-efficient 0.9978 
  Slope 37810.71429 
  Intercept 97.21 
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Precision Study for Analytical Method Validation of Furosemide and 
Spironolactone  Tablests 
 
 For Furosemide 
 
Standard weight (mg) 20.1     
Standard dilution 100 10 50   
Standard potency 100.0 %     
Label claim (mg) 20     
Mean test weight (mg) 1071.3     
Standard concentration (mg/ml) 0.0402     
      
Replicate 1 2 3 4 5 
Standard area 1123 1144 1201 1198 1163 
Mean standard area 1166     
Stdev 33.88     
% RSD 2.91     
 
Description Mean area Test weight (mg) % Assay 
Set 1 1117 1070 98.0 
Set 2 1139 1070.5 99.9 
Set 3 1151 1072.7 100.7 
Set 4 1118 1070.8 98.0 
Set 5 1103 1071 96.6 
Set 6 1145 1072.9 100.1 
  Mean 98.9 
  Stdev 1.58 
  % RSD 1.60 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
1070
500
50
10
100
1.20
1166
1117% ×××=Assay 100
20
8.217
10
50
×××  
 
 =  98.0 %      
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 For Spironolactone 
 
Standard weight (mg) 49.7     
Standard dilution 100 10 50   
Standard potency 100.0 %     
Label claim (mg) 50     
Mean test weight (mg) 1071.3     
Standard concentration (mg/ml) 0.0994     
      
Replicate 1 2 3 4 5 
Standard area 4203 4097 4159 4174 3958 
Mean standard area 4118     
Stdev 97.57     
% RSD 2.37     
 
 
 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
1070
500
50
10
100
7.49
4118
3986% ×××=Assay 100
50
8.217
10
50
×××  
 
          =  97.9 % 
 
 
 
 
 
 
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 3986 1070 97.9 
Set 2 3976 1070.5 97.6 
Set 3 3969 1072.7 97.2 
Set 4 4044 1070.8 99.3 
Set 5 4082 1071 100.2 
Set 6 3941 1072.9 96.5 
  Mean 98.1 
  Stdev 1.35 
  % RSD 1.37 
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Intermediate Precision Study for Analytical Method Validation of Furosemide and 
Spironolactone  Tablets 
 
 For Furosemide 
 
Standard weight (mg) 20.3     
Standard dilution 100 10 50   
Standard potency 100.0 %     
Label claim (mg) 20     
Mean test weight (mg) 1071.3     
Standard concentration (mg/ml) 0.0406     
      
Replicate 1 2 3 4 5 
Standard area 1220 1164 1201 1188 1143 
Mean standard area 1183     
Stdev 30.33     
% RSD 2.56     
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 1113 1070 97.1 
Set 2 1150 1071 100.3 
Set 3 1132 1071.9 98.7 
Set 4 1130 1070.6 98.6 
Set 5 1114 1071.2 97.2 
Set 6 1152 1072 100.3 
  Mean 98.7 
  Stdev 1.42 
  % RSD 1.44 
 
Calculation: 
 
Prototype calculation for one set: 
 
1070
500
50
10
100
3.20
1183
1113% ×××=Assay 100
20
8.217
10
50
×××  
 
          = 97.1 % 
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 For Spironolactone 
 
Standard weight (mg) 50.5     
Standard dilution 100 10 50   
Standard potency 100.0 %     
Label claim (mg) 50     
Mean test weight (mg) 1071.3     
Standard concentration (mg/ml) 0.101     
      
Replicate 1 2 3 4 5 
Standard area 4243 4078 4189 4184 4048 
Mean standard area 4148     
Stdev 82.01     
% RSD 1.98     
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 3977 1070 98.5 
Set 2 4007 1071 99.2 
Set 3 3965 1071.9 98.1 
Set 4 4065 1070.6 100.7 
Set 5 4018 1071.2 99.5 
Set 6 3946 1072 97.6 
  Mean 98.9 
  Stdev. 1.10 
  % RSD 1.11 
 
Calculation: 
 
Prototype calculation for one set: 
 
1070
500
50
10
100
5.50
4148
3977% ×××=Assay 100
50
8.217
10
50
×××  
 
       = 98.5 % 
  
 
 
 
 
 
 
 
 
Furosemide and Spironolactone…   Part-C  
 
 
 
255 
 
Comparison for Precision and Intermediate Precision Study for Analytical Method 
Validation for Furosemide Spironolactone Tablets 
 
 For Furosemide  
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 For Spironolactone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Set % Assay 
Precision study 
1 98 
2 99.9 
3 101.1 
4 98 
5 96.6 
6 100.1 
Intermediate precision study 
1 97.1 
2 100.3 
3 98.7 
4 98.6 
5 97.2 
6 100.3 
 Mean 98.8 
 Stdev 1.49 
 % RSD 1.50 
 
 
Set 
 
%Assay 
Precision study 
1 97.9 
2 97.6 
3 97.2 
4 99.3 
5 100.2 
6 96.5 
Intermediate precision 
study 
1 98.5 
2 99.2 
3 98.1 
4 100.7 
5 99.5 
6 97.6 
 Mean 98.5 
 Stdev 1.27 
 % RSD 1.29 
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Accuracy Study for Analytical Method Validation of Furosemide and 
Spironolactone Tablets 
 
 For Furosemide  
 
Standard weight (mg) 20     
Standard dilution 100 10 50   
Standard potency 100.0 %     
Standard concentration (mg/ml) 0.0400     
      
Replicate 1 2 3 4 5 
Standard area 1229 1263 1196 1209 1243 
Mean standard area 1228     
Stdev 26.62     
% RSD 2.17     
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  For Spironolactone 
 
Standard weight (mg) 20.0     
Standard dilution 100 10 50   
Standard potency 100.00 %     
Standard concentration (mg/ml) 0.1000     
      
Replicate 1 2 3 4 5 
Standard area 4030 4064 4135 4187 4224 
Mean standard area 4128     
Stdev 81.31     
% RSD 1.97     
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Robustness Study for Analytical Method Validation of Furosemide and 
Spironolactone  Tablets (Furosemide) 
 
 
 
E.A.: Hexane 
(82:18) 
E.A.: Hexane 
(78:22) 
Analyst 
Change 
Replicate Standard Area Standard Area Standard Area 
1 1038 1273 1176 
2 1024 1284 1143 
3 1014 1239 1096 
4 1078 1198 1144 
5 1058 1223 1163 
Mean 1042 1243 1144 
Stdev 25.8612 35.4302 30.3694 
% RSD 2.48 2.85 2.65 
Replicate Test Area Test Area Test Area 
1 987 1197 1062 
2 1002 1148 1101 
Mean 995 1173 1082 
Standard weight (mg) 20.5 20.5 20.5 
Test weight (mg) 1071.1 1071.1 1071.1 
Label claim (mg) 20 20 20 
Average test weight (mg) 217.8 217.8 217.8 
% Assay 99.4 98.3 98.5 
 
 
Calculation: 
 
 Prototype calculation for one set:  
 
1.1071
500
50
10
100
5.20
1042
995% ×××=Assay 100
50
8.217
10
50
×××   
     
    =  99.4 % 
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Robustness Study for Analytical Method Validation of Furosemide and 
Spironolactone Tablets (Spironolactone) 
 
 
 
E.A.: Hexane 
(82:18) 
E.A.: Hexane 
(78:22) 
Analyst 
Change 
Replicate Standard Area Standard Area Standard Area 
1 4097 4365 4199 
2 4021 4258 4037 
3 3949 4208 4110 
4 3961 4215 4079 
5 3900 4398 4190 
Mean 3986 4289 4123 
Stdev 75.72 87.54 70.30 
% RSD 1.90 2.04 1.70 
Replicate Test Area Test Area Test Area 
1 3818 4190 3964 
2 3906 4133 4057 
Mean 3862 4162 4011 
Standard weight (mg) 49.8 49.8 49.8 
Test weight (mg) 1071.1 1071.1 1071.1 
Label claim (mg) 50 50 50 
Average test weight (mg) 217.8 217.8 217.8 
% Assay 98.1 98.3 98.5 
 
 
Calculation: 
 
Prototype calculation for one set:  
 
1.1071
500
50
10
100
0.20
3986
3862% ×××=Assay 100
20
8.217
10
50
×××  
     
     =  98.1 % 
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UV-VISIBLE SPECTROPHOTOMETRIC METHOD DEVELOPMENT AND 
VALIDATION OF LAMOTRIGINE AND IT’S TABLETS FORMULATION      
                                                                                                                              
1. INTRODUCTION  
1.1 Spectroscopy  Methods [1,2] 
It is the branch of science dealing with the study of interaction between 
electromagnetic radiation and matter. It is a most powerful tool available for the study of 
atomic and molecular structure/s and is used in the analyses of wide range of samples. 
Optical spectroscopy includes the region on electromagnetic spectrum between 100 Å and 
400 μm. The regions of electromagnetic spectrum are: 
    
Region Wavelength 
Far (or vacuum)ultraviolet 10-200 nm 
Near ultraviolet 200-400 nm 
Visible 400-750 nm 
Near infrared 0.75- 2.2 µm 
Mid infrared 2.5-50 µm 
Far infrared 50-1000 µm 
 
1.2 Ultraviolet-Visible spectrophotometry [3] 
  UV-Visible spectrophotometry is one of the most frequently employed technique       
in pharmaceutical analysis. It involves measuring the amount of ultraviolet or visible 
radiation absorbed by a substance in solution. Instrument which measure the ratio, or 
function of ratio, of the intensity of two beams of light in the U.V.visible region are called 
ultraviolet-visible spectrophotometers.   
 In qualitative analysis, organic compounds can be identified by use of spectrophotometer, 
if any recorded data is available, and quantitative spectrophotometric analysis is used to 
ascertain the quantity of molecular species absorbing the radiation. Spectrophotometric 
technique is simple, rapid, moderately specific and applicable to small quantities of 
Spectrophotometric…   Part-D  
 
 
 
265 
 
compounds. The fundamental law that governs the quantitative spectrophotometric analysis 
is the Beer -Lambert law. 
 
1.2.1 Beer’s law  
 It states that the intensity of a beam of parallel monochromatic radiation decreases 
exponentially with the number of absorbing molecules. In other words, absorbance is 
proportional to the concentration. 
1.2.2 Lambert’s law 
 It states that the intensity of a beam of parallel monochromatic radiation decreases 
exponentially as it passes through a medium of homogeneous thickness. 
A combination of these two laws yields the Beer-Lambert law. 
1.2.3 Beer-Lambert law 
 When beam of light is passed through a transparent cell containing a solution of an  
absorbing substance , reduction of the intensity of light may occur.    
Mathematically, Beer-Lambert law is expressed as 
                               A = a b c 
                              Where, A = absorbance or optical density  
                                           a = absorptivity or extinction coefficient  
                                           b = path length of radiation through sample (cm) 
                                           c = concentration of solute in solution. 
Both b and   a are constant so a is directly proportional to the concentration c 
When c is in gm/100 ml, then the conctant is called A (1%, 1cm) 
 
 Quantification of medicinal substance using spectrophotometer may   carried out by 
preparing solution in transparent solvent and measuring it’s absorbance at suitable 
wavelength. The wavelength normally selected is wavelength of maximum absorption   (λ 
max), where small error in setting the wavelength scale have little effect on measured 
absorbance. Ideally, concentration should be adjusted to give an absorbance of 
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approximately, 0.9, around which the accuracy and precision of the measurements are 
optimal. 
The assay of single component sample, which contains other absorbing substances, is 
then calculated from the measured absorbance by using one of three principal procedures. 
They are, use of standard absorptivity value, calibration graph and single or double point 
standardization. 
In standard absorptive value method, the use of standard A (1%, 1cm) or E values are 
used in order to determine its absorptivity. It is advantageous in situations where it is difficult 
or expensive to obtain a sample of the reference substance. In calibration graph method, the 
absorbances of a number of standard solutions of the reference substance at concentrations 
encompassing the sample concentrations are measured and a calibration graph is constructed. 
The concentration of the analyte in the sample solution is read from the graph as the 
concentration corresponding to the absorbance of the solution. The single point 
standardization procedure involves the measurement of the absorbance of a sample solution 
and of a standard solution of the reference substance. The concentration of the substances in 
the sample is calculated from the proportional relationship that exists between absorbance 
and concentration. 
     Atest x C
                  C
std 
test       = 
          Astd 
Where Ctest and Cstd are the concentrations in the sample and standard  
solutions respectively and Atest and Astd are the absorbances of the sample         and 
standard solutions respectively. 
 
For assay of substance/s in multi component samples by spectrophotometer; the 
following methods are being used routinely, which includes13
 Simultaneous equation method 
; 
 Derivative spectrophotometric method 
 Absorbance ratio method ( Q-Absorbance method) 
 Difference spectrophotometry 
 Solvent extraction method 
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2. INTRODUCTION TO LAMOTRIGINE 
 
Lamotrigine is currently available in about 60 countries. The drug is currently only 
approved for the treatment of people with seizures. There are no systematic studies that 
establish the safety or efficacy of lamotrigine as a treatment for people with mood disorders. 
While such studies are in the planning stages, what is currently known about the use of 
lamotrigine for the control of mood disorders comes from uncontrolled case reports.  
Lamotrigine is an anticonvulsant that is chemically unrelated to any other 
anticonvulsant or mood regulating medication. Lamotrigine received final approval for 
marketing in the USDA on 27 December 1994 and is labeled for use as an anticonvulsant. It 
has full patent protection and a generic version is not available yet.  
The two major differences between lamotrigine and other mood regulating drugs are:  
• Lamotrigine's frequent effectiveness for patients who have failed to respond to 
antidepressants or mood stabilizers;  
• Lamotrigine's relatively benign side-effect profile 
Lamotrigine has been successful in controlling rapid cycling and mixed bipolar states 
in people who have not received adequate relief from carbamazepine and/or valproate. It also 
appears that lamotrigine has significantly more antidepressant potency than either 
carbamazepine or valproate. 
The initial use of lamotrigine was to treat depressed, manic and mixed states that did 
not respond to existing medications. Some patients are now being maintained on lamotrigine 
on a long term basis in an attempt to prevent future episodes. The effectiveness of 
lamotrigine as a long-term prophylactic agent is currently being established.  
 
2.1     Description 
Lamotrigine is chemically 6-(2, 3-Dichlorophenyl)-1, 2, 4-triazine-3, 5-diamine and 
its molecular formula is C9H7N5Cl2, and molecular weight is 256.09 gm/mole. Lamotrigine, 
an antiepileptic drug (AED) of the phenyltriazine class, is chemically unrelated to existing 
antiepileptic drugs, has been used successfully to treat essential trigeminal neuralgia (TN) 
[4-7].  
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N
N
N
Cl
Cl
NH2NH2  
Figure: 1   6-(2, 3-Dichlorophenyl)-1, 2, 4-triazine-3, 5-diamine 
LAMICTAL tablets are supplied for oral administration as 25-mg (white), 100-mg 
(peach), 150-mg (cream), and 200-mg (blue) tablets. Each tablet contains the labeled amount 
of lamotrigine and the following inactive ingredients: lactose; magnesium stearate; 
microcrystalline cellulose; povidone; sodium starch glycolate; FD&C Yellow No. 6 Lake 
(100-mg tablet only); ferric oxide, yellow (150-mg tablet only); and FD&C Blue No. 2 Lake 
(200-mg tablet only).  
LAMICTAL chewable dispersible tablets are supplied for oral administration. The 
tablets contain 2 mg (white), 5 mg (white), or 25 mg (white) of lamotrigine and the following 
inactive ingredients: blackcurrant flavor, calcium carbonate, low-substituted 
hydroxypropylcellulose, magnesium aluminum silicate, magnesium stearate, povidone, 
saccharin sodium, and sodium starch glycolate.  
2.2 Mechanism of action 
One proposed mechanism of action for lamotrigine involves an effect on sodium 
channels, although this remains to be established in humans. In vitro pharmacological studies 
suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing 
neuronal membranes and consequently modulating presynaptic transmitter release of 
excitatory amino acids (for example glutamate and aspartate) [8].  
2.3 Pharmacokinetics 
The pharmacokinetics of lamotrigine is quite complicated, with highly varying half-
life and blood plasma levels. Lamotrigine has fewer drug interactions than many 
anticonvulsant drugs, although pharmacokinetic interactions with sodium valproate in 
particular is an indication for blood monitoring. 
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3 LITERATURE REVIEW 
The literature reviews regarding lamotrigine suggest that various analytical methods 
were reported for its determination as drug, in pharmaceutical formulation and in various 
biological fluids. The literature reviews for analysis of lamotrigine are as under: 
 
3.1 Bartoli, Anna; Marchiselli, Roberto; Gatti, Giuliana have developed a rapid and 
specific assay for the determination of lamotrigine in human plasma by normal-phase HPLC.  
Lamotrigine is extracted with dichloromethane from buffered plasma to which an internal std. 
has been added.  The solvent is directly injected into a 250 × 4.6-mm Spherisorb Silica 
column and the drug is eluted by using a mixture of methanol, n-heptane, dichloromethane, 
and 28-30% ammonium hydroxide (20:40:40:0.3 vol/vol) at a flow rate of 1 mL/min.  The 
eluates are detected at 240 nm.  The assay requires 250 μl of sample, and concentrations as 
low as 0.4 µg/mL can be measured accurately.  The method is linear in the range of 0.4-16 
µg/mL, with a mean coefficient of correlation (r) ≥ 0.997.  Within- and between-day relative 
std. deviations at three different concentration levels (1, 4, and 8 µg/mL) are ≤ 8.6% [9]. 
3.2 Gasgupta, Amitava; Hart, Amy P. developed a method for lamotrigine analysis in 
plasma by gas chromatography-mass spectrometry after conversion to a tert-
butyldimethylsilyl derivative. Lamotrigine was extracted from alkaline serum with CHCl3
3.3 Fraser, Albert D.; MacNeil, Wallace; Isner, Arthur F.; Camfield, Peter R. have 
developed Lamotrigine analysis in serum by high-performance liquid chromatography. 
Lamotrigine was extracted from serum at alkaline pH into Ethyl acetate after addition of the 
internal standard (BW725C78). After mixing, the organic layer was evaporated to dryness 
before dissolving the residue in methanol for isocratic separation on a RP-8 column (5 µm) 
with a mobile phase of H
 and 
derivatized with N-methyl-N-(tert-butyldimethylsilyl) trifluoroacetamide content 2% tert-
butyldimethylchlorosilane.  Oxazepam-d5 was used as an internal standard. The assay was 
linear for serum lamotrigine concns. of 0.5=2.0 µg/mL.  The detection limit was 0.25 µg/mL 
[10]. 
2O-pH 6.5 0.5M phosphate buffer-MeCN (790:10:200) with eluant 
monitoring at 306 nm. Interference studies were performed on serum specimens content 
commonly monitored drugs. The only potentially interfering drug was carbamazepine, which 
elutes longer than lamotrigine [11]. 
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3.4 Sinz, Michael W.; Remmel, Rory P. have developed a method for analysis of 
lamotrigine and lamotrigine 2-N-glucuronide in guinea pig blood and urine by reserved-phase 
ion-pairing liquid chromatography. The extraction procedure and reversed-phase high-
performance liquid chromatography (HPLC) assay employed sodium dodecylsulfate (SDS) as 
an ion-pairing reagent to selectively separation. lamotrigine and lamotrigine 2-N-glucuronide 
from endogenous blood components, other anticonvulsant drugs, and their metabolites.  The 
mobile phase was composed of acetonitrile-50 mM phosphoric acid (pH 2.2) content 10 mM 
SDS (33:67, vol./vol.), and components were detected at 277 nm [12]. 
3.5 Patil Kuldeep M; Bodhankar Subhash L. have developed high-performance thin-
layer chromatographic determination of lamotrigine in serum. The method involves extraction 
of the drug by ethyl acetate followed by separation on TLC silica plates using a mixture of 
toluene-acetone-ammonia (7:3:0.5), as eluting solvent. Densitometric analysis was carried out 
at 312 nm with lamotrigine being detected at Rf of 0.54. The analytical method has excellent 
linearity (r=0.998) in the range of 20-300 ng/spot. The limit of detection and limit of 
quantification were found to be 6.4 and 10.2 ng, respectively. Good accuracy is reported in the 
range of 92.06-97.12% and high precision with %CV in range of 0.53-2.59.  The method was 
applied for determination of serum lamotrigine levels in epileptic patients and in 
pharmacokinetic study of lamotrigine administered orally to rabbits [13]. 
3.6 Wyszomirska E; Czerwinska K  have developed method for identification and 
assay of lamotrigine in human milk with gas chromatography and densitometry.  Conditions 
necessary for isolation and assay of lamotrigine in the human milk with gas chromatography 
in the range of concentrations 2-20 micrograms/ml, and densitometry in the range of 2-10 
micrograms/ml are discussed.  Lamotrigine was extracted with methylene chloride from the 
alkaline solution.  In gas chromatography capillary column DB-17, flame-ionizing detector, 
and octacozanole as the internal standard have been used.  Densitometric measurements have 
been performed at 217 nm [14]. 
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4.  AIM OF PRESENT WORK 
 
As per discussion in the literature review, Gas Chromatographic, High Perfomance 
Thin Layer Chromatography and HPLC methods for the determination of lamotrigine in 
pharmaceutical dosage forms or in biological fluids are reported. Gas chromatographic, 
HPTLC methods simply used for estimation of lamotrigine from pharmaceutical formulation 
and HPLC methods also applied for the determination of lamotrigine. So far to our present 
knowledge, no validated spectrophotometric assay method for the determination of 
lamotrigine in pharmaceutical formulation was available in literature. This work also deals 
with the validation of the developed method for the assay of lamotrigine from its dosage 
form (tablets). Hence, the method is use for routine quality control analysis and also stability. 
 
The aim and scope of the proposed work are as under: 
 To develop suitable spectrophotometric method for lamotrigine. 
 Perform the validation for the developed method. 
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5. EXPERIMENTAL 
5.1 Materials 
 Lamotrigine standard of was provided by Aarti Drugs Ltd., Boisar (India). 
Lamotrigine  tablets containing 308mg lamotrigine and the inactive ingredient used in drug 
matrix were obtained from market. Analytical grade methanol and water were obtained from 
Spectrochem Pvt. Ltd., Mumbai (India). 
 
5.2 Diluent Preparation  
 Methanol and Water (50:50, v/v) used as a diluents. 
 
5.3 Standard Preparation 
 A  lamotrigine  standard stock solution containing 500μg/ml was prepared in a 50 ml 
volumetric flask by dissolving 25.00 mg of lamotrigine and then diluted to volume with 
methanol as diluents. 
Further 2 ml of this stock solution in 25 ml volumetric flask and make up to mark with 
diluents. (Final concentration of standard solution is 40μg/ml) 
 
5.4 Test Preparation 
Twenty tablets were weighed and the average weight of tablet was determined. From 
these, five tablets were weighed and transfer into a 250 ml volumetric flask. About 50 ml 
diluents was added and sonicated for a minimum 30 min. with intermittent shaking. Then 
content was brought back to room temperature and diluted to volume with methanol. The 
sample was filtered through 0.45μm nylon syringe filter. The concentration obtained was 500 
μg/ml of lamotrigine.  
Further take 2 ml this filtrate solution in 25 ml volumetric flask and make up to mark 
with diluents. The concentration obtained was 40 μg/ml of  lamotrigine.  
 
5.5 Instrumentation 
UV-Visible double beam spectrophotometer with matched quartz cells (1cm) 
 Model: PharmaSpec1700 
 Make: Shimadzu, Kyoto, Japan. 
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6.   RESULTS AND DISCUSSION 
6.1 Development and Optimization of the Spectrophotometric Method 
Proper wave length selection of the methods depends upon the nature of the sample 
and its solubility. To develop a rugged and suitable spectrophotometric method for the 
quantitative determination of  lamotrigine, the analytical condition were selected after testing 
the different parameters such as diluents, buffer, buffer concentration, and other 
chromatographic conditions.  
Our preliminary trials using different composition of diluents consisting of water with 
buffer and methanol. By using diluent consisted of methanol – water (50:50, v/v) best result 
was obtained and degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). Below 
figures represent the spectrums of blank, standard and test preparation respectively. 
 
6.1.1 Selection of Wavelength 
 Scan standard solution in UV spectrophotometer between 200 nm to 400 nm on 
spectrum mode, using diluents as a blank. 
 The spectrums are shown as under: 
 
 
Figure 1: UV spectrum of a lamotrigine in Diluent (Blank) solution 
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Figure 2: UV spectrum of Lamotrigine in Standard solution 
 
 
 
Figure 3: UV spectrum of lamotrigine in Sample solution 
 
Lamotrigine shows λ max at 308 nm. The proposed analytical method is simple, 
accurate and reproducible. 
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6.2 Method Validation 
6.2.1 Specificity 
  The specificity of the method was determined by checking the interference of 
placebo with analyte. There was no interference is observed. 
 
6.2.2 Linearity 
Seven points calibration curve were obtained in a concentration range from 16-64 
μg/ml for lamotrigine. The response of the drug was found to be linear in the investigation 
concentration range and the linear regression equation was  y =29.75x-0.018 with correlation 
coefficient 0.999. (Figure 4) 
 
 
 
 
Figure 4: Linearity curve for Lamotrigine 
 
 
6.2.3 Precision 
  The result of repeatability and intermediate precision study are shown in Table 1. 
The developed method was found to be precise as the %RSD values for the repeatability and 
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intermediate precision studies were < 0.98 % and < 0.79 %, respectively, which confirm that 
method was precise. 
Table 1: Evaluation data of precision study 
Set Intraday (n = 6) Interday (n = 6) 
1 101.8 100.5 
2 101.2 99.0 
3 99.1 98.2 
4 101.3 98.6 
5 100.6 99.0 
6 101.5 99.3 
Mean 101.1 99.1 
Standard deviation 0.99 0.78 
% RSD 0.98 0.79 
 
 
6.2.4 Accuracy  
 The spectrophotometer absorbance responses for accuracy determination are depicted 
in Table 2. The result shown that best recoveries (98.82- 100.61 %) of the spiked drug were 
obtained at each added concentration, indicating that the method was accurate.  
Table 2: Evaluation data of accuracy study 
Level (%) 
 
Amount added 
concentration a
Amount found 
concentration 
(mg/ml) 
 a % Recovery  
(mg/ml) 
% RSD 
50 0.01960 0.01953 99.65 1.82 
100 0.04040 0.03992 98.82 1.13 
150 0.06067 0.06104 100.61 0.20 
 
a Each value corresponds to the mean of three determinations 
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6.2.5 Solution stability study 
  Table 3 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 5˚ C and ambient temperature, as during this time the result was not 
decrease below the minimum percentage. 
Table 3: Evaluation data of solution stability study 
Intervals 
% Assay for test 
preparation solution 
stored at 2-8 ˚C 
% Assay for test preparation 
solution stored at ambient 
temperature 
Initial 100.2 100.2 
12 h 98.7 98.7 
24 h 100.1 101.0 
36 h 100.8 100.5 
48 h 101.3 101.8 
 
6.2.6 Robustness 
  The result of robustness study of the developed assay method was established in 
Table 4. The result shown that during all variance conditions, assay value of the test 
preparation solution was not affected and it was in accordance with that of actual. System 
suitability parameters were also found satisfactory; hence the analytical method would be 
concluded as robust.  
 
Table 4: Evaluation data of robustness study 
 
Robust conditions % Assay 
Methanol : Water(55:45,v/v) 102.0 
Methanol : Water(45:55,v/v) 101.6 
Analyst change 99.6 
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6.2.7 System suitability 
  A system suitability test of the spectrophotometric system was performed before each 
validation run. Five replicate reading of standard preparation were taken and % RSD of 
standard reading were taken for same. Acceptance criteria for system suitability, % RSD of 
standard reading not more then 2.0%, were full fill during all validation parameter.  
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7. CALCULATIONS AND DATA 
 
 Calculation formula used: 
 
   
1. Calculation formula for % assay of Lamotrigine 
 
 
25
2
50
% ××=
WeightStandard
AbsorbanceStandardMean
AbsorbanceTestMean
Assay  
 
Standard
2
25250 ofPotency
ClaimLable
WeightTestMean
WeightTest
××××  
 
 
2. Relative standard deviation 
 
100×=
sMeasurmentofValueMean
sMeasurmentofDeviationStandard
RSD%  
 
 
3. Recovery 
 
100×=
AddedAmount
foundAmount
Recovery%  
 
 
4. Amount found  
 
ionConcentratStandard
AbsorbanceMean
AbsorbanceTestMean
mlmgFoundAmount ×=
Standard
)/(  
 
 
5. Amount added 
 
Volume
Weight(mg/ml)AddedAmount =  
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Specificity Study for Analytical Method Validation of Lamotrigine Tablets 
 
 
Standard weight (mg) 24.9     
Standard dilution 50 2 25   
Standard potency 100 %     
Standard concentration (mg/ml) 0.03984     
      
Replicate 1 2 3 4 5 
Standard absorbance 1.156 1.155 1.157 1.157 1.159 
Mean standard absorbance 1.157     
Stdev. 0.0015     
% RSD 0.13     
 
 
Replicate Test Area 
1 1.162 
2 1.164 
Mean test absorbance 1.163 
Test weight (mg) 502.9 
Label claim (mg) 25 
Mean test weight (mg) 100.5 
% Assay 100.1 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
25
2
50
9.24
1.157
1.163% ××=Assay 100
25
5.100
2
25
9.502
250
××××  
 
              
     = 100.1 % 
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Linearity Study for Analytical Method Validation of Lamotrigine Tablets 
 
 
 
 
 
 
 
 
 
 
 
 
Standard weight (mg) 25      
Standard dilution 50 2 25   
Standard potency 100.0 %     
Standard concentration (mg/ml) 0.040     
Concentration of linearity stock solution (mg/ml) 0.500     
      
Replicate 1 2 3 4 5 
Standard absorbance 1.152 1.151 1.152 1.155 1.154 
Mean standard absorbance 1.153     
Stdev 0.0015     
% RSD 0.13     
Concentration 
level (%) 
Volume of 
linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final 
concentration 
(mg/ml) 
Mean 
absorbance 
40 0.8 25 0.016 0.467 
60 1.2 25 0.024 0.675 
80 1.6 25 0.032 0.929 
100 2.0 25 0.040 1.159 
120 2.4 25 0.048 1.396 
140 2.8 25 0.056 1.637 
160 3.2 25 0.064 1.922 
  Correlation co-efficient 0.9994 
  Slope 30.16964286 
  Intercept -0.03771 
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Precision Study for Analytical Method Validation of Lamotrigine Tablets 
 
 
Standard weight (mg) 25.1     
Standard dilution 50 2 25   
Standard potency 100.0 %     
Label claim (mg) 25     
Mean test weight (mg) 100.5     
Standard concentration (mg/ml) 0.04016     
      
Replicate 1 2 3 4 5 
Standard absorbance 1.157 1.157 1.159 1.158 1.16 
Mean standard absorbance 1.158     
Stdev. 0.0013     
% RSD 0.11     
 
 
Description Mean absorbance Test weight (mg) % Assay 
Set 1 1.152 502.4 99.8 
Set 2 1.156 503.1 100.1 
Set 3 1.174 502.2 101.8 
Set 4 1.159 502.8 100.4 
Set 5 1.150 503 99.5 
Set 6 1.160 502.5 100.5 
  Mean 100.4 
  Stdev 0.80 
  % RSD 0.80 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
25
2
50
1.25
1.158
1.152% ××=Assay 100
25
5.100
2
25
4.502
250
××××  
     
    = 99.8 % 
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Intermediate precision study for Analytical Method Validation of tablet 
 
 
Standard weight (mg) 24.9     
Standard dilution 50 2 25   
Standard potency 100.0 %     
Label claim (mg) 25     
Mean test weight (mg) 100.5     
Standard concentration (mg/ml) 0.03984     
      
Replicate 1 2 3 4 5 
Standard absorbance 1.144 1.149 1.144 1.147 1.146 
Mean standard absorbance 1.146     
Stdev. 0.0021     
% RSD 0.2     
 
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 1.153 502.6 100.2 
Set 2 1.161 503.2 100.7 
Set 3 1.164 502.9 101.1 
Set 4 1.158 501.9 100.8 
Set 5 1.165 502.5 101.2 
Set 6 1.161 502.2 101.0 
 
Mean 100.8 
Stdev 0.36 
% RSD 0.36 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
25
2
50
9.24
1.146
1.153% ××=Assay 100
25
5.100
2
25
6.502
250
××××  
 
 
    = 100.2 % 
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Comparison for Precision and Intermediate Precision Study for Analytical Method 
Validation for Lamotrigine Tablets 
 
 
 Set %Assay 
Precision study 
1 99.8 
2 100.1 
3 101.8 
4 100.4 
5 99.5 
6 100.5 
Intermediate precision study 
1 100.2 
2 100.7 
3 101.1 
4 100.8 
5 101.2 
6 101 
 Mean 100.6 
 Stdev 0.64 
 % RSD 0.64 
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Accuracy study for Analytical Method Validation of Lamotrigine tablets 
 
  
Standard weight (mg) 25     
Standard dilution 50 2 25   
Standard potency 100.0 %     
Standard concentration (mg/ml) 0.040     
      
Replicate 1 2 3 4 5 
Standard absorbance 1.153 1.154 1.157 1.159 1.158 
Mean standard absorbance 1.156     
Stdev 0.00259     
% Rsd 0.22     
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Solution Stability Study for Analytical Method Validation of   Lamotrigine Tablets 
 
 
 
System suitability of standard preparation for solution stability 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Abs Abs Abs Abs Abs 
1 1.154 1.154 1.149 1.151 1.158 
2 1.155 1.153 1.152 1.152 1.15 
3 1.154 1.153 1.152 1.153 1.154 
4 1.157 1.157 1.151 1.152 1.156 
5 1.158 1.156 1.155 1.155 1.156 
Mean 1.156 1.155 1.152 1.153 1.155 
Stdev 0.0018 0.0018 0.0022 0.0015 0.0030 
%RSD 0.16 0.16 0.19 0.13 0.26 
 
 
 
 
Solution stability for standard preparation at 2 -8°C 
 After 12 hours After 24 hours After 36 hours After 48 hours Standard Standard Standard Standard 
Replicate  Abs Abs Abs Abs 
1 1.154 1.154 1.154 1.154 
2 1.155 1.155 1.155 1.155 
3 1.154 1.154 1.154 1.154 
4 1.157 1.157 1.157 1.157 
5 1.158 1.158 1.158 1.158 
1 1.148 1.158 1.172 1.168 
2 1.15 1.157 1.173 1.167 
Mean 1.154 1.156 1.160 1.159 
Stdev 0.0036 0.0018 0.008 0.0060 
%RSD 0.31 0.15 0.72 0.52 
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Solution stability for test preparation at 2 -8°C 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate  Abs Abs  Abs Abs  Abs 
1 1.154 1.154 1.149 1.151 1.158 
2 1.155 1.153 1.152 1.152 1.15 
3 1.154 1.153 1.152 1.153 1.154 
4 1.157 1.157 1.151 1.152 1.156 
5 1.158 1.156 1.155 1.155 1.156 
Replicate Test Abs Test Abs Test Abs Test Abs Test Abs 
1 1.160 1.148 1.167 1.172 1.180 
2 1.159 1.149 1.166 1.173 1.181 
Mean 1.160 1.149 1.167 1.173 1.181 
% Assay 99.9 99.4 100.8 101.7 102.6 
Standard weight (mg) 24.9 25.0 24.9 25.0 25.1 
Test weight (mg) 502.8 502.8 502.8 502.8 502.8 
% Difference compare 
to that of Initial  0.5 -0.9 -1.8 -2.7 
Solution stability for standard preparation at room temperature 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate  Abs Abs Abs Abs 
1 1.154 1.154 1.154 1.154 
2 1.155 1.155 1.155 1.155 
3 1.154 1.154 1.154 1.154 
4 1.157 1.157 1.157 1.157 
5 1.16 1.158 1.158 1.158 
1 1.149 1.16 1.164 1.169 
2 1.152 1.164 1.165 1.168 
Mean 1.154 1.157 1.158 1.159 
Stdev 0.0035 0.0036 0.0046 0.0065 
%RSD 0.30 0.31 0.40 0.56 
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Calculation: 
 
Prototype calculation for one set: 
 
25
2
50
9.24
1.156
1.160% ××=Assay 100
25
5.100
2
25
8.502
50
××××  
 
  =  99.9 % 
Solution stability for test preparation at room temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate  Abs  Abs  Abs Abs Abs 
1 1.154 1.154 1.149 1.151 1.158 
2 1.155 1.153 1.152 1.152 1.15 
3 1.154 1.153 1.152 1.153 1.154 
4 1.157 1.157 1.151 1.152 1.156 
5 1.158 1.156 1.155 1.155 1.156 
Replicate Test Abs Test Abs Test Abs Test Abs Test Abs 
1 1.160 1.15 1.167 1.174 1.181 
2 1.159 1.151 1.165 1.176 1.184 
Mean 1.160 1.151 1.166 1.175 1.183 
% Assay 99.9 99.6 100.8 101.9 102.8 
Standard weight (mg) 24.9 25 24.9 25 25.1 
Test weight (mg) 502.8 502.8 502.8 502.8 502.8 
% Difference compare 
to that of Initial  0.3 -0.9 -2.0 -2.9 
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